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Abstract 
FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase (RTK) 
expressed in approximately 90% of acute myeloid leukaemia (AML) patients. Internal 
tandem duplication of sequences in the juxtamembrane domain of the FLT3 receptor 
(FLT3-ITD) is the most prevalent FLT3 mutation accounting for 15-35% of AML 
cases. FLT3-ITD expressing cells produce elevated levels of reactive oxygen species 
(ROS), particularly NADPH oxidase 4 (NOX4) - and p22phox-generated ROS which 
act as pro-survival signals. Increased ROS production in AML is linked to enhanced 
cell survival and proliferation as well as a differentiation block. Little was known of 
the mechanism in which the FLT3-ITD oncoprotein activates NOX4-generated 
hydrogen peroxide (H2O2) and thus this PhD project was designed to elucidate the 
mechanism. 
The FLT3-ITD mutation results in ligand-independent constitutive activation 
of the FLT3 receptor at the plasma membrane and impaired trafficking of the FLT3 
receptor in compartments of the endomembrane system, such as the endoplasmic 
reticulum (ER). Firstly, we investigated FLT3-ITD-induced activation of aberrant pro-
survival signalling cascades resulting in the activation and generation of NOX4- and 
p22phox-generated H2O2 at the plasma membrane and ER. To this end, receptor 
trafficking inhibitors, tunicamycin and brefeldin A were employed and resulted in ER 
retention of FLT3-ITD in the FLT3-ITD expressing AML MV4-11 cell line. Inhibition 
of FLT3-ITD cell surface expression resulted in decreased NOX4 and p22phox protein 
levels, suggesting an important role for FLT3-ITD subcellular localisation in the 
generation of pro-survival ROS. We found that PI3K/AKT signalling only occurs 
downstream of FLT3-ITD at the plasma membrane and is required for the generation 
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of NOX4- and p22phox-generated pro-survival H2O2 in AML. Taken together, these 
findings identify that FLT3-ITD at the plasma membrane is responsible for the 
production of NOX4- and p22phox-generated H2O2.  
Next, we investigated and identified the pro-survival signalling pathways 
downstream of FLT3-ITD at the plasma membrane and the ER. The PI3K/AKT and 
ERK1/2 signalling pathways are activated and GSK3β signalling is inhibited 
downstream of FLT3-ITD at the plasma membrane. STAT5 signalling is activated 
downstream of FLT3-ITD at the ER. Activation of the ERK1/2 pathway results in the 
inhibition of GSK3β signalling through phosphorylation of serine at position 9. 
NOX4 is a major source of ROS in AML. Given its constitutive activity we 
investigated its subcellular localisation. We show for the first time that FLT3-ITD 
expressing patient samples and cells express the NOX4 splice variant D (NOX4D 28 
kDa). FLT3-ITD expressing AML cells express NOX4D in the nuclear membrane 
where it is contributing to endogenous H2O2 and may be involved in genetic 
instability. We have also identified that prototype NOX4 and p22phox colocalise to the 
nuclear membrane of MV4-11 and 32D/FLT3-ITD cells. Glycosylation of NOX4 and 
NOX4D is critical for their oncogenic effects. We have shown that the PI3K/AKT and 
STAT5 pathways are responsible for the production of NOX4D-generated pro-
survival H2O2 in FLT3-ITD expressing AML. 
 In summary, this thesis elucidates the mechanism in which activation 
and localisation of FLT3-ITD stimulates the PI3K/AKT and STAT5 pro-survival 
signalling pathways. This in turn leads to elevated production of NOX4-, NOX4D- 
and p22phox-generated H2O2 in AML which may contribute to DNA damage and 
vi 
 
genetic instability. My work therefore presents FLT3-ITD at the plasma membrane 
and NOXs as attractive therapeutic targets in the treatment of AML. 
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1.1. Leukaemia 
The term leukaemia refers to cancer of the blood and bone marrow and is 
characterised by the abnormal growth and proliferation of white blood cells or 
leukocytes. The word leukaemia is derived from the Greek words leukos ‘white’ and 
haima ‘blood’. In 2012, 352,000 new leukaemia cases were diagnosed worldwide, 
which accounts for 2.5% of all cancers (Ferlay et al., 2015). Leukaemia is classified 
according to the lineage of the white blood cells affected, myeloid or lymphoid, and 
acute or chronic depending on the aggressiveness of the disease. Chronic forms of 
leukaemia are characterised by the excessive accumulation of mature, abnormal blood 
cells, and acute forms of leukaemia are characterised by the rapid increase in immature 
blood cells or ‘blasts’. There are four major subtypes of leukaemia: Chronic Myeloid 
Leukaemia (CML), Chronic Lymphocytic Leukaemia (CLL), Acute Myeloid 
Leukaemia (AML) and Acute Lymphocytic Leukaemia (ALL) (LLS, 2011). 
 
1.1.1. Acute Myeloid Leukaemia (AML) 
1.1.1.1. Epidemiology and current treatment of AML 
AML accounts for approximately 25% of all leukaemia cases (Kumar, 2011) 
and is the second most frequent form of leukaemia after CLL (Bhayat et al., 2009, 
Yamamoto and Goodman, 2008). AML is the most common malignant myeloid 
disorder in adults and has an incidence of 3.8 cases per 100,000 rising to 17.9 per 
100,000 in adults aged 65 years and over (Estey and Döhner, 2006). It is responsible 
for approximately 50% of leukaemic deaths in children (Meshinchi and Arceci, 2007). 
Acute myeloid leukaemia is a heterogeneous clonal disorder of haematopoietic 
progenitor cells ‘blasts’ which are unable to differentiate into mature and functional 
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monocytes or granulocytes, but accumulate in bone marrow, peripheral blood and 
spleen and interfere with normal haematopoiesis (Bonnet and Dick, 1997, Estey and 
Döhner, 2006, Preisler and Lyman, 1977). Several factors that influence the risk of 
acquiring AML include epigenetics, chromosomal aberrations, genetic mutations, 
gender, environmental conditions and haematological disorders (Levine and 
Bloomfield, 1992).  
The strategy of AML treatment has not changed substantially in over 30 years. 
The worldwide standard of care for AML patients who are not participating in clinical 
trials, receive an induction of chemotherapy with a cytarabine and an anthracycline 
(idarubicin and daunorubicin), followed by either one to four cycles of consolidation 
chemotherapy, autologous stem cell transplantation or allogeneic stem cell 
transplantation (Roboz, 2012). This standard treatment with chemotherapy maximally 
results in 70-80% of patients less than 65 years achieving complete remission, most 
will eventually relapse and an overall survival rate of only 40-50% at 5 years (Emadi 
and Karp, 2014). Several factors have been associated with more severe outcomes at 
relapse including unfavourable cytogenetics at diagnosis, old age and also prior history 
of haematopoietic stem cell transplantation (Breems et al., 2005). More novel 
treatments have not been approved in recent times due to high levels of toxicity or 
little level of effectiveness. This demonstrates the importance and need for 
development of new drugs. 
 
1.1.1.2. Haematopoiesis 
Haematopoiesis is the process of creating new blood cells in the body and is 
derived from the Greek words haima ‘blood’ and poiesis ‘to make’ (Figure 1.1.). 
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Normal haematopoiesis is dependent upon tightly controlled and inter-related 
mechanisms regulating cell survival, proliferation and differentiation. It is initiated in 
the bone by haematopoietic stem cells (HSC). The HSC population is relatively 
quiescent (Bradford et al., 1997), however, upon entry to the cell cycle it gives rise to 
differentiating progenitor cells that undergo extensive proliferative expansion in order 
to replenish the blood system and also in response to stresses including infection and 
injury (Pietras, 2017). In haematological malignancies normal haematopoiesis is 
interrupted due to the uncontrolled growth of genetically altered stem cells that retain 
the ability of self-renewal (Aleem and Arceci, 2015). 
 
Figure 1.1. Schematic of haematopoiesis. AML is an aggressive malignancy characterised by a block 
in myeloid differentiation. HSCs are responsible for the generation of mature blood cells. Normal 
haematopoiesis is interrupted in AML due to the uncontrolled growth of genetically altered leukaemic 
stem cells resulting in the uncontrolled accumulation and proliferation of abnormal myeloid progenitors 
that accumulate in the peripheral blood, bone marrow and spleen. (Taken from (Ramsay and Gonda, 
2008)) 
 
In AML, the haematopoietic progenitor acquires abnormalities including the 
imbalance of the three key processes: cell survival, proliferation and differentiation 
5 
 
resulting in the expansion of the leukaemic stem cell (LSC) (Bonnet and Dick, 1997). 
In order to develop into a fully malignant disease, these abnormalities require multiple 
independent genetic and epigenetic alterations in oncogenes and/or tumour suppressor 
genes. LSCs are characterised by unlimited self-renewal, cytoprotection and 
attenuated telomerase activity (Lane and Gilliland, 2010). LSCs are not found 
circulating in the blood, they primarily reside in the bone marrow microenvironment. 
This is of great importance from a clinical perspective as it enables them to avoid the 
cytotoxic effects of chemotherapy and to re-emerge, resulting in relapse of the disease 
(Lane et al., 2009). 
 
1.1.1.3. Pathogenesis in AML 
AML refers to a heterogeneous group of diseases, the molecular basis of which 
can be multi-factorial or complex. A range of genetic, as well as cytogenetic 
abnormalities, have been identified that lead to the molecular alterations giving rise to 
the AML phenotype. The European Leukaemia Net Prognostic system categorises 
AML patients into four risk groups: favourable, intermediate-I, intermediate-II and 
adverse (Mrózek et al., 2012).  The groups are classified depending on the subsets of 
cytogenetic and molecular markers. This classification allows prediction of response 
to chemotherapy or stem cell transplantation. For example, internal tandem 
duplications of sequences in the juxtamembrane domain of macrophage colony-
stimulating factor receptor (FMS)-like tyrosine kinase 3 (FLT3-ITD) are associated 
with a poor prognosis due to an aggressive disease phenotype. The primary diagnosis 
of AML is based on the presence of leukaemic myeloblasts in preparations of 
peripheral blood and bone marrow stained with Wright-Giemsa. Once AML diagnosis 
is confirmed, the genetic and morphological subtype must be identified. The most 
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commonly used method of classification was developed by the French-American-
British (FAB) group which categorises AML into nine distinct subgroups that differ 
in respect to the myeloid lineage involved and the rate of leukaemia-cell differentiation 
(Table 1.1.) (Lowenberg et al., 1999). The World Health Organization (WHO) has a 
newer system of classifying AML ‘World Health Organization (WHO) Classification 
of Tumours of Haematopoietic and Lymphoid Tissues’ into several groups based on 
genetic abnormalities such as translocation or inversion of chromosomes, revised in 
2016 (Cazzola, 2016). 
 
FAB subtype Name % of 
cases 
M0 Undifferentiated acute myeloblastic leukaemia 3% 
M1 Acute myeloblastic leukaemia with minimal 
maturation 
15-20% 
M2 Acute myeloblastic leukaemia with maturation 25-30% 
M3 Acute promyelocytic leukaemia (APL) 5-10% 
M4 Acute myelomonocytic leukaemia 20% 
M4Eo Acute myelomonocytic leukaemia with 
eosinophilia 
5-10% 
M5 Acute monocytic leukaemia 2-9% 
M6 Acute erythroid leukaemia 3-5% 
M7 Acute megakaryocytic leukaemia 3-12% 
 
Table 1.1. The French-American-British (FAB) classification of AML. 
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1.1.1.4. Chromosomal aberrations in AML 
AML is polyclonal, particularly at initial diagnosis (Levis, 2013). The clonal 
origin of AML was initially described by the presence of acquired non-random 
chromosomal aberrations present in haematopoietic progenitor cells (Guan et al., 
2002, Döhner and Döhner, 2008). 749 chromosomal abnormalities have been recorded 
in AML (Kumar, 2011). Non-random chromosomal aberrations including deletions, 
translocations, inversions and monosomies have been detected in 55% of AML 
patients and are very important prognostic factors in terms of remission, relapse and 
survival (Döhner and Döhner, 2008). This evidence suggests that leukaemogenesis is 
a multi-step process. The most prevalent targets of chromosomal-associated 
translocations in AML are genes that encode DNA-binding transcription factors or the 
regulatory components of transcriptional complexes (Lowenberg et al., 1999). 
Patients with myelodysplastic syndromes (MDS) have an increased risk of 
disease evolution to leukaemia and this is associated with chromosomal alterations. 
Approximately 30% of MDS cases progress to AML (Nolte and Hofmann, 2010). The 
most common chromosomal aberrations in AML include 1% inversion 
(3)/translocation (3;3), 1% translocation (6;9), 2% translocation (11q23), 6% inversion 
(16)/translocation (16;16), 5% translocation (8;21), 23% are described as having 
various karyotypes including trisomy 8, 11, 13, 21 and 22, loss of 5q and chromosome 
X, Y or 7 (CCAAT/enhancer binding protein α (CEBPA), mixed lineage leukaemia 
gene (MLL) and Nucleophosmin 1 (NPM1) and Runt-related transcription factor 1 
(RUNX1) mutations), and 11% defined as having a complex karyotype of multiple 
gains, losses and rearrangements (TP53 mutations) (Nolte and Hofmann, 2010, 
Döhner and Döhner, 2008, Lal et al., 2017). 
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Oncogenic fusion proteins are generated as a consequence of specific 
chromosomal translocations and at sites of chromosomal breaks. For example, 
chromosomal translocations, such as translocation (8;21) in core-binding factor AML 
(CBF-AML) result in the formation of chimeric fusion protein Runt-related 
transcription factor 1 (RUNX1)-RUNX1 translocation partner 1 (RUNX1T1) (Döhner 
and Döhner, 2008). The RUNX1-RUNX1T1 fusion protein results in impaired 
myeloid differentiation (De Kouchkovsky and Abdul-Hay, 2016), however the fusion 
protein does not result in a fully leukaemic phenotype in a murine model (Döhner and 
Döhner, 2008). The initiating fusion oncogenes have to be followed by a 
complementing mutation that activates signal transduction pathways, resulting in 
increased cell survival and proliferation, and a block in differentiation and apoptosis. 
Often these mutations result in the activation of receptor tyrosine kinase signalling 
pathways, for example, FLT3, stem cell/steel factor receptor (KIT) and 
Neuroblastoma RAS Viral Oncogene Homologues (NRAS) (Döhner and Döhner, 
2008). 
 
1.1.1.5. Genetic alterations in AML 
AML mutations have been classified into two classes collectively known as 
the ‘two-hit’ model. Class I mutations are mutations that result in the activation of 
signal transduction pathways leading to increased cell survival and proliferation, for 
example, FLT3, Breakpoint cluster-Abelson murine leukaemia viral oncogene (BCR-
ABL), Rat sarcoma viral oncogene (RAS) or Janus kinase 2 (JAK2) (Conway O'Brien 
et al., 2014). Class II mutations are mutations that affect differentiation preventing the 
maturation of cells and also affect self-renewal, for instance, CCAAT/enhancer 
binding protein α (CEBPA), mixed lineage leukaemia gene (MLL) and 
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Nucleophosmin 1 (NPM1). In order for the disease to develop, a class I AML mutation 
must be accompanied by a class II mutation (Shih et al., 2012, Naoe and Kiyoi, 2013).  
 
1.1.1.6. Epigenetic abnormalities in AML 
For many years, AML mutations also known as the ‘two-hit’ model were the 
accepted model of leukaemogenesis in AML (Conway O'Brien et al., 2014, Shih et al., 
2012). However, class I and class II AML mutations are only one part of a more 
complex picture. Epigenetic alterations are now recognised as playing an equally 
important role in the pathogenesis of AML (Plass et al., 2008). The term epigenetics 
is the study of inheritable changes in gene expression that do not involve changes in 
the DNA sequence itself (Shih et al., 2012). Epigenetics involves the interplay between 
three main components: DNA methylation, chromatin and non-coding RNA (Plass et 
al., 2008). DNA methyltransferases and histone methyltransferases are well known 
epigenetic modifiers (Islam et al., 2017). Mutations in genes regulating histone 
modification, DNA methylation and DNA hydroxymethylation states in 
haematopoietic progenitors are emerging as critical events in AML (Shih et al., 2012). 
Studies have identified more than 1,300 highly methylated gene promoters in 
AML. Approximately 1,100 of these genes are hypermethylated in 5% of AML 
patients while 200 gene promoters are hypermethylated in 90% of AML patients 
(Islam et al., 2017). DNA methyltransferases are responsible for de novo methylation 
and are frequently mutated in AML, for example, DNA methyltransferase 3A 
(DNMT3A) (Islam et al., 2017, Conway O'Brien et al., 2014). DNA 
methyltransferases catalyse the addition of a methyl group to the 5’ position of the 
cytosine ring specifically in 5’-cytosine-phosphate-guanine-3’ (CpG) dinucleotide 
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sequences (Plass et al., 2008, Conway O'Brien et al., 2014). DNMT3A is mutated in 
15-25% of AML (Shih et al., 2012, Ley et al., 2010, Patel  et al., 2012, Conway 
O'Brien et al., 2014, Ferreira et al., 2015), resulting in impaired catalytic activity 
(Holz-Schietinger et al., 2012). DNMT3A is necessary for normal haematopoietic cell 
differentiation (Mehdipour et al., 2015, Challen et al., 2011). Mutations in DNMT3A 
have been linked to decreased methylation of some genes in AML (Hájková et al., 
2012). Other genes involved in the regulation of DNA hydroxymethylation include 
Tet methylcytosine dioxygenase 2 (TET2) and isocitrate dehydrogenase 1 and 2 
(IDH1 and IDH2) (Mehdipour et al., 2015, Conway O'Brien et al., 2014). TET2 is 
mutated in 7-23% of AML (Metzeler et al., 2011, Ahn et al., 2015, Shih et al., 2012) 
and IDH1 and IDH2 are mutated in 15-30% of AML (Figueroa et al., 2010, Rakheja 
et al., 2012, Paschka et al., 2010). Cancers have altered patterns of DNA methylation 
and the global level of DNA methylation is often lower in malignant cells (Wajed et 
al., 2001, Ehrlich, 2009). Hypermethylation of cytosines in CpG islands is associated 
with silencing of tumour suppressor genes contributing to carcinogenesis (Plass et al., 
2008, Conway O'Brien et al., 2014, Mehdipour et al., 2015, Baylin, 2005, Ehrlich, 
2009). Some of the genes implicated in the regulation of histones are also mutated in 
AML, for example, enhancer of zeste homologue 2 (EZH2) and additional sex combs-
like 1 (ASXL-1) (Conway O'Brien et al., 2014, Shih et al., 2012). 
Alterations in genome wide methylation patterns and mutations in epigenetic 
modifiers presents deregulation of epigenetics as one of the fundamental causal agents 
in the development of AML (Islam et al., 2017). Pharmacological reversal of aberrant 
epigenetic changes that result in silencing of genes in haematopoiesis can restore the 
normal function of the bone marrow as well as showing a clinical response in AML 
(Plass et al., 2008).  Some of the epigenetic compounds currently approved for clinical 
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use in myeloid malignancies include inhibitors of DNA methyltransferases, 5-
azacytidine (azacitidine) and 5-aza-2’ deoxycytidine (decitabine) and histone 
deacetylase (HDAC) inhibitors that have been tested in clinical trials for the treatment 
of malignancies including AML (Wouters and Delwel, 2016). 
 
1.1.2. FLT3 signalling in AML 
1.1.2.1. FLT3 
FMS-like tyrosine kinase 3 (FLT3) also known as foetal liver kinase-2 (FLK-
2), is a type III receptor tyrosine kinase (RTK) expressed in approximately 90% of 
acute myeloid leukaemia cases. FLT3 is involved in the early stages of haematopoiesis 
and is important for normal development of stem cells and the immune system 
(Stirewalt and Radich, 2003, Gilliland and Griffin, 2002). Mutations in FLT3 are 
present in 25-45% of AML patients, making it the most prevalent genetic aberration 
in AML (Stirewalt and Radich, 2003). FLT3 has structural similarities to other class 
III RTKs including macrophage colony-stimulating factor receptor (FMS) and 
platelet-derived growth factor receptor (PDGF). Class III RTKs play an important role 
in cell growth and differentiation of leukaemic cells (Berenstein, 2015).  
 
1.1.2.2. FLT3 structure 
The FLT3 gene encodes a 993-amino acid protein in humans and is expressed 
in early lymphoid and myeloid haematopoietic cells (Rosnet et al., 1996). The RTK 
FLT3 is composed of five extracellular immunoglobulin-like domains, a 
transmembrane domain, a juxtamembrane dimerization domain and  two cytoplasmic 
domains or an interrupted kinase domain (Levis and Small, 2003) (Figure 1.2.). Two 
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forms of FLT3 exist,  a mature glycosylated 160 kDa protein and an immature 
unglycosylated 130 kDa protein (Stirewalt and Radich, 2003). 
 
 
Figure 1.2. FLT3 structure. The FLT3 protein is composed of an extracellular ligand-binding domain, 
a transmembrane domain, a juxtamembrane domain, and two cytoplasmic domains with tyrosine kinase 
motifs. 
 
The unstimulated form of the FLT3 receptor resides as a monomer in the 
plasma membrane, unphosphorylated with an inactive kinase domain (Köthe et al., 
2013, Grafone et al., 2012). Upon interaction with the FLT3 ligand (FL), the receptor 
autophosphorylates and undergoes a conformational change resulting in unfolding of 
the protein, leading to the exposure of the dimerization domain, thus allowing 
receptor-receptor dimerization and activation of the kinase domain to occur (Levis and 
Small, 2003). FLT3 signalling is tightly controlled by the internalisation of FLT3-FL 
complex and is partly involved in the negative regulation of FLT3 signalling 
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monitoring survival and proliferation in these cells (Turner et al., 1996). Activation of 
the FLT3 receptor results in the activation of pro-survival cell signalling pathways 
including Raf/MEK/ERK, PI3K/AKT and JAK/STAT (Masson and Rönnstrand, 
2009). 
 
1.1.2.3. FLT3 mutations in haematological malignancies 
There are two types of FLT3 mutations implicated in AML- the FLT3 internal 
tandem duplication (FLT3-ITD) mutation and mutations within the activation loop of 
the tyrosine kinase domain of FLT3 (FLT3-TKD). Internal tandem duplications in 
exons 14 and 15  of FLT3 (FLT3-ITD) are the most common mutation expressed in 
15-35% of AML cases, 1-3% of ALL cases and 5-10% of patients with 
myelodysplastic syndromes (MDS) (Stirewalt and Radich, 2003). FLT3-ITD results 
in structural and conformational changes to the juxtamembrane domain, disrupting 
auto-inhibitory functions of the receptor resulting in constitutive activation of the 
receptor at the plasma membrane, and impaired trafficking of the receptor in 
compartments of its biosynthetic route, such as the endoplasmic reticulum (ER) 
(Choudhary et al., 2009, Moloney et al., 2017b), as well as activation of downstream 
effectors. AML patients with the FLT3-ITD mutation have a poor prognosis (Thiede 
et al., 2002, Small, 2008), with an increased risk of relapse following treatment with 
chemotherapy and a lower rate of overall survival (Grafone et al., 2012, Stirewalt and 
Radich, 2003). FLT3-ITD harbouring cases relapse more often and quicker than 
people without the mutation (Grafone et al., 2012) and patients with other AML 
subtypes (Levis and Small, 2003). The FLT3-TKD mutation is less common with an 
incidence of approximately 7% in AML (Thiede et al., 2002). In its inactive state, the 
conformation of the activation loop prevents access for adenosine triphosphate (ATP) 
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and substrate, resulting in an inactive kinase. Following interaction with FL, 
phosphorylation of the activation loop results in a folded out conformation providing 
access for ATP and substrate (Weiss and Schlessinger, 1998). One of the most 
common FLT3-TKD mutations is a missense mutation where aspartic acid is 
substituted with a tyrosine in exon 20 (D835Y) causing the activation loop to remain 
in the folded out conformation, resulting in tyrosine kinase activity. This mutation 
occurs in 5-10% of AML cases, 1-3% of ALL cases and 2-5% of patients with MDS 
(Yamamoto et al., 2001). 
 
1.1.2.4. Current treatment of AML patients with FLT3 mutations 
Newly diagnosed FLT3-ITD patients receive standard induction chemotherapy 
with similar results to other AML patients. However, patients that are hemizygous for 
FLT3-ITD mutations have a shorter remission and relapse at much higher rate 
compared to patients without the mutation (Grafone et al., 2012, Levis and Small, 
2003). The median rate of survival in FLT3-ITD AML cases after first remission is 
less than five months (Ravandi et al., 2010, Levis et al., 2011, Levis, 2011). The 
survival rate is also the poorest in patients with the FLT3-ITD mutation (Grafone et 
al., 2012). Allogeneic stem cell transplantation in patients with the FLT3-ITD 
mutation at first remission have a better outcome than the conventional consolidation 
chemotherapy (Levis, 2013). Yet there are some patients that cannot undergo intensive 
induction chemotherapy or allogeneic stem cell transplantation, for example, the 
elderly, hence treatment options for these patients are limited. 
The current rationale in terms of treatment of FLT3 mutations in AML is to 
target deregulated pathways that drive blast proliferation. Inhibition of tyrosine 
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kinases using tyrosine kinase inhibitors (TKIs) has been identified as a popular 
strategy. However, TKIs have been shown to have inhibitory effects against other 
RTKs due to the structural homology of the receptor, causing off-target effects. Some 
of the tyrosine kinase inhibitors currently undergoing clinical trials include lestaurtinib 
(CEP-701) and quizartinib (AC220). Lestaurtinib and midostaurin are two of the most 
extensively studied TKIs in FLT3-expressing AML (Grafone et al., 2012). However, 
treatment with lestaurtinib following chemotherapy has been shown to have no effect 
on response rate and survival (Levis et al., 2011). Quizartinib is the most recent FLT3 
tyrosine kinase inhibitor under clinical investigation (Fathi and Levis, 2011) and has 
been shown to increase survival rate in vivo in a mouse model of FLT3-ITD AML. It 
has also been found to inhibit FLT3 activity in primary AML cells (Zarrinkar et al., 
2009). Rydapt (midostaurin, formerly known as PKC412), a protein tyrosine kinase 
inhibitor targeted towards FLT3-ITD positive AML is the first new treatment in over 
25 years (Schiller, 2013, Lin and Levy, 2012, Rydapt, 2017) following Food and Drug 
Administration (FDA) approval in 2017. Rydapt treatment regime in FLT3-ITD 
expressing AML demonstrated a significant improvement in overall survival with a 
23% reduction in the risk of death (Rydapt, 2017). Rydapt will be used in combination 
with certain chemotherapy drugs to effectively target FLT3-ITD in AML. 
 
1.1.2.5. FLT3 glycosylation 
Glycosylation is the most common post-translational modification (Zhang and 
Wang, 2016, Stanley, 2011, Ungar, 2009) occurring in approximately 50% of proteins 
in cells (Jefferis, 2007, An et al., 2009, Christiansen et al., 2014) providing greater 
proteomic diversity than any other post-translational modification (Lis and Sharon, 
1993). Some of the proteins known to be glycosylated within a cell include secreted 
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proteins (Lis and Sharon, 1993), cell surface receptors and ligands and organelle-
resident proteins (Bieberich, 2014). The glycosylation reaction involves the covalent 
attachment of a carbohydrate or sugar moiety to functional groups of amino acids in 
proteins and lipids (Spiro, 2002). Accurate glycosylation must occur in the ER to 
ensure that only correctly folded proteins are trafficked to the Golgi apparatus, the 
centre of the secretory pathway (Zhang and Wang, 2016, Lis and Sharon, 1993). 
Glycosylation is the most complex post-translational modification as there is no 
template involved compared to other cell processes including transcription and 
translation (An et al., 2009). Cells rely on highly ordered stepwise reactions and a host 
of enzymes including glycotransferases, glycosidases and nucleic sugar transporters 
(Zhang and Wang, 2016). There are several types of glycosylation classified according 
to the identity of the atom of the amino acid that binds to the carbohydrate chain. These 
include C-linked glycosylation, N-linked glycosylation, O-linked glycosylation, 
phosphoglycosylation and glypiated linkage (Spiro, 2002, Zhang and Wang, 2016). C-
linked glycosylation involves the covalent attachment of mannose to the indole ring 
of the amino acid tryptophan within extracellular proteins in the ER (Zhang and Wang, 
2016, Gonzalez de Peredo et al., 2002, Spiro, 2002). N-linked glycosylation is the 
most complex form of glycosylation in which oligosaccharides bind to the amino 
group of asparagine in the ER (Zhang and Wang, 2016, An et al., 2009, Helenius and 
Aebi, 2004, Bieberich, 2014). O-linked glycosylation occurs when monosaccharides 
bind to the hydroxyl group of serine or threonine in the ER, Golgi, cytosol and nucleus 
(Zhang and Wang, 2016, An et al., 2009, Gonzalez de Peredo et al., 2002, Hounsell et 
al., 1996). Phosphoglycosylation reaction involves the binding of a glycan to serine 
via a phosphodiester bond (Haynes, 1998). Glypiation linkage occurs when the glycan 
core links a phospholipid and a protein (Zhang and Wang, 2016, Pierleoni et al., 2008). 
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Protein glycosylation has been shown to play a role in protein folding and trafficking, 
stability and sorting of proteins, protein-protein interactions, cell attachment, 
stimulation of signal transduction, cell-cell interactions and immunity (Stanley, 2011, 
Freeze and Ng, 2011, Moremen et al., 2012, Ungar, 2009). 
Two forms of FLT3 exist, a mature glycosylated 160 kDa protein and an 
immature unglycosylated 130 kDa protein (Stirewalt and Radich, 2003). The 130 kDa 
protein is predominantly present in FLT3-ITD expressing cells and there is 
proportionally more 160 kDa protein in FLT3-WT expressing cells (Schmidt-Arras et 
al., 2005, Koch et al., 2008). Previous studies have proven that the two forms of FLT3 
differ in size due to differences in glycosylation. In this study they showed that the 
mannose rich 130 kDa glycoprotein is exclusively present in the ER and also showed 
evidence of the 160 kDa FLT3 glycosylation to be complex (Schmidt-Arras et al., 
2005). Initially the nascent 110 kDa FLT3 polypeptide chains become glycosylated 
with mannose rich oligosaccharides in the ER to produce the 130 kDa protein. This 
protein is then subjected to partial deglycosylation by glycosidases prior to transport 
to the Golgi apparatus where further processing leads to the production of the mature 
160 kDa protein which translocates to the cell surface (Schmidt-Arras et al., 2005). 
Tunicamycin inhibits N-linked glycosylation and has been show to inhibit FLT3 
glycosylation (Choudhary et al., 2009, Williams et al., 2012) as well as prevent the 
binding of the FLT3 ligand to the receptor and consequently inhibit FLT3 activity 
(Williams et al., 2012). This data presents FLT3 glycosylation as having an important 
role in signal transduction in FLT3-ITD expressing AML. 
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1.2. Reactive oxygen species (ROS) 
Reactive oxygen species (ROS), are generally considered by-products of 
oxygen consumption and cellular metabolism (Giorgio et al., 2007, Zorov et al., 2014). 
ROS are short-lived molecules containing unpaired electrons, formed by the partial 
reduction of molecular oxygen. They are oxygen containing derivatives comprised of 
highly unstable oxygen free radicals, for example, superoxide (O2
•-) and hydroxyl 
(OH•), which can be quickly converted into more stable, freely diffusible non-radicals 
including hydrogen peroxide (H2O2) and hypochlorous acid (Dickinson and Chang, 
2011, Jayavelu et al., 2016b, Winterbourn and Hampton, 2008).  
O2
•- and H2O2 are the most well studied ROS in cancer, and H2O2 is the best 
described ROS signalling molecule (Finkel, 2011, Reczek and Chandel, 2015). It is 
important to note that although the sources of H2O2 (discussed in section 1.2.1.1) are 
important when considering its role in pro-survival in cancer, it is also important to 
understand H2O2 signalling and its interactions with downstream target molecules. 
H2O2 is distinct in its signalling activity; it oxidises nucleic acids and critical residues 
in proteins. Due to their abundance, proteins are the biomolecules most frequently  
affected by oxidation and are believed to be the main target of ROS (Davies, 2005). 
Elevated ROS levels can cause reversible post-translational modification of cysteine 
(Miki and Funato, 2012), selenocysteine (Hawkes and Alkan, 2010), methionine 
(Hoshi and Heinemann, 2001) and histidine (Lee and Helmann, 2006). For example, 
cysteines (Cys-SH) are readily oxidised by H2O2 to cysteine sulphenic acid (Cys-
SOH) or cysteine disulphide (Cys-S-S-Cys). Exposure to ROS leads to oxidation of 
thiol groups of key cysteine residues in many proteins including kinases, phosphatases 
and transcription factors (Groeger et al., 2009, Veal et al., 2007).  
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ROS have long been associated with cancer where different types of tumour 
cells have been shown to produce elevated levels of ROS compared to their normal 
counterpart (Panieri and Santoro, 2016). Increased levels of ROS are thought to be 
oncogenic, causing damage to DNA, proteins and lipids, promoting genetic instability 
and leading to tumourigenesis (Figure 1.3.) (Liou and Storz, 2010, Roy et al., 2015, 
Stanicka et al., 2015, Ames et al., 1993, Szatrowski and Nathan, 1991). 
 
1.2.1. Cellular sources and regulation of ROS 
1.2.1.1. Cellular sources of ROS 
Elevated levels of ROS and O2
•- in cancer may be as a result of reduced free 
radical scavenging enzymes, increased glucose metabolism (Warburg effect), 
increased receptor activity in the cell, oncogenic activity, increased presence of growth 
factors and cytokines. Increased intracellular oxidant production from mitochondria, 
NADPH oxidases (NOX), cyclooxygenases, lipoxygenases, xanthine oxidases and 
cytochrome P450 enzymes (Panieri and Santoro, 2016, Vander Heiden et al., 2009, 
Finkel, 2011, Holmstrom and Finkel, 2014, Sundaresan et al., 1995) results in elevated 
levels of ROS and O2
•-. Mitochondria and NADPH oxidases are two major 
contributors of endogenous ROS in cancer. Recent studies have shown that crosstalk 
exists between these two producers (Kröller-Schön et al., 2014). 
 
 
 
 
20 
 
 
 
 
Figure 1.3. Production and regulation of reactive oxygen species (ROS). Mitochondria and 
membrane bound NADPH oxidases (NOXs) are the two main contributors of endogenous ROS. O2•- is 
formed from molecular oxygen (O2) by accepting a single electron from the electron transport chain 
(ETC) in the mitochondria or from NOXs. The superoxide dismutase (SOD) enzymes convert O2•- into 
H2O2. H2O2 can then undergo Fenton chemistry with Fe2+ to form OH•, which is extremely reactive 
causing damage to DNA, proteins and lipids. H2O2 can be reduced and converted to H2O by 
peroxiredoxins (PRX), glutathione peroxidases (GPX) and catalase. H2O2 is a major signalling 
molecule involved in cancer resulting in the development and progression of the disease. 
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1.2.1.1.1 Mitochondria 
Mitochondria are one of the largest contributors to the endogenous ROS pool, 
and it has been estimated that approximately 1% of oxygen (O2) consumed by 
mitochondria is used to produce O2
•- (Handy and Loscalzo, 2012). This organelle also 
generates ATP through the oxidation of amino acids, glucose and lipids. The 
tricarboxylic acid (TCA) cycle is involved in the removal of one electron from these 
metabolites and transfer to the electron transport chain (ETC) resulting in a reduction 
of O2 to O2
•- (Sabharwal and Schumacker, 2014). Mitochondria have up to ten known 
sites capable of generating O2
•- (Goncalves et al., 2015). ROS generated from complex 
I and III of the ETC have been documented to have a role in cellular signalling 
(Murphy, 2009) (Figure 1.4.). Complex III has been shown to release O2
•- and H2O2 
into both the intermembrane space and the mitochondrial matrix, and these ROS are 
required for many biological processes including cell differentiation, oxygen cell 
sensing and adaptive immunity (Muller et al., 2004, Sena and Chandel, 2012). Most 
of the O2
•- generated in mitochondria are dismutated to H2O2 by manganese superoxide 
dismutase (MnSOD) in the mitochondrial matrix (Murphy, 2009, Buettner et al., 
2006). H2O2 is a second messenger that is highly diffusible and has been shown to 
cross the mitochondrial membrane through specific members of the aquaporin family 
(Bienert et al., 2007). 
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Figure 1.4. ROS production by the mitochondrial respiratory chain. The inner mitochondrial 
membrane-bound respiratory chain consists of complex I-V. Complex I- NADH dehydrogenase 
complex, II- succinate dehydrogenase coenzyme Q reductase, III- cytochrome b-c1 complex, IV- 
cytochrome oxidase complex and V- ATP synthase. O2•- is produced in the mitochondria at complex I 
and III of the respiratory chain during the transfer of electrons from NADPH to O2 and through the 
generation of ATP. Mitochondrial antioxidants manganese SOD (MnSOD) in the mitochondrial matrix 
and copper/zinc SOD (Cu/ZnSOD), localised to the intermembrane space, converts O2•- into membrane 
permeable H2O2.   
 
Mitochondrial ROS can have a damaging role, in addition to their cellular 
signalling properties. Deregulation of mitochondrial ROS can result in the initiation 
and progression of various cancers. Some of the cancer cases associated with elevated 
mitochondrial ROS levels include chronic lymphocytic leukaemia (CLL) (Jitschin et 
al., 2014), AML (Moloney et al., 2017b) and breast cancer (Hart et al., 2015). 
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1.2.1.1.2. NADPH oxidase (NOX) 
NADPH oxidases (NOXs) are thought to be the first family of enzymes that 
generate ROS not as a by-product, but as their primary function (Bedard and Krause, 
2007, Brewer et al., 2015). The NOX family were first described in the context of 
leukocytes where they produce ROS in response to inflammatory mediators 
(Holmstrom and Finkel, 2014). The NOX family consists of seven NOX isoforms 
NOX1-5 and dual oxidase (DUOX) 1-2, which possess similarities in terms of 
structure and enzyme function (Figure 1.5.). The seven isoforms are all 
transmembrane proteins with a NADPH-binding site, a flavin adenine dinucleotide 
(FAD)-binding site, six transmembrane domains and four heme-binding histidines. 
NOXs transfer electrons across biological membranes to produce O2
•- (Bedard and 
Krause, 2007) that is rapidly converted into H2O2. H2O2 can diffuse across the 
membrane through aquaporin channel proteins with the potential to affect multiple 
cellular signalling events (Bienert and Chaumont, 2014). Although the NOX proteins 
are structurally similar, each is activated by specific mechanisms and regulatory 
subunits. Furthermore, activation of each system is initiated in response to a variety of 
stimuli, ranging from B and T cell receptor stimulation (Jackson et al., 2004, Richards 
and Clark, 2009), inflammatory mediators including lipopolysaccharide (LPS), the 
activity of oncoproteins including FLT3-ITD in AML and BCR-ABL in chronic 
myeloid leukaemia (CML) (Naughton et al., 2009, Woolley et al., 2012), as well as 
stimulation from growth factors, including platelet-derived growth factor (PDGF) and 
tumour necrosis factor-α (TNF-α) (Brown and Griendling, 2009). 
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Figure 1.5. Activation of NOX isoforms and the production of ROS. The NOX family consists of 
seven family members NOX1-5 and DUOX1 and 2. Upon activation, the catalytic subunit removes an 
electron from cytosolic NADPH and transfers this electron to O2, to produce O2•-. p22phox is required 
for activation of NOX1-4. NOX1-3 activation also requires the recruitment of cytosolic subunits and 
RAC1. NOX5 as well as DUOX1 and 2 appear to only require Ca2+ for activation, and they contain a 
Ca2+ binding site in the EF hand region. DUOX1 and 2 also require a peroxidase-like transmembrane 
domain; however, the function of this is not known. 
 
NOX2, also known as gp91phox, is the prototype of the NOX family and was 
first identified in phagocytes. Further studies of its expression have revealed that 
NOX2 is the most widely distributed NOX isoform in humans (Bedard and Krause, 
2007). p22-phagocyte oxidase (p22phox) is a membrane partner protein and is required 
for the activation of NOX1-4 (Brandes et al., 2014, Ambasta et al., 2004). Other 
partner proteins of the NOX family include RAC1, p67phox/NOX activator 1 (NOXA1) 
and p47phox/NOX organiser 1 (NOXO1). The activation of NOX2 requires the 
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translocation of other cytosolic subunits (Groemping and Rittinger, 2005). 
Phosphorylated p47phox interacts with p22phox and organises translocation of other 
cytosolic subunits (Bedard and Krause, 2007, Groemping et al., 2003). The fully 
assembled and activated NOX2 complex allows the generation of O2
•- through the 
transfer of an electron from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) in the cytosol to oxygen in the extracellular space (Sumimoto et al., 1996).  
NOX1 is most highly expressed in the colon epithelium, but it is also expressed 
in other tissues, including endothelial cells (Ago et al., 2005, Kobayashi et al., 2004) 
and the prostate (Bánfi et al., 2000). Similarly to NOX2, NOX1 requires p22phox for 
activation. NOX1 also requires small G-protein RAC1, p47phox and p67phox in order to 
be activated (Cheng et al., 2006).  
NOX3 is primarily expressed in the octonia of the inner ear but is known to be 
expressed in lower levels in other tissues (Bánfi et al., 2004a). The regulation of NOX3 
is less well known, ROS generation requires p22phox and is enhanced by p47phox and 
p67phox (Ueno et al., 2005).  
NOX4 was originally identified as being highly expressed in the kidney, 
amongst other tissues (Cheng et al., 2001). Unlike NOX1, NOX2 and NOX3, NOX4 
only requires p22phox for activation and is constitutively activated. Insulin like growth 
factor-1 (IGF-1), bone morphogenetic protein-2 (BMP-2), transforming growth factor-
β (TGFβ) and toll like receptor 4 (TLR4) are examples of growth factors and receptors 
that have been shown to activate NOX4 without the requirement of regulatory subunits 
(Lee et al., 2007, Maloney et al., 2009, Liu et al., 2010, Mandal et al., 2011, 
Edderkaoui et al., 2011). Stimulation of IGF-1 receptor has been shown to induce 
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NOX4-generated ROS in pancreatic tumour cells, contributing to cell survival (Lee et 
al., 2007).  
NOX5 is expressed in a variety of tissues including the bone marrow, lymph 
nodes, ovary, pancreas, placenta, spleen, stomach, testis, uterus, vascular smooth 
muscle and various foetal tissues (Cheng et al., 2001). DUOX1 and DUOX2 are 
expressed mainly in the thyroid and the respiratory epithelia (Donkó et al., 2005). 
NOX5, DUOX1 and DUOX2, unlike NOX1-4 do not require p22phox or the cytosolic 
subunits for activation (Bánfi et al., 2004b, Kawahara et al., 2005b). Their activation 
is dependent on intracellular calcium levels, via binding to the calcium binding site in 
the EF hand region in the N-terminal domain, resulting in a conformational change 
and subsequent ROS production (Bánfi et al., 2004b, Bedard et al., 2012). DUOX1 
and DUOX2 contain a peroxidase-like domain. 
NOX-generated ROS production downstream of activated signalling cascades 
is tightly regulated, through the activity of antioxidants and ROS-scavenging enzymes. 
Unfortunately, deregulation of NOX ROS occurs, and this results in elevated 
production of ROS, which has been implicated in many diseases, including 
cardiovascular disease (Shah, 2015), retinal degeneration (Usui et al., 2009), diabetic 
kidney disease (Gorin and Block, 2013), asthma (van der Vliet, 2011), Alzheimer’s 
and Parkinson’s diseases (Gao et al., 2012). 
The important role of NOX proteins is well established and documented 
downstream of various signalling transduction cascades. NOX-generated ROS often 
act as secondary signalling molecules downstream of growth factor stimulation 
(Sundaresan et al., 1995). It is not surprising that the activity of NOX proteins can be 
deregulated by the aberrant tyrosine kinase activity as a result of oncogenic signalling, 
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for example, FLT3-ITD in AML (Stanicka et al., 2015). Increased NOX-derived ROS 
in cancer has two roles; stimulation of cell survival and genomic instability, the two 
most influential characteristics of cancer progression (Gough and Cotter, 2011). 
Elevated levels of NOX-derived ROS are involved in the transformation and 
progression of many common cancers including: bladder, breast, colon and rectal, 
kidney, leukaemia, lung, melanoma, oesophagus, ovarian, pancreatic, prostate, 
stomach and thyroid (Table 1.2.). In these cancers, NOX proteins have been shown to 
drive oncogenesis through proliferation, cell survival, metastasis, invasion, 
angiogenesis and increased genomic instability (Block and Gorin, 2012).  
 
Cancer type NADPH oxidase References 
Bladder NOX1 (Shimada et al., 2009) 
 NOX4 (Shimada et al., 2011) 
Breast NOX1 (Desouki et al., 2005, Choi et al., 2010) 
 NOX5 (Juhasz et al., 2009) 
Colon and rectal NOX1 (Juhasz et al., 2009, Fukuyama et al., 2005) 
 NOX4 (Bauer et al., 2012) 
Kidney NOX1 (Block et al., 2010) 
 NOX4 (Block et al., 2010, Block et al., 2007) 
Leukaemia NOX2 (Juhasz et al., 2009, Prata et al., 2008) 
 NOX4 (Stanicka et al., 2015, Prata et al., 2008, Naughton et 
al., 2009) 
 NOX5 (Kamiguti et al., 2005) 
Lung NOX4 (Han et al., 2016) 
 DUOX1/2 (Luxen et al., 2008) 
Melanoma NOX2 (Aydin et al., 2017) 
 NOX4 (Brar et al., 2002) 
 NOX5 (Juhasz et al., 2009) 
Oesophagus NOX5 (Fu et al., 2006) 
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Ovarian NOX1 (Desouki et al., 2005) 
 NOX4 (Juhasz et al., 2009, Xia et al., 2007, Graham et al., 
2010) 
Pancreatic NOX4 (Vaquero et al., 2004) 
Prostate NOX1 (Arnold et al., 2007, Lim et al., 2005) 
 NOX2 (Kumar et al., 2008) 
 NOX4 (Kumar et al., 2008) 
 NOX5 (Brar et al., 2003, Huang et al., 2012) 
 DUOX1/2 (Pettigrew et al., 2012) 
Stomach NOX1 (Kawahara et al., 2005a, Tominaga et al., 2007) 
Thyroid NOX4 (Weyemi et al., 2010) 
 
Table 1.2. NOX isoforms expression in common cancer types. 
 
1.2.1.1.3. Other enzymes 
In addition to mitochondria and NOX proteins, there are several other sources 
of ROS including cyclooxygenases (COXs), lipoxygenases, xanthine oxidases, nitric 
oxide synthases and cytochrome P450 enzymes. Elevated production of ROS from 
these enzyme systems is also linked to cancer (Moloney and Cotter, 2017).  
 
1.2.1.2. Regulation of ROS 
ROS homeostasis is essential for cell survival and normal cell signalling, 
preventing cells from damage (Figure 1.6.). Detoxification of ROS is achieved by non-
enzymatic or enzymatic antioxidants which are involved in scavenging of different 
types of ROS. Non-enzymatic molecules include glutathione, flavonoids, vitamin A, 
C and E. Enzymatic antioxidants include superoxide dismutase (SOD), superoxide 
reductase, catalase, glutathione peroxidase (GPX), glutathione reductase, 
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peroxiredoxin (PRX) and thioredoxin (TRX).  Antioxidants have an important role in 
the degradation of O2
•- and H2O2, preventing oxidative damage and maintaining a 
reduction-oxidation (redox) balance.  
SODs are metalloenzymes located in various cellular compartments and are 
involved in rapid conversion of O2
•- to H2O2.  SOD1 (Cu/ZnSOD) is located in the 
cytosol, SOD2 (MnSOD) is located in the mitochondria and SOD3 (Cu/ZnSOD) is 
extracellular. SODs utilise metal ions, such as copper (Cu2+), iron (Fe2+), manganese 
(Mn2+) and zinc (Zn2+) as cofactors (Fukai and Ushio-Fukai, 2011). 
Various antioxidants exist to maintain H2O2 levels for cellular signalling, by 
reduction of intracellular H2O2 to H2O. Some of the antioxidants involved in this 
conversion include: catalase, glutathione peroxidase (GPX), peroxiredoxins (PRX) 
and thioredoxin (TRX) (Reczek and Chandel, 2015). PRXs and TRXs facilitate in the 
reduction of peroxynitrites and hydroperoxides to water (H2O) through oxidation of 
their cysteine residues (Wood et al., 2003, Cox et al., 2010).  
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Figure 1.6. Model of ROS effects in cells. Healthy cells have developed adequate adaptations to 
overcome the damaging effects of ROS. Balanced generation of ROS, sufficient antioxidant activity 
and cellular repair result in low concentrations of ROS, resulting in limited cell survival and 
proliferation. Metabolic activity of tumour cells yields high ROS concentrations enhancing cell survival 
and proliferation leading to DNA damage, decreased cellular repair by faithful DNA damage repair 
pathways and genetic instability. Elevated ROS levels can cause cellular damage; however, tumour 
cells readjust with adequate adaptations to conditions, including hypoxia, and also through activation 
of unfaithful alternative cellular repair pathways. Tumour cells express increased antioxidant activity 
to remove excessive ROS while maintaining pro-tumourigenic signalling. If ROS levels increase 
dramatically to toxic ROS concentrations, for example, by ROS-inducing agents such as chemotherapy, 
oxidative stress results in irreparable damage to the cell, inadequate adaptations and eventually tumour 
cell death. 
 
As mentioned already, tumour cells produce elevated levels of ROS compared 
to their normal cell counterparts, which are involved in the initiation and progression 
of cancer. The overproduction of ROS can be the result of oncogene activation, 
increased cellular metabolism and diminished tumour suppressor activity. However, 
the regulation of ROS in tumour cells must be tightly regulated to prevent tumour cell 
death. An overproduction of ROS results in increased antioxidant levels and 
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scavenging enzymes. However, antioxidant capacity cannot cope with high 
concentrations of ROS in cancer and is involved in the maintenance of pro-
tumourigenic signalling, allowing the disease to progress and develop resistance to 
apoptosis (Gorrini et al., 2013). Several mechanisms in which ROS overcome 
antioxidant functions will be mentioned here. Elevated ROS production in cancer can 
lead to increased SOD protein expression (Janssen et al., 1999, Miranda et al., 2000), 
inactivation of H2O2 scavenging enzymes (Toledano et al., 2010), inactivation of 
tumour suppressor gene and protein tyrosine phosphatase (PTP) phosphatase and 
tensin homolog (PTEN) alongside oxidation and inactivation of many other PTPs 
(Leslie et al., 2003). Cancer has also been linked to mutations in transcription factors, 
for example, Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and also mutations in 
tumour suppressor genes including p53 (see section 1.3.1.), both of which are involved 
in increased antioxidant production, all of which contribute to ROS overcoming 
antioxidant capabilities, resulting in disease progression.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
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1.3. ROS signalling in cancer 
ROS also act as signalling molecules in cancer, contributing to abnormal cell 
growth, metastasis, resistance to apoptosis, angiogenesis and in some types of cancer, 
a differentiation block (Sabharwal and Schumacker, 2014, Moloney et al., 2017b). The 
overproduction of ROS in cancer has been shown to induce a variety of biological 
effects including enhanced cell proliferation, DNA damage and genetic instability, 
adaptation, cellular injury and cell death, autophagy and resistance to drugs (Moloney 
and Cotter, 2017). The outcome is dependent on the genetic background of the cancer, 
the types of ROS involved (O2
•- , H2O2, etc.) and the levels and duration of ROS 
exposure. 
 
1.3.1. Enhanced cell proliferation and cell survival 
ROS have a well-established role in cell signalling. An increase in ROS, such 
as O2
•- and H2O2, has been implicated in enhanced cell proliferation (Hole et al., 2013), 
increased cellular growth, cell survival and in the development of cancer through the 
regulation of mitogen activated-protein kinase (MAPK)/extracellular signal-regulated 
kinase 1/2 (ERK1/2) (Irani et al., 1997, Roberts and Der, 2007, Steelman et al., 2008), 
phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) (Liu et al., 2006) and 
protein kinase D (PKD) signalling pathways (Storz and Toker, 2003, Wang et al., 
2004b, Liou et al., 2016). Additionally through the negative regulation of 
phosphatases, PTEN and protein tyrosine phosphatase 1B (PTP1B) (Lee et al., 2002, 
Salmeen et al., 2003, Wu et al., 2003), regulation of nuclear factor-κB (NF-κB) 
activating pathways (Duffey et al., 2000, Ahmed et al., 2006, Wang et al., 2007), as 
well as mutations in transcription factors and tumour suppressor genes including Nrf2 
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(Padmanabhan et al., 2006, Yoo et al., 2012, No et al., 2014) and p53 (Levine and 
Oren, 2009, Kruiswijk et al., 2015) (Figure 1.7.). 
 
 
Figure 1.7. ROS-induced cellular signalling in cancer. Elevated ROS production in cancer has been 
shown to have a role in pro-tumourigenic and anti-tumourigenic signalling. Increased ROS levels 
contribute to sustained cell survival and proliferation through many pathways including PI3K/AKT, 
MAPK/ERK1/2 and PKD and inactivation of their downstream targets including Bad, Bax, Bim, Foxo 
(Brunet et al., 1999, Pastorino et al., 1999, Limaye et al., 2005, Xin and Deng, 2005, Qi et al., 2006, 
Kawamura et al., 2007) and PTEN. Elevated ROS production has also been linked to inhibition of the 
JNK pathway. However, toxic levels of ROS in the cell is known to cause cell death initiated by intrinsic 
apoptotic signalling in the mitochondria or extrinsic apoptotic signalling by death receptor pathways. 
Toxic ROS levels cause damage to the mitochondrial membrane resulting in the release and 
translocation of cytochrome c to the cytoplasm. Cytochrome c forms a complex with apoptotic protease 
activating factor-1 (Apaf-1) and pro-caspase 9 which induces the cleavage of caspase-3 and 7 resulting 
in apoptosis. Binding of TNFα ligand to TNFR1 death receptor triggers the activation of the initiator 
caspase 8 resulting in cleavage of caspase 3. Caspase 8 activation also induces cleavage of Bcl-2 BH3 
domain-only death agonist protein (Bid) to tBid feeding back into the release of cytochrome c in the 
intrinsic apoptotic pathway. 
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1.3.2. DNA damage and genetic instability 
Genomic instability has been suggested to be a major driving force of 
oncogenesis and can account for genetic diversity in many cancers (Loeb et al., 2003, 
Sieber et al., 2003). The initiation and progression of various cancers is associated 
with the accumulation of multiple mutated genes, resulting in abnormal cell growth, 
cell survival and in some cases a block in cell differentiation. Tumour cells require 
some form of genetic instability to allow the tumour cell to evolve and drive 
tumourigenesis (Sieber et al., 2003). The overproduction of ROS is associated with an 
increase in DNA damage, and this may be important in terms of genetic instability 
(Hole et al., 2011). DNA damage causes oxidation of DNA, resulting in a variety of 
alterations to DNA including deletions, insertions and base pair mutations and double 
strand breaks (dsbs), which are one of the most deleterious lesions resulting in 
deletions and translocations (Cooke et al., 2003, Pelicano et al., 2004). Insufficient 
repair of DNA damage and dsbs by non-homologous end joining (NHEJ) and 
homologous recombination are also involved in the generation of genomic instability 
(Jayavelu et al., 2016b). DNA damage and genetic instability in FLT3-ITD expressing 
AML is discussed in greater detail in section 1.4.3. 
 
1.3.3. Adaptation 
Cells employ a variety of adaptation mechanisms in response to ROS and 
oxidative stress. The antioxidant system in cells is a form of defence against elevated 
ROS production as mentioned previously in section 1.2.1.2. In order to maintain a 
redox balance, increased ROS levels leads to up-regulation of antioxidant system 
activity. However, as already mentioned this adaptation in tumour cells is very limited. 
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Increased activity of antioxidants such as SOD2/MnSOD or inactivation of scavenging 
enzymes including PRX1 are both observed in the development and progression of 
cancers (Janssen et al., 1999, Miranda et al., 2000, Toledano et al., 2010).  
Tumour cells acquire adaptations under hypoxic conditions. Hypoxia arises in 
primary or metastatic tumours as a result of a deficiency in O2 supply to the tumours. 
Prolonged exposure to hypoxia in normal cells results in cell death. Tumour cells adapt 
to hypoxia through a metabolic switch activating glucose metabolism, a phenomenon 
known as the Warburg effect, and this contributes to an aggressive phenotype (Dang 
and Semenza, 1999, Harris, 2002). Tumour cells utilise glycolysis regardless of 
sufficient O2 supply (Dang, 2012). Previous studies show tumour cells adapt to 
glucose-deprivation through the increase of glycolysis to prevent H2O2 induced cell 
death (Aykin-Burns et al., 2009).  
 
1.3.4. Cell death 
Toxic levels of ROS in cells are known to induce cell cycle arrest, apoptosis 
and senescence (Figure 1.7.) (Moon et al., 2010, Moloney and Cotter, 2017). A 
disproportional increase in ROS can be achieved with chemotherapy, elevated ROS 
generation by immune cells or by depletion of antioxidant proteins within cells (Liou 
and Storz, 2010). Activation of the c-Jun N-terminal protein kinase (JNK) pathway by 
elevated ROS production can result in apoptosis initiated by intrinsic apoptotic 
signalling in the mitochondria or extrinsic apoptotic signalling by death receptor 
pathways (Carmody and Cotter, 2001, Dhanasekaran and Reddy, 2008, Pelicano et al., 
2003). Inactivating JNK pathway mutations have been observed in various cancers 
suggesting that this pathway may be implicated in apoptotic signalling (Kennedy and 
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Davis, 2003). Activation of caspases is one of the most understood hallmarks of 
apoptosis and ultimately results in cleavage of poly ADP ribose polymerase (PARP), 
DNA fragmentation and cell death (Groeger et al., 2009). Elevated ROS can directly 
affect caspase function in the intrinsic- and extrinsic-apoptotic pathways. 
Overproduction of ROS may also effect the activity of apoptotic effectors including 
the B-cell lymphoma 2 (Bcl-2) family of proteins and cytochrome c (Groeger et al., 
2009).  
 
1.3.5. Autophagy 
Autophagy is the controlled lysosomal pathway involved in the degradation 
and recycling of proteins and organelles within a cell that regulates cellular 
homeostasis (Poillet-Perez et al., 2015). It is one of the first defences against oxidative 
stress damage and has been found to be up-regulated in response to elevated ROS 
levels (Li et al., 2012). Impaired autophagy is observed in various pathologies 
including cancer, Crohn’s disease, diabetes and neurodegenerative disorders 
including, Alzheimer’s and Parkinson’s diseases (Tal et al., 2009, Quan et al., 2012). 
Deregulated autophagy has also been found to have a role both in tumour progression 
(Aita et al., 1999, Liang et al., 1999, Choi et al., 2013, Laddha et al., 2014) and tumour 
suppression (Morselli et al., 2009, Debnath, 2011, Komatsu et al., 2010) in response 
to elevated ROS production. The relationship between elevated ROS levels and 
autophagy in cancer is quite complex. 
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1.3.6. Resistance to drugs 
Elevated ROS production in cancer has major implications for drug therapy. 
As mentioned previously, increased ROS production results in pro-tumourigenic 
signalling, enhanced cell proliferation and survival, genetic instability and DNA 
damage and also metabolic adaptations, all of which contribute to drug resistance and 
further progression of cancer. DNA oxidation and dsbs generated by the 
overproduction of ROS results in the accumulation of multiple mutations, contributing 
to an increased risk of tumour cells developing resistance to therapies used. DNA 
damage-driven drug resistance to the frequently used protein tyrosine kinase 
inhibitors, midostaurin and imatinib, is observed in both AML and CML (Stanicka et 
al., 2015, Skorski, 2002, Skorski, 2007, Nowicki et al., 2004). 
 
1.3.7. Current strategy for targeting ROS in cancer therapy 
The pro-tumourigenic and anti-tumourigenic signalling effects of ROS can be 
manipulated in the treatment of cancer to prevent ROS production or to induce tumour 
cell death. 
1.3.7.1. Increasing ROS levels to drive oxidative stress-induced tumour 
cell death 
Anti-tumourigenic signalling of ROS can be targeted as a therapy in cancer, 
by the increased production of ROS levels to toxic levels and exhaustion of the 
antioxidant system capacity causing programmed cell death. Chemotherapy is widely 
used in the treatment of cancer and is known to increase ROS production resulting in 
irreparable damage and cell death. Examples of chemotherapy drugs used include, 
anthracyclines, cisplatin, bleomycin, arsenic trioxide (Pelicano et al., 2004). 
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Daunorubicin, an anthracycline, is used in the treatment of AML, acute lymphoblastic 
leukaemia (ALL) and acute promyelocytic leukaemia (APL). It reacts with 
cytochrome P450 reductase (Goodman and Hochstein, 1977, Pan et al., 1981) in the 
presence of reduced NADPH to form semiquinone radical intermediates (Bachur et 
al., 1977, Bates and Winterbourn, 1982) that react with O2 to form O2
•- (Bachur et al., 
1977, Bachur et al., 1978, Bustamante et al., 1990, Benchekroun et al., 1993). This 
leads to increased activation of neutral sphingomyelinase enzyme and increased 
ceramide, resulting in activation of the JNK pathway leading to apoptosis (Mas et al., 
1999, Gouazé et al., 2001). Doxorubicin is another widely used anthracycline in the 
treatment of a broad spectrum of cancers, including breast and oesophageal 
carcinomas, endometrial carcinomas, bile duct, pancreatic, gastric, liver, Hodgkin’s 
and non-Hodgkin’s lymphoma, osteosarcoma, Kaposi’s sarcoma and soft tissue 
sarcomas (Singal  and Iliskovic 1998, Buzdar et al., 1985). It causes increased 
production of ROS and activation of the tumour suppressor p53, resulting in tumour 
cell death (Wang et al., 2004a, Lotem et al., 1996). Chemotherapy may be used in 
combination with radiotherapy, amongst other treatments including immunotherapy, 
hormone therapy and surgery. Sulindac, a nonsteroidal anti-inflammatory drug 
(NSAID), has been shown to elevate ROS production in the treatment of colon and 
lung cancer, resulting in damage to the mitochondrial membrane and tumour cells 
becoming more sensitive to H2O2-induced cell death (Marchetti et al., 2009). 
As mentioned previously, tumour cells adapt to oxidative stress through 
increased glucose metabolism resulting in increased ROS generation. Adaptations 
resulting in increased glucose metabolism are involved in cell survival, inhibiting 
apoptosis through the redox inactivation of cytochrome c (Vaughn and Deshmukh, 
2008). Glucose inhibition using 2 deoxy-glucose (2DG) causes elevated ROS 
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production and results in cell death in pancreatic and prostate cancer (Ahmad et al., 
2008, Coleman et al., 2008). 
Previous work in our laboratory has reported how an isoellipticine derivative, 
7-hydroxyisoellipticine induces apoptosis in AML cells (Russell et al., 2014). More 
recently, we have shown a more potent isoellipticine derivative, 7-formyl-10-
methylisoellipticine, induces increased mitochondrial ROS production and 
cytotoxicity in AML. This significantly delays the tumour growth in vivo, with no 
cytotoxic effects to any organs (Russell et al., 2016). 
 
1.3.7.2. Suppressing ROS levels to prevent tumour cell proliferation 
Inhibition of ROS production in tumour cells could well result in suppressed 
pro-tumourigenic signalling. Reduction in ROS levels would lead to decreased cell 
survival and proliferation, fewer metabolic adaptations and lower levels of DNA 
damage and genetic instability. 
Metformin, used in the treatment of type 2 diabetes is a known inhibitor of 
complex I of the mitochondrial ETC and has been found to reduce cancer incidence 
and mortality (El-Mir et al., 2000, Owen et al., 2000, Wheaton et al., 2014, Noto et 
al., 2012). Metformin has been shown to have pro-apoptotic effects in pancreatic 
cancer, through the increased protein expression of MnSOD/SOD2 and decreased 
levels of NOX2 and NOX4 proteins (Cheng and Lanza-Jacoby, 2015). 
Studies have shown, inhibition of NOX-generated ROS results in decreased 
pro-tumourigenic effects in various cancers. Suppressed NOX4-generated ROS 
production in pancreatic cancer treated with flavoprotein inhibitor 
diphenyleneiodonium (DPI) resulted in apoptosis via the AKT/apoptosis signal-
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regulating kinase 1 (ASK1) pathway (Mochizuki et al., 2006). Recent studies in our 
laboratory have shown, inhibition of the protein tyrosine kinase FLT3-ITD, as well as 
inhibition of p22phox and NOX4 activity in AML cells, results in decreased cell 
survival, as well as a decrease in DNA damage and genomic instability. This identifies 
NOX as a potential target in the treatment of FLT3-ITD expressing AML (Stanicka et 
al., 2015). 
Treatment with antioxidants is thought to dampen ROS production in cancer 
through scavenging systems. Studies have shown that the overexpression of 
antioxidant SOD3 reduced breast cancer metastasis in vivo, implicating antioxidants 
in the reduction of ROS in cancer therapy (Teoh-Fitzgerald et al., 2014). However, 
antioxidants have also been linked to increased incidence of cancer. Vitamin A and E 
and also carotene have been linked to an increased risk of cancer (Omenn  et al., 1996, 
Klein et al., 2011). These mixed results show the complexity of antioxidants in the 
treatment of cancer.  
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1.4. NOX-driven ROS formation in cell transformation of 
FLT3-ITD-positive AML 
1.4.1. Oncogenic kinases as drivers of ROS formation in myeloid 
leukaemia 
Disease progression in leukaemia is caused by the accumulation of mutated 
genes resulting in resistance to apoptosis, abnormal cell  growth and differentiation 
(Blume-Jensen and Hunter, 2001). Many genetic mutations have been identified in 
myeloid leukaemia, yet the mechanism in which these mutations lead to genetic 
instability remains unclear. Tumour cells must acquire some form of genetic instability 
as the normal rate of mutation is not sufficient for the oncogenic transformation (Loeb 
et al., 2003). Reactive oxygen species (ROS), for example, H2O2, are considered to 
play an important function in leukaemia (Rhee, 2006). Increasing evidence has shown 
that genetic alterations in the genes associated with the myeloid malignancies is linked 
to an increase in reactive oxygen species (ROS), which is associated with an increase 
in DNA damage.  
More than 90% of chronic myelogenous leukaemia (CML) cases develop from 
a chromosomal abnormality known as the Philadelphia chromosome (Achkar et al., 
2010), which results from a reciprocal translocation between chromosomes 9 and 22 
(Rowley, 1973), generating the chimeric kinase BCR-ABL (Shtivelman et al., 1985). 
BCR-ABL is known to activate downstream pro-survival pathways, for example, 
PI3K/AKT, JAK/STAT and Raf/MEK/ERK, resulting in resistance to apoptosis and 
proliferation (Steelman et al., 2004). BCR-ABL expressing cells have been shown to 
generate increased levels of ROS compared to untransformed cells (Kim et al., 2005). 
Various sources of ROS have been examined in CML including leakage from the 
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mitochondrial electron transport chain and NADPH oxidase-generated ROS, 
particularly NOX4. Naughton et al., demonstrated NOX4-generated ROS contribute 
significantly to total endogenous ROS upon BCR-ABL induction (Naughton et al., 
2009). Treatment of CML cells with the BCR-ABL inhibitors, imatinib and nilotinib 
showed a significant decrease in ROS. This coincides with a post-translational down- 
regulation of the small membrane-bound protein p22phox, a key component of the NOX 
complex (Ambasta et al., 2004). Treatment of BCR-ABL expressing cells with NOX 
inhibitors, DPI or VAS2870, resulted in a reduction in ROS levels. Inhibition of both 
the PI3K/AKT and Raf/MEK/ERK pathways in combination resulted in p22phox down-
regulation. BCR-ABL induced, NOX4-generated ROS are dependent on PI3K/AKT 
and Raf/MEK/ERK activation and glycogen synthase kinase-3 β (GSK3β) inhibition 
(Landry et al., 2013). Mitochondrial ROS also appear to contribute to total ROS in 
CML cells.  
FLT3-ITD is the most frequent FLT3 mutation present in acute myeloid 
leukaemia (AML) patients and has been associated with a poor outcome (Stirewalt 
and Radich, 2003, Small, 2008). In fact, FLT3 is the most frequently mutated gene in 
AML (Gilliland and Griffin, 2002). FLT3-ITD mutation result in ligand independent 
constitutive activation of the FLT3 receptor both at the plasma membrane and the 
endoplasmic reticulum (Choudhary et al., 2009, Moloney et al., 2017b). Constitutive 
auto-phosphorylation of FLT3-ITD activates downstream pro-survival signalling 
pathways including PI3K/AKT, JAK/STAT and Raf/MEK/ERK (Choudhary et al., 
2005a), which are known to promote survival, proliferation and transformation 
(Hayakawa et al., 2000, Brandts et al., 2005). Recent findings have identified that in 
order for PI3K/AKT and Raf/MEK/ERK pro-survival pathways to be activated they 
must be located downstream of FLT3-ITD at the plasma membrane, and signal 
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transducer and activator of transcription 5 (STAT5) is located downstream of FLT3-
ITD at the ER (Choudhary et al., 2009). FLT3-ITD expressing cell lines have been 
shown to produce increased levels of ROS, DNA oxidation and double strand breaks 
(dsbs) compared to FLT3-wild type (FLT3-WT) expressing cell lines (Godfrey et al., 
2012, Sallmyr et al., 2008b). NOX-generated ROS have been identified as the primary 
source of ROS in FLT3-ITD expressing AML cells. Mutated FLT3 cells have been 
shown to produce increased levels of NOX2 and NOX4 and their partner protein 
p22phox, compared to wild-type FLT3 cells. Stimulation of FLT3-WT expressing cells 
with FLT3 ligand results in an increase in p22phox protein levels and endogenous H2O2 
(Stanicka et al., 2015). There is no significant difference in mitochondrial ROS in 
FLT3-ITD and FLT3-WT cells (Stanicka et al., 2015). Thus, it can be said that NOX-
generated ROS are a potential target for treatment of leukaemia. 
Adaption to higher concentrations of ROS by stimulation of survival 
mechanisms and antioxidant systems may well give cells a mechanism for the 
induction of resistance to drugs. This coincides with the high relapse risk associated 
with FLT3-ITD expressing AML cases. 
 
1.4.2. ROS-mediated alteration of transforming signal transduction: 
Role of PTP oxidation 
Protein phosphorylation of tyrosine residues plays a fundamental role in 
diverse cellular functions including proliferation, growth, metabolism, and 
differentiation. Protein-tyrosine kinase (PTK)-mediated signal transduction is 
regulated by protein-tyrosine phosphatases (PTPs), and failure of regulation of either 
protein family can contribute to unfavourable diseases like cancer. The human PTP 
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superfamily consists of more than 100 members. Many of these enzymes are identified 
by the unique consensus signature motif HCX5R involved in the catalytic function. 
Despite their sequence and structural similarity, PTPs exhibit a wide range of substrate 
specificity (Alonso and Pulido, 2016, Tonks, 2013). 
Several members of the PTP superfamily were found to be altered by genetic 
aberration, promoter methylation, or gene overexpression in AML. Protein tyrosine 
phosphatase non-receptor 11 (PTPN11) (also known as Src homology region 2-
containing protein tyrosine phosphatase 2 (SHP-2)) positively regulates FLT3 ligand 
(FL)-mediated FLT3 receptor signalling (Muller et al., 2008), and not surprisingly, 
activating mutations (commonly found SHP-2 E76K (glutamic acid substituted with a 
lysine at amino acid 76) mutant) were identified in AML (Tartaglia et al., 2003, 
Nabinger et al., 2013). Phosphatase PTEN negatively regulates PI3K signalling 
downstream of the FLT3 receptor and is also mutated, though rarely in AML (Patel  et 
al., 2012). Several recent findings claim a role for deregulated gene expression of dual-
specificity phosphatases, such as phosphatase of regenerating liver 2 and 3 (PRL2 and 
PRL3) and dual-specificity phosphatase 6 (DUSP6), in AML cases in the presence and 
absence of a FLT3 mutation (Park et al., 2013, Zhou et al., 2011, Arora et al., 2012). 
Recently, suppressor of T cell signalling proteins 1 and 2 (STS1 and STS2) (also 
known as ubiquitin-associated and SH3 domain containing protein 3B and 3A 
(UBASH3B and UBASH3A)), which belong to a PTP subfamily with histidine-based 
catalysis (Alonso and Pulido, 2016), were identified to be directly regulating the FLT3 
receptor tyrosine phosphorylation in haematopoietic stem cells (Zhang et al., 2015). 
However, their potential role in regulating constitutively activated FLT3-ITD 
phosphorylation or FLT3 signalling in AML remains unknown. Other examples 
include the transmembrane PTP protein tyrosine phosphatase receptor type D 
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(PTPRD/PTPδ), which is down-regulated by promoter methylation and may be a 
tumour suppressor in paediatric AML (Song et al., 2016), and CDC25, which is 
mutated in familial platelet disorder with predisposition to AML (Yoshimi et al., 
2014). 
PTPs can modulate signal transduction in many ways, both negatively and 
positively. For example, they prevent the nonspecific activation of PTKs, for example, 
by averting the ligand-independent activation of RTKs. In other contexts, PTPs can 
promote signalling by activation of Rous sarcoma oncogene cellular homolog (Src) 
family kinases or of the RAS pathway (Tonks, 2013). PTP activity is regulated by 
several mechanisms (Hertog et al., 2008), and one such regulatory process is the 
reversible oxidation of the catalytic cysteine by ROS. H2O2 is considered an important 
ROS species in the PTP oxidation process. Upon oxidation, the active-site thiol moiety 
(–SH) is converted to a sulphenyl moiety (–SOH), which further reacts to more stable 
reaction products, like sulphenylamides or disulphides, in intramolecular reactions. 
The widely presumed role of H2O2 in PTP oxidation may in fact be 
indirect (Winterbourn and Hampton, 2008), and other oxidants, such as lipid 
peroxides, can also effectively oxidise PTPs (Östman et al., 2011, Conrad et al., 2010). 
PTP oxidation is typically transient, and reduction back to the active state is 
accomplished by interaction with cellular antioxidants like glutathione (GSH) and 
thioredoxin (Östman et al., 2011). Reversible PTP inactivation facilitates the efficient 
RTK signal transduction in the cells on ligand/growth factor stimulation (Holmstrom 
and Finkel, 2014). Emerging reports claim, however, that PTPs are also important 
targets of pathologically generated ROS, and that in such circumstances, ROS-
mediated PTP inactivation could contribute to diseases like cancer. In support that 
such processes play a role in leukaemia, an early study indicated that high ROS levels 
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in BCR-ABL-transformed cells were associated with low levels of overall PTP 
activity, and treatment with antioxidants reversed these effects (Sattler et al., 2000). 
As outlined above, apart from BCR-ABL, other myeloid leukaemia-specific PTK 
oncoproteins including FLT3-ITD also cause constitutive formation of elevated levels 
of ROS, and their possible consequences for PTP deregulation deserve attention.  
The transmembrane PTP protein tyrosine phosphatase receptor type J  (PTPRJ; 
also known as density-enhanced phosphatase-1 (DEP-1) or CD148) was previously 
identified as bona fide PTP negatively regulating FLT3 receptor signalling in myeloid 
cells (Arora et al., 2011). DEP-1 regulates FL-induced FLT3 receptor signalling by 
associating with (Böhmer et al., 2013) and dephosphorylating FLT3 directly, thereby 
attenuating the activation of FLT3. When the role of DEP-1 in the regulation of the 
FLT3-ITD oncoprotein was analysed, DEP-1 was discovered to be oxidised and 
partially inactivated because of high levels of sustained ROS generation, leading to 
elevated FLT3 activity. This promotes downstream signalling pathways, including 
STAT5 and RAS/ERK1/2 activation, and causally contributes to cellular 
transformation (Godfrey et al., 2012). Recently, investigation of the relevant ROS 
sources convincingly indicated that NOX4 messenger RNA (mRNA) and protein 
levels are elevated in FLT3-ITD-positive AML cells and that NOX4 expression is 
transcriptionally regulated by STAT5 directly (Jayavelu et al., 2016a). 
The NOX4 promoter possesses STAT binding elements, and STAT5 was found by 
chromatin immunoprecipitation (ChIP) assays to bind to these elements in a FLT3-
ITD-dependent manner. General interference with ROS formation by different means 
including down-regulation of NOX4 with RNA interference (RNAi) or treatments 
with potential small molecule NOX4 inhibitors caused a pronounced decrease in ROS 
levels, rescued DEP-1 PTP activity, and attenuated transforming FLT3-ITD-driven 
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signalling and cell transformation in vitro and in vivo. Double depletion of DEP-1 and 
NOX4 partially rescued the effect of NOX4 depletion on transformation in vitro, 
suggesting that DEP-1 reactivation is essential for the inhibitory effect of NOX4 
depletion. Interestingly, murine haematopoietic stem cells transduced with a 
combination of FLT3-ITD and other potent oncogenic drivers (Homeobox A9 
(Hoxa9)/Meis homeobox1 (Meis1) or MLL-AF9), and with genetic inactivation or 
down-regulation of NOX4, did not grow in the absence of cytokines in vitro, and were 
impaired in their capacity to elicit a myeloproliferative disease in sub-lethally 
irradiated recipient mice in vivo, respectively (Jayavelu et al., 2016a). These findings 
revealed an important role played by NOX4-dependent ROS formation in oxidation 
of DEP-1, a bona fide PTP of FLT3, as a transforming event in FLT3-ITD harbouring 
aggressive AML (Figure 1.8.). It will be interesting to know whether NOX4-
dependent, oxidative inactivation of DEP-1 is a selective mechanism or reflects a more 
general attenuation of PTPs in FLT3-ITD cells. Although NOX4 may indeed be of 
interest as a therapeutic target in FLT3-ITD subtype AML, there are still several other 
potential sources of ROS formation whose investigation is warranted. 
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Figure 1.8. Role of ROS formation in leukaemic cell transformation by the oncoprotein FLT3-
ITD. FLT3-ITD causes elevated ROS levels in AML cells. This involves activation of STAT5, which 
can directly bind to the promoter of NADPH oxidase 4 (NOX4), leading to elevated transcription. 
Increased NOX4 levels cause elevated formation of ROS, which oxidise the catalytic cysteine of 
density-enhanced phosphatase-1 (DEP-1; a transmembrane protein-tyrosine phosphatase, also known 
as PTPRJ or CD148). In contrast to its activity in normal cells, the oxidised and thereby (reversibly) 
inactivated DEP-1 can no longer dephosphorylate FLT3-ITD, enabling elevated signal transduction and 
promoting cell transformation. 
 
1.4.3. ROS-mediated DNA damage and potential implications for 
leukaemia biology 
Genomic instability has been suggested to be the main cause of genetic 
diversity in cancer (Sieber et al., 2003). FLT3-ITD mutation initiates a cycle of 
genomic instability- increased production of ROS leads to enhanced DNA damage 
(DNA oxidation and double strand breaks (dsbs)) and compromised DNA error repair, 
by alternative, less well-defined, end joining pathways, causing an aggressive 
phenotype of AML (Sallmyr et al., 2008b).  
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As mentioned ROS contribute to the initiation, promotion and progression of 
cancers, including leukaemia. Oxidative DNA damage can cause a wide range of DNA 
alterations such as base pair mutations, insertions and deletions (Cooke et al., 2003). 
Dsbs are one of the most dangerous lesions resulting in translocations and deletions. 
Alternative mechanisms involved in the generation of genomic instability include 
unfaithful or insufficient repair of DNA damage (Pelicano et al., 2004). There are two 
DNA repair systems responsible for DNA dsb repair: a precise homologous 
recombination and a less precise non-homologous end-joining (NHEJ) (Sallmyr et al., 
2008b). In cancer, alternative end-joining (AEJ) plays a significant role and results in 
severe errors in DNA damage. Increased expression of the unfaithful AEJ repair 
pathway and down-regulation of the faithful NHEJ pathway is associated with FLT3-
ITD and BCR-ABL oncogenic signalling (Fan et al., 2010). It has also been shown 
that increased repair of FLT3-ITD stimulated DNA damage contributes to drug 
resistance, which coincides with the high relapse rate associated with FLT3-ITD 
expressing AML cases. 
FLT3-ITD expressing cells have been shown to generate increased levels of 
ROS, resulting in excessive DNA damage in comparison to FLT3-WT expressing 
cells, and have been shown to activate alternative unfaithful pathways of DNA repair, 
leading to an increase in levels of unrepaired DNA damage (Sallmyr et al., 2008b). 
p22phox and p22phox dependent NOX isoforms, particularly NOX4, have been shown 
to be the primary source of ROS in FLT3-ITD expressing cells (Woolley et al., 2012). 
A significant amount of research has been carried out to investigate the effects of 
FLT3-ITD generated NOXs on genomic instability in AML, examining nuclear levels 
of H2O2. Inhibition of FLT3-ITD, NOX and p22
phox (by siRNA) resulted in a 
significant decrease in nuclear H2O2. NOX4 and p22
phox have been shown to colocalise 
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to the nucleus, thus reinforcing the idea that NOX activity contributes to genomic 
instability in AML (Stanicka et al., 2015). FLT3-ITD expressing cells produce a 100% 
increase in H2O2 compared to FLT-WT, as quantified by flow cytometry using 
endogenous H2O2 specific probe Peroxy Orange 1 (PO1), and a 25% increase in 
nuclear H2O2, in FLT3-ITD compared to WT. There was no significant difference in 
mitochondrial generated ROS between ITD- and WT-expressing cells (Stanicka et al., 
2015).  
Phosphorylated histone H2A, member X (ϒH2AX) is one of the most widely 
used measures of DNA dsbs (Kuo and Yang, 2008). 8-hydroxy-2’ deoxyguanosine (8-
OHdG) is the predominant form of ROS-induced DNA lesion and therefore is widely 
used as a marker of oxidative stress (Roszkowski et al., 2011). FLT3-ITD expressing 
cells, MV4-11, showed a 50% increase in dsbs compared to the FLT3-WT expressing 
cell line, HL-60. 32D cells, a murine immortalised myeloblast-like cell line transfected 
with FLT3-ITD and FLT3-WT plasmids showed a similar result with a 75% increase 
in levels of dsbs in 32D/FLT3-ITD cells compared to 32D/FLT3-WT cells. 
32D/FLT3-ITD cells possess 100% more oxidative stress, as assessed by levels of 8-
OHdG compared to WT (Stanicka et al., 2015). A study has shown that inhibition of 
FLT3 using PKC412 resulted in a decrease in protein levels of NOX4 and its partner 
protein p22phox, coinciding with a decrease in total endogenous H2O2. FLT3-ITD 
expressing cells treated with PKC412 showed a significant decrease in dsbs and 
inhibited the homologous repair of DNA damage. On the other hand, PKC412 had no 
effect on dsbs or DNA repair pathway in FLT3-WT expressing cells (Seedhouse et al., 
2006). The decrease in dsbs in FLT3-ITD expressing cells coincides with a 35% 
decrease in DNA oxidation using the marker 8-OHdG. Thus these findings highlight 
the importance and involvement of the FLT3-ITD oncogene in genomic instability. 
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Knockdown of p22phox and p22phox dependent NOX isoforms in FLT3-ITD 
expressing cells, MV4-11, resulted in a decrease in endogenous and nuclear H2O2 
accompanied by a 30% decrease in the number of dsbs and DNA oxidation following 
p22phox knockdown. p22phox knockdown in FLT3-WT expressing cells showed an 
increase in endogenous H2O2 and dsbs in comparison to scramble control. FLT3-ITD 
expressing cells have higher p22phox protein levels compared to wild-type cells, thus 
reinforcing the oncogenic effects of the FLT3-ITD mutation in AML. p22phox is 
necessary for NOX-generated ROS to oxidatively damage DNA. Interestingly, NOX4 
knockdown had a greater effect than p22phox knockdown resulting in a 30% decrease 
in endogenous H2O2 levels and dsbs. NOX inhibition using DPI also resulted in a 30% 
decrease in dsb marker, ϒH2AX, in 32D/FLT3-ITD cells. Hence, the NOX4/p22phox 
complex produces DNA-damaging H2O2 in FLT3-ITD cells, MV4-11. ϒH2AX levels 
were not altered following NOX1 knockdown. However, NOX2 knockdown resulted 
in a 20% decrease in endogenous H2O2 and a 30% decrease in dsbs (Stanicka et al., 
2015). 32D/FLT3-WT expressing cells, when stimulated with FLT3 ligand, results in 
an increase in p22phox protein levels, a 40% increase in endogenous H2O2 and a 20% 
increase in nuclear H2O2. The increase in p22
phox protein levels coincides with a 50% 
increase in the number of dsbs, demonstrating the DNA damaging properties of FLT3-
induced H2O2. 
The BCR-ABL mutation in CML is involved in a similar cycle of genomic 
instability to the FLT3-ITD mutation. The oncogenic effects of BCR-ABL leads to 
increased levels of NOX ROS production leading to enhanced DNA damage and 
compromised DNA repair (Nowicki et al., 2004, Naughton et al., 2009). Similar to 
FLT3-ITD, levels of DNA damage are much higher in BCR-ABL transformed cells 
compared to non-transformed cells, and the rate of DNA repair by unfaithful end 
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joining systems is much higher (Skorski, 2007). The accumulation of DNA damage 
and genetic abnormalities contributes to resistance against drugs that are commonly 
used in the treatment of CML, including imatinib (Skorski, 2002, Koptyra et al., 2006) 
(Figure 1.9.).  
Unfortunately, ROS-mediated damage in AML and CML has major 
implications in the treatment of leukaemia. It is increasingly more difficult to treat 
leukaemia due to the accumulation of genetic abnormalities leading to resistance to 
protein tyrosine kinases inhibitors, for example, PKC412 and imatinib, and this 
furthers the progression of the malignancy. For detailed information on ROS-mediated 
damage and genomic instability in leukaemia, the reader is referred to the following 
reviews (Jayavelu et al., 2016b, Sallmyr et al., 2008b). 
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Figure 1.9. Oncoprotein-driven ROS formation in myeloid cells causes DNA damage. FLT3-ITD, 
but also ligand-activated FLT3 or the BCR-ABL oncoprotein, can drive oxidative DNA damage 
through a signalling chain involving AKT activation, elevated expression of p22phox, and activation of 
p22phox-interacting NADPH oxidases. DNA damage, involving DNA oxidation and generation of 
double-strand breaks, contributes to genetic instability and the accumulation of mutations associated 
with aggressive phenotypes, drug resistance, and relapse. 
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1.5. Objectives 
Increased ROS production is becoming a well-recognised hallmark of various 
cancers, resulting in pro-tumourigenic and anti-tumourigenic signalling. Elevated 
ROS levels downstream of the FLT3-ITD mutation contributes to pro-tumourigenic 
signalling in acute myeloid leukaemia (AML) through sustained cell survival and 
proliferation, a differentiation block resulting in the accumulation of immature 
haematopoietic progenitor cells or ‘blasts’, as well as DNA damage and genetic 
instability contributing to drug resistance. As with many cancer studies, the main goal 
is to identify targets for selective and effective therapies and to overcome drug 
resistance. The aims of this study were firstly to investigate the effect of subcellular 
localisation of the FLT3-ITD oncogene on NOX4- and p22phox-generated H2O2 in 
AML. We also wished to examine the pro-survival signalling pathways activated 
downstream of FLT3-ITD at the plasma membrane and endoplasmic reticulum, 
responsible for the production of NOX4-generated ROS. Previous studies in our 
laboratory have identified NOX4 as a major contributor of endogenous H2O2 in FLT3-
ITD-expressing AML cell lines where it is located in the nuclear membrane, 
contributing to DNA damage and genetic instability. The final aim of this study was 
to investigate the expression, localisation and regulation of the NOX4 28 kDa splice 
variant, NOX4D, in FLT3-ITD-expressing AML. NOX4D has previously been shown 
to localise to the nucleus in various cell types and is implicated in the generation of 
ROS and DNA damage. 
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Chapter 2. Materials and Methods 
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2.1. Cell culture and treatments  
Human patient-derived leukaemic cell lines MV4-11 (homozygous for the 
FLT3-ITD mutation), MOLM13 (heterozygous for the FLT3-ITD mutation) and K562 
were all purchased from DSMZ (Braunschweig, Germany). 32D, a murine 
immortalised myeloblast-like cell line, stably transfected with FLT3-WT and FLT3-
ITD (Mizuki et al., 2000), were a kind gift from Prof. Hubert Serve from Goethe 
University Frankfurt and Prof. Frank D. Böhmer from the Universitatsklinkium Jena 
in Germany. The cell lines were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 medium (Sigma-Aldrich, Dublin, Ireland) supplemented with 10% 
Foetal Bovine Serum (FBS) (Thermo Scientific/Bio-Sciences, Dublin, Ireland), 2mM 
L-glutamine (Thermo Scientific/Bio-Sciences, Dublin, Ireland) and 1% 
penicillin/streptomycin (Sigma-Aldrich, Dublin, Ireland) in a humidified incubator at 
37°C with 5% CO2. For 32D cells, 10% WEHI-conditioned medium was added as a 
source of interleukin-3 (IL-3). The WEHI conditioned medium was harvested from a 
48 h culture of WEHI, a macrophage-like, derived from a BALB/c mouse treated for 
tumour induction cell line, which produce and secrete IL-3. Prior to carrying out 
experiments that involved a comparison of 32D/FLT3-ITD and 32D/FLT3-WT, the 
cells were washed twice with phosphate buffered saline (PBS) and IL-3-starved 
overnight in 10% FBS medium as recommended previously (Choudhary et al., 2009, 
Sallmyr et al., 2008a, Songyang et al., 1997).  
All cell lines, except for 32D cells were maintained between 0.1-1.5 x 106 
cells/ml and were sub-cultured every 2-3 days. 32D cells were maintained between 
0.2-1.0 x 106 cells/ml and were sub-cultured every 2 days. Cell counts were obtained 
using a haemocytometer under a light microscope. Cell viability was determined by 
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trypan blue exclusion (#T8154, Sigma-Aldrich, Dublin, Ireland). 
HEK 293-T cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 10% FBS, 10 mM L-glutamine and 1% 
penicillin/streptomycin in a humidified incubator at 37°C with 5% CO2. 
 
2.2. Primary AML patient samples  
Blood samples from newly diagnosed untreated de novo AML patients were 
obtained in accordance with the Declaration of Helsinki and with approval of the 
institutional review board of the University Hospital Jena, Germany. Mononuclear 
cells were purified as previously described (Godfrey et al., 2012). FLT3 mutational 
analysis was done by standard polymerase chain reaction (PCR) methods to group the 
patients into FLT3-WT or FLT3-ITD. Primary AML patient blood samples were a 
kind gift from Dr. Sebastian Scholl from Jena University Hospital, Germany. 
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2.3. Reagents and chemicals 
Protein Reagent/ 
inhibitor 
Supplier Cat # Vehicle Conc. Dura-
tion 
FLT3-ITD PKC412 Tocris 2992 DMSO 50-250 
nM 
24 h 
FLT3-ITD AC220 Selleck-
chem 
S1526 DMSO 5-30 nM 12 h 
Glycosylation Tunicamycin Sigma T7765 DMSO 1-10 
µg/ml 
16 h 
Receptor 
trafficking 
Brefeldin A Sigma B7651 Ethanol 1-10 
µg/ml 
16 h 
PI3K/AKT LY294002 CST 9901 DMSO 20-50 
µM 
16 h 
ERK1/2 U0126 Sigma U120 DMSO 10-100 
µM 
16 h 
STAT5 Pimozide Millipore 573110 DMSO 5-20 µM 16 h 
GSK3β SB216763 Tocris 1616 DMSO 1-5 µM 16 h 
GSK3β Lithium 
chloride 
Sigma L9650 Water 10-50 
mM 
16 h 
COX Diclofenac Sigma D6899 Water 1-50 µM 2 h 
Mitochondrial 
ROS 
Rotenone Tocris 3616 DMSO 1-50 µM 1 h 
20S 
proteasome 
Lactacystin Millipore 426100 DMSO 5 µM 16 h 
 
Table 2.1. List of inhibitors and modulators used throughout the course of this thesis. Tocris: 
Tocris Bioscience (Bristol, UK), Selleckchem: Selleckchem from Stratech (Suffolk, UK), Sigma: 
Sigma-Aldrich (Dublin, Ireland), CST: Cell Signaling Technology (Boston, MA, USA), Millipore: 
Merck Millipore (Cork, Ireland). In all cases, if not shown, inhibitor and modulator concentrations were 
chosen based on their greatest effect with a negligible decrease in cellular viability. All treatment time-
points chosen were as optimised in previous studies. 
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2.4. Antibodies 
Gene Supplier Cat # Host Dilution 
WB 
Dilution 
IF 
AKT CST 9272 Rabbit 
polyclonal 
1/1000  
Phospho-AKT 
ser473 
CST 9271 Rabbit 
polyclonal 
1/1000  
β-actin Sigma A5441 Mouse 
monoclonal 
1/5000  
Calreticulin Abcam Ab22683 Mouse 
monoclonal 
1/1000  
ERK1/2 CST 4696 Mouse 
monoclonal 
1/1000  
Phospho-
ERK1/2 
thr202/tyr204 
CST 9106 Mouse 
monoclonal 
1/1000  
Flt-3 Santa Cruz SC480 Rabbit 
polyclonal 
 1/100 
GAPDH CST 5174 Rabbit 
monoclonal 
1/1000  
GSK3β CST 9315 Rabbit 
monoclonal 
1/1000  
Phospho-
GSK3β ser9 
CST 9336 Rabbit 
polyclonal 
1/1000  
HA Cambridge 
Bioscience 
MMS-
101R 
Mouse 
monoclonal 
1/1000  
HDAC1 CST 5356 Mouse 
monoclonal 
1/1000  
Histone H3 Abcam Ab1220 Mouse 
monoclonal 
1/5000  
KDEL Abcam Ab12223 Mouse 
monoclonal 
1/1000 1/100 
Lamin A/C CST 2032 Rabbit 
polyclonal 
1/1000  
NOX4 Novus Bio NB110-
58849 
Rabbit 
polyclonal 
1/1000  
NOX4 Abcam Ab10922
5 
(UOTR1
B492) 
Rabbit 
monoclonal 
1/1000  
NOX4 Prof. Ajay 
Shah 
In-house 
antibody 
Rabbit 
polyclonal 
1/1000  
NUP98 Abcam Ab17991
1 (13C1) 
Mouse 
monoclonal 
1/500  
p22phox Santa Cruz SC20781 Rabbit 
polyclonal 
1/1000  
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STAT5 BD  610191 Mouse 
monoclonal 
1/1000  
Phospho-
STAT5 
tyr694/699 
Millipore 04-886 Rabbit 
monoclonal 
1/1000  
α-tubulin Sigma T5168 Mouse 
monoclonal 
1/5000  
Vinculin Biozol BZL031
06 
Mouse 
monoclonal 
1/10000  
 
Table 2.2. List of antibodies used throughout the course of this thesis. WB: Western Blotting, IF: 
Immunofluorescence, CST: Cell Signaling Technology (Boston, MA, USA), Sigma: Sigma-Aldrich 
(Dublin, Ireland), Abcam (Cambridge, UK), Santa Cruz: Santa Cruz Biotechnology Inc. (Dublin, 
Ireland), Cambridge Bioscience (Cambridge, UK), Novus Bio: Novus Biologicals (Abingdon, UK), 
BD: BD Biosciences Europe (Oxford, UK), Millipore: Merck Millipore (Cork, Ireland), Biozol: Biozol 
Diagnostics (Eching, Germany). 
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2.5. RT-qPCR primers 
2.5.1. Qiagen QuantiTect Primer Assays 
 
Gene Qiagen 
primer 
Product 
size 
Ref Seq ID# 
β-actin (ACTB) QT00095431 146 bp NM_001101 
Beta-2-microglobulin (B2M) QT00088935 98 bp  NM_004048 
XM_005254549 
XM_006725182 
Proteasome 
(prosome/macropain) subunit, 
beta type, 2 (PSMB2) 
QT00082999 64 bp NM_001199779 
NM_001199780 
NM_002794 
p22phox/Cytochrome b-245, 
alpha polypeptide 
QT00082481 106 bp NM_000101 
NOX4 QT00057498 77 bp NM_001143836 
NM_001143837 
NM_016931 
NR_026571 
NM_001291926 
NM_001291927 
NM_001291929 
NM_001300995 
XM_006718848 
XM_006718849 
XM_006718852 
XM_006718853 
 
Table 2.3.1. List of Qiagen QuantiTect primers used throughout the course of this thesis. All 
primers are from Qiagen (West Sussex, UK). 
 
2.5.2. Eurofins Primers 
 
Gene Eurofins 
primer 
Sequence (5’→3’) RefSeq 
ID# 
Ref 
NOX
4 
NOX4_4 fwd:  
5’ TCTGTTGTGGACCCAATTCA 3’ 
rev:  
5’ AGCTGATTGATTCCGCTGAG 3’ 
XM_011
542857.2 
(Reddy 
et al., 
2011) 
 
Table 2.3.2. Forward and reverse sequence of NOX4_4 Eurofins primers used to amplify NOX4 
(186 bp) throughout the course of this thesis. NOX4_4 primers are from Eurofins (Wolverhampton, 
UK). 
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2.6. Flow cytometry 
2.6.1. Measurement of intracellular H2O2 
Total intracellular hydrogen peroxide (H2O2) was measured by incubating cells 
with 5 μM of cell-permeable H2O2-probe Peroxy Orange 1 (PO1) (Tocris Bioscience, 
cat# 4944) added to the medium for 1 h at 37°C in the dark. Cells were then briefly 
washed with PBS and immediately viewed under the microscope or quantified by flow 
cytometry using FACSCalibur (BD Bioscience, Europe) and Cellquest Pro software 
(Becton Dickinson). The probe was excited using the FL2-H (red) flow cytometry 
laser. Healthy populations of cells were gated and the mean fluorescent intensity of 
10,000 events was recorded. The viability/healthiness of the cells was estimated, based 
on their size and granularity using the forward scatter-height (FSC-H) and side scatter-
height (SSC-H) lasers. The geometric mean fluorescence of three biological (N=3) 
and three technical (n=3) replicates of viable cells was calculated. The fluorescence of 
the vehicle control (control) cells was set to 100% and the fluorescence of treated cells 
was expressed as a percentage of the control. 
 
2.6.2. Flow cytometry analysis 
The fluorescence of control/32D/FLT3-WT cells was set to 100% in all 
experiments to rule out variations in experimental set up, for example, experiments 
being carried out on different days, different passages of cells, any slight variation in 
probe incubation times, etc., and also variations in instrument settings, such as 
differences in gating, calibration, etc. The relative mean fluorescence of 
treated/32D/FLT3-ITD cells was expressed as a percentage of control/32D/FLT3-WT 
cells in each of the biological and technical replicates. For simplicity, one control set 
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to 100% is presented in the bar chart showing relative mean FLT3/PO1 fluorescence 
of treated cells expressed as percentage of control. This control is representative of 
individual controls (DMSO/Ethanol/water) for each of the drug concentrations tested. 
The relative mean FLT3/PO1 fluorescence of treated cells was expressed as a 
percentage of the individual matched controls and statistical significance was 
analysed. The relative mean FLT3/PO1 fluorescence is not being compared between 
the different drug concentrations. Flow cytometric statistical significance was 
analysed by Student’s t-test using GraphPad, Prism 6. Values of p<0.05 were 
considered statistically significant. 
 
2.7. Immunofluorescence 
2.7.1. Fixed cell immunofluorescence 
MV4-11 cells were cytospun onto glass slides at 500 rpm for 2 min with a 
Shandon CytoSpin 11 Cytocentrifuge (Shandon). Cells were fixed for 10 min using 
4% paraformaldehyde (PFA)/PBS, washed in PBS and permeabilised with 0.2% 
Triton-X-100 for 5 min at room temperature. Following two 5 min-washings with 
PBS, the antigens were blocked for 30 min with 5% FBS/PBS. The cells were 
incubated with 50 μl of KDEL and FLT3 antibody solutions (1/100 in 5% FBS/PBS) 
for 1 h at room temperature in a humidity chamber followed by two 5 min-washings 
with PBS. 50 μl of goat anti-rabbit Alexa fluor 488 (Abcam, cat# Ab150077) or goat 
anti-mouse Alexa fluor 594 (Abcam, cat# Ab150116) secondary antibody solutions 
(1/100 in 5% FBS/PBS) were added onto the slides and incubated for 1 h at room 
temperature. The slides were subsequently washed thoroughly with PBS, followed by 
water and finally mounted on the coverslips using 5 μl of mowiol (Sigma-Aldrich, 
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Dublin, Ireland). The slides were dried overnight at room temperature. As controls, 
fixed cells were incubated with 50 μl of goat anti-rabbit Alexa fluor 488 (Abcam, cat# 
Ab150077) or goat anti-mouse Alexa fluor 594 (Abcam, cat# Ab150116) secondary 
antibody solutions (1/100 in 5% FBS/PBS). Eliminating the primary antibody in 
solution served as a negative control. 
 
2.7.2. Live cell immunofluorescence 
Labelling of plasma membrane FLT3-ITD– Live cell immunofluorescence of 
FLT3-ITD at the plasma membrane of MV4-11, 32D/FLT3-ITD and 32D/FLT3-WT 
cells was performed on ice. Following centrifugation at 1,000 rpm for 5 min, cells 
were incubated with anti-FLT3 primary antibody (1/100 in 5% FBS/PBS containing 
approximately 0.01% Sodium Azide) for 1 h. Following three by 5 min-washings with 
PBS, the cells were incubated with anti-rabbit Alexa fluor 488 (1/100 in 5% FBS/PBS) 
for 1 h. Secondary antibody only controls were used. Cells were washed three by 5 
min-washings with PBS and viewed under the microscope in ice cold PBS and 
quantified by flow cytometry using FACSCalibur (BD Biosciences, Europe) and 
Cellquest Pro software (Becton Dickinson). Healthy populations of cells were gated 
and the mean fluorescent intensity of 10,000 events was determined.  
 
2.7.3. Microscopy 
Mounted slides were viewed on a Leica DM LB2 microscope with Nikon 
Digital Sight DS-U2 camera, using 40x and 100x objectives. Digital images were 
captured using the software NIS-Elements version 3.0, Nikon, Japan. 
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2.8. Western blotting 
2.8.1. Whole cell lysis 
Following the treatments of indicated durations or siRNA transfections, cells 
were washed with ice-cold PBS and centrifuged at 1,000 rpm for 5 min at 4°C. 
Following careful removal of PBS, cells were incubated in radio immunoprecipitation 
assay (RIPA) lysis buffer [Tris-HCl (50 mM; pH 7.4), 1% NP-40, 0.25% sodium 
deoxycholate, NaCl (150 mM), EGTA (1mM), sodium orthovanadate (1 mM), sodium 
fluoride (1 mM), cocktail protease inhibitors (Roche, Welwyn, Hertforshire, UK) and 
phenylmethylsulfonyl fluoride (1mM)] for 35-45 min at 4°C in vortex, followed by 
centrifugation at 14,000 rpm for 15 min to remove cell debris. In all cases equivalent 
amounts of protein (50-100 μg per lane), as determined by the Bio-Rad Protein Assay 
(Bio-Rad, Hemel, Hempstead, UK) were resuspended in 4X Protein Sample Loading 
Buffer (LI-COR, cat# P/N 928-40004) containing β-mercaptoethanol (Sigma-Aldrich, 
Dublin, Ireland) and loaded into 12% (w/v) sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE). The proteins were stacked at 90 V for 10-15 min 
and resolved at 120 V using SDS-PAGE. The proteins were then transferred from the 
SDS-polyacrylamide gel to the nitrocellulose membrane at 100 V for 1 h (Schleicher 
and Schuell, Dassel, Germany). Total protein levels were analysed using Ponceau or 
REVERT total protein stain (LI-COR, cat# P/N 926-11011 as per manufacturer’s 
instructions and imaged on a LI-COR Odyssey infrared imaging system (LI-COR 
Biosciences UK Ltd, Cambridge, UK)). The membranes were incubated for 1 h at 
room temperature with 5% (w/v) non-fat dry milk or 5% (w/v) bovine serum albumin 
(BSA) solutions, based on the manufacturer’s recommendations, to block non-specific 
protein binding. The membranes were then incubated overnight at 4°C with the 
appropriate primary antibodies diluted in blocking solution. Following incubation with 
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primary antibody, the membranes were washed two times with TBST for 5 min each 
time. The membrane was then incubated in the secondary antibody (dilution 1:10,000) 
coupled with Alexa Fluor 680 or 800 (LI-COR Biosciences UK Ltd, Cambridge, UK) 
diluted in the blocking solution for 1 h at room temperature, followed by two TBST 
washes and one TBS wash for 5 min each time. In all analyses of whole cell lysate 
western blots, we normalised for differences in protein loading using REVERT total 
protein stain or loading controls (β-actin, α-tubulin or Vinculin). Antibody reactive 
bands were detected using a LI-COR Odyssey infrared imaging. All experiments were 
carried out in triplicate (N=3 biological samples per condition). Western blots shown 
in results are representative images of three or more independent experiments, using 
different samples each time. Densitometry was performed using Image Studio Lite 
Version 5.0 (LI-COR Biosciences UK Ltd, Cambridge, UK). 
 
2.8.2. Subcellular fractionation 
Subcellular fractionation was performed to detect the localisation of NOX4D 
in FLT3-ITD expressing AML cells, MV4-11 and 32D/FLT3-ITD and BCR-ABL 
expressing CML cells, K562 using a subcellular protein fractionation kit (Thermo 
Scientific). According to the manufacturer’s protocol, extracts from subcellular 
compartments generally have less than 15% contamination between fractions, which 
is sufficient purity for most experiments studying protein localisation. Subcellular 
fractionation is a very useful technique but has many steps requiring optimisation and 
careful pipetting of fractions following each extraction step. Manufacturer’s 
instructions were modified to ensure optimal amounts of protein were obtained from 
each fractionation step. In brief, for MV4-11, 32D/FLT3-ITD and 32D/FLT3-WT 
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cells, we assumed 1x106 cells were equivalent to 1 µl packed cell volume and for K562 
cells, 1x106 cells were equivalent to 2 µl packed cell volume. For the cytoplasmic 
fraction, one sixth of the recommended quantity of buffer was added followed by 
gentle mixing for 6-7 min. In the membrane extraction step, one eighth of the 
recommended quantity of buffer was added. Finally, for the nuclear extraction, one 
fifth of the recommended quantity of buffer was added for soluble nuclear and 
chromatin bound nuclear extractions. RIPA lysis buffer was used as an alternative to 
the nuclear extraction buffers provided. RIPA buffer was added at a volume of 10 µl 
per initial 10 µl packed cell volume. Soluble nuclear- and chromatin bound nuclear-
extraction buffers provided in the kit were used for the majority of experiments as they 
were found to obtain better protein concentrations than that of RIPA lysis buffer. In 
all analyses of subcellular fractionation western blots, we normalised for differences 
in protein loading of membrane and soluble nuclear fractions using ER membrane 
marker, calreticulin, and nuclear membrane marker, NUP98. Antibody reactive bands 
were detected using a LI-COR Odyssey infrared imaging. All experiments were 
carried out in triplicate (N=3 biological samples per condition). Western blots shown 
in results are representative images of three or more independent experiments, using 
different samples each time. Densitometry was performed using Image Studio Lite 
Version 5.0 (LI-COR Biosciences UK Ltd, Cambridge, UK). 
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2.9. Small interfering RNA (siRNA) and small hairpin 
(shRNA) transfections 
The siRNA transfection of MV4-11 cells was performed using the 
Nucleofector Kit L (Amaxa, Cologne, Germany) and AmaxaNucleofector Technology 
according to the company’s protocol. The predesigned siRNA used for silencing was 
p22phox
 
(ID: S3786 (A)). For the negative control, the siRNA used was Silencer Select 
Negative Control #1 siRNA (Control). All were purchased from Ambion, Warrington, 
UK. Cells were seeded at 0.5×106/ml 16 h before the transfection. Before the 
procedure siRNA solutions were prepared in 50 μl of the nucleofection buffer 
provided. Approximately 2×106
 
cells were cytospun at 1,000 rpm for 5 min at room 
temperature and resuspended in 50 μl of the same nucleofection buffer. The solutions 
of cells and siRNA were combined and immediately transferred into the certified 
nucleofection cuvette. The cuvette was inserted into the nucleofection cuvette holder 
and the correct nucleofection program was applied (Q-001). The contents of the 
cuvette were immediately diluted in the fresh medium (0.5 ml) and added drop wise 
onto the 6-well plate with more of fresh medium in it (1.5 ml). The final density of 
cells in the well following the transfection was 1×106/ml. The plate was transferred to 
a humidified incubator (37°C with 5% CO2) for 24 h. NOX4 siRNA and shRNA in 
32D/FLT3-ITD cells was carried out by our collaborator as previously decribed 
(Jayavelu et al., 2016a). 
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2.10. NOX4 overexpression transfections 
For NOX4 overexpression in HEK 293-T cells, cells were transfected using 
calcium phosphate. Briefly, cells were seeded 5 h prior to transfection to allow 
confluency of 70%. 4 µg of pCMV3-C-HA encoding full length cDNA clone of Homo 
sapiens NOX4 (#HG15189-CY; Sino Biological, UK) was added to CaCl2. The 
DNA/CaCl2 mixture was then added dropwise to 2X Hanks’ balanced salt solution 
(HBSS) at a ratio of 1:1. Samples were allowed to stand for 1-2 min after which the 
solution was distributed to the pre-seeded cells in a dropwise manner. Cells were then 
incubated overnight to allow the transfection to proceed, after which cells were 
reseeded for experimental purposes and lysed 48 h later. 
 
2.11. Total RNA isolation and RT-qPCR 
Total RNA was isolated from whole cells using RNeasy Mini Kit (Qiagen, 
West Sussex, UK) following manufacturer’s protocol. All samples were treated for 
DNase using RNase free DNase set (Qiagen) and 1 μg complementary DNA (cDNA) 
was synthesised using QuantiTect Reverse Transcription Kit (Qiagen) according to 
manufacturer’s instructions. The cDNA product was then diluted 1:5 with RNase free 
water (Sigma) and RT-PCR was performed using SYBR Green JumpStart Taq 
ReadyMix (Sigma-Aldrich) in a 384 well plate (Starstedt AG & Co.). Plates were run 
using the Applied Biosystems 7900HT Fast Real-Time PCR System (Life 
Technologies Ltd., Paisley, UK) and each set of reactions included both a non-reverse 
transcription control and a no template sample negative control (data not shown). The 
protocol consisted of a cycling profile of 30s at 95°C, 60s at 60°C, and 30s at 72°C 
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for 40 cycles. Qiagen QuantiTect Primer assays were used for housekeeping genes, 
NOX4 and p22phox (Table 2.3.1.). NOX4 primers (Eurofins) were used (Table 2.3.2.), 
as designed by (Reddy et al., 2011). Melt curve analysis confirmed that a single PCR 
product was present for all genes amplified by Qiagen QuantiTect Primer Assays 
except for NOX4. Primer efficiency was checked for each primer-set using a 
representative test sample prepared as the experimental sample (untreated cDNA from 
MV4-11 cells). A serial dilution was used to evaluate the slope of the log (relative 
concentration) versus Ct and primer efficiency was calculated by the equation m = 
(1/log E), where m = slope of the line and E = the efficiency (Mygind et al. 2002). All 
primer sets were between 86% and 105% efficient and within 20% efficiency of each 
other, as is recommended (Schmittgen and Livak, 2008). NOX4 melt curve analysis 
identified a variety of PCR products following amplification with Eurofins NOX4 
primer, primer efficiency was tested and subsequent gene sequencing was carried out 
by GATC Biotech, London, United Kingdom. Relative changes in gene expression 
were quantified using the comparative Ct (ΔΔCt) method as described by (Livak and 
Schmittgen, 2001, Schmittgen and Livak, 2008). The Ct value of the gene of interest 
was normalised to an average of the three endogenous housekeeping genes (ACTB, 
B2M and PSMB2). This was then compared to the normalised control sample - i.e. the 
equivalent dimethyl sulfoxide (DMSO; for tunicamycin and PKC412)/Ethanol control 
(for brefeldin A). All experiments were carried out in triplicate (PKC412) or 
quadruplicate (tunicamycin and brefeldin A) (N=3 or N=4 biological samples per 
condition and n=3 technical replicates per biological sample). Alterations in mRNA 
expression of target genes was defined as fold difference in the expression level in 
cells after treatment, relative to that of the control. 
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2.11.1. Agarose gel electrophoresis of RT-qPCR product 
Approximately 20 μl of the gene sequences amplified by RT-qPCR were 
resuspended in 5X DNA loading buffer (Bioline, cat# BIO-37045) and run on 2% 
agarose gel containing SYBR Safe DNA gel stain (Invitrogen, cat# S33102) at 100 V 
for 1 h. The ladder used was BioLabs Quick-load 100 bp DNA ladder (New England 
BioLabs, cat# N0467). 
 
2.12. Analysis of cell number and cell viability 
Cells were incubated in 1 ml of RPMI 1640 medium in 24-well plates at 37°C 
for indicated time points with the indicated concentration of drugs used, equivalent 
volumes of DMSO (for all drugs unless otherwise stated), ethanol (for brefeldin A) 
and sterile H2O (for LiCl and diclofenac) were added to cells as controls. Numbers 
and viability of the cells were determined by counting with a haemocytometer after 
staining with trypan blue (#T8154, Sigma-Aldrich, Ireland, Dublin). All experiments 
were carried out in duplicate (N=2 biological samples per condition). 
 
2.13. Haematoxylin staining 
MV4-11 cells were cytospun onto glass slides at 500 rpm for 2 min with a 
Shandon CytoSpin 11 Cytocentrifuge (Shandon). Slides were fixed using ethanol, 
methanol/acetone (1:1) or 4% PFA/PBS. Ethanol fixation- slides were immersed in 
100% ethanol for 15 min, 70% ethanol for 5 min, 50% ethanol for 5 min and 25% 
ethanol for 5 min. Methanol/acetone fixation- the glass slides were immersed in ice-
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cold methanol/acetone and incubated at -20°C for 10-15 min. 4% PFA/PBS fixation- 
slides were fixed with 4% PFA/PBS for 5 min at room temperature followed by brief 
wash with PBS to remove excess 4% PFA/PBS. Following fixation, slides were left 
to dry and stained for 3-4 min with haematoxylin (GH5232, Sigma-Aldrich, Dublin, 
Ireland) and washed gently under running tap water for 5 min. Slides were dehydrated 
and coverslips were mounted using distyrene plasticizer xylene (DPX) (100503-834, 
VWR) and left to dry in a fume hood overnight before imaging. 
 
2.14. Statistical analysis 
Image Studio Lite Version 5.0 (LI-COR Biosciences UK Ltd, Cambridge, UK) 
was used to analyse all western blots. Values in all graphs are representative of mean 
± standard deviation (SD) and are representative of at least three independent 
experiments. Statistical significance was analysed using the appropriate test (see 
individual figure legends) using GraphPad, Prism 6. Values of p<0.05 were considered 
statistically significant.  
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Chapter 3. Subcellular localisation of 
FLT3-ITD and ROS generation 
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3.1. Abstract 
Internal tandem duplication of the juxtamembrane domain of FMS-like 
tyrosine kinase 3 (FLT3-ITD) receptor is the most prevalent FLT3 mutation 
accounting for 15-35% of acute myeloid leukaemia (AML) patients. FLT3-ITD 
mutation results in ligand-independent constitutive activation of the receptor at the 
plasma membrane and ‘impaired trafficking’ of the receptor in compartments of the 
endomembrane system, such as the endoplasmic reticulum (ER). FLT3-ITD 
expressing cells have been shown to generate increased levels of reactive oxygen 
species (ROS), in particular NADPH oxidase (NOX)-generated ROS which act as pro-
survival signals. The purpose of this study was to investigate FLT3-ITD production of 
ROS at the plasma membrane and ER in the FLT3-ITD expressing AML cell line 
MV4-11. Receptor trafficking inhibitors, tunicamycin and brefeldin A, induce ER 
retention of FLT3-ITD, resulting in a decrease in protein levels of NOX4 and its 
partner protein p22phox. This demonstrates the critical importance of FLT3-ITD 
localisation for the generation of pro-survival ROS. NOX- and mitochondrial-
generated ROS contribute to total endogenous hydrogen peroxide (H2O2) in AML as 
quantified by flow cytometry using the cell-permeable H2O2-probe Peroxy Orange 1 
(PO1). ER retention of FLT3-ITD resulted in NOX4 deglycosylation and decreased 
p22phox at both RNA and protein levels.  
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3.2. Introduction 
Constitutively active mutations in receptor tyrosine kinases (RTKs) are 
frequently observed in human cancers (Blume-Jensen and Hunter, 2001, Köthe et al., 
2013). FMS-like tyrosine kinase 3 (FLT3) is a type III RTK expressed in 
approximately 90% of acute myeloid leukaemia (AML) cases and regulates early steps 
of haematopoiesis (Stirewalt and Radich, 2003, Gilliland and Griffin, 2002). Internal 
tandem duplication (ITD) of the juxtamembrane domain is the most prevalent 
mutation of FLT3 present in 15-35% of AML patients, resulting in ligand-independent 
constitutive activation of the receptor at the plasma membrane and impaired 
trafficking of the receptor in compartments of its biosynthetic route, such as the 
endoplasmic reticulum (ER) (Gilliland and Griffin, 2002, Smith et al., 2012, Schmidt-
Arras et al., 2009, Jayavelu et al., 2016b). AML patients with the FLT3-ITD mutation 
have a poor prognosis (Thiede et al., 2002, Small, 2008). Ligand-independent 
constitutive activation of FLT3 stimulates autophosphorylation of the receptor and 
downstream signalling pathways including PI3K/AKT, ERK and STAT5 resulting in 
abnormal cell growth, resistance to apoptosis and a differentiation block (Choudhary 
et al., 2005a, Brandts et al., 2005, Hayakawa et al., 2000, Mizuki et al., 2000). Our 
group demonstrated that cells expressing FLT3-ITD produce higher levels of pro-
survival reactive oxygen species (ROS) in comparison to cells expressing wild-type 
FLT3 (Sallmyr et al., 2008a, Godfrey et al., 2012, Woolley et al., 2012, Stanicka et 
al., 2015). 
Increased production of ROS has been linked to various pathophysiological 
states including leukaemia (Hole et al., 2011). Little is known about how FLT3-ITD 
generates such a stress. NADPH oxidases (NOXs) are one of the known sources of 
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ROS in FLT3-ITD expressing cells (Stanicka et al., 2015). There are seven NOX 
isoforms NOX1-5 and dual oxidase 1-2 (DUOX1-2), varying in structure, subcellular 
localisation, biochemical characteristics and regulatory subunit requirements (p22phox, 
p47phox, p67phox and RAS-related C3 Botulinum Toxin substrate 1/2 (RAC1/2)). 
NOX1-4 require p22phox to produce functionally active NOX (Brandes et al., 2014, 
Ambasta et al., 2004). NOX2 and NOX4 have been shown previously to be expressed 
in leukaemia (Jayavelu et al., 2016a, Block and Gorin, 2012). Other sources of ROS 
include mitochondrial ROS, cyclooxygenase (COX), xanthine oxidase, cytochrome 
P450 enzymes and lipoxygenases (Holmstrom and Finkel, 2014, Finkel, 2011, Gough 
and Cotter, 2011). 
Previous studies have looked at the molecular mechanisms through which 
FLT3-ITD initiates aberrant signalling of pro-survival pathways (PI3K, ERK, STAT5) 
at the plasma membrane and ER using receptor trafficking inhibitors, tunicamycin and 
brefeldin A (Choudhary et al., 2009). However, the molecular mechanism describing 
how mislocalised activation of FLT3-ITD and aberrant signalling of downstream 
pathways leads to the production of ROS and sources of ROS remains unknown. To 
analyse the role of the cellular localisation of FLT3-ITD in the generation of ROS and 
its signalling outcome, we utilised a panel of inhibitors of glycosylation/receptor 
trafficking and ROS production, FLT3-ITD and the 20S proteasome, alongside ROS 
specific antibodies, probes and RT-qPCR. Experiments were carried out in the FLT3-
ITD AML expressing MV4-11 cell line. 
Receptor trafficking inhibitors, tunicamycin and brefeldin A, induce ER 
retention of FLT3-ITD, resulting in a decrease in protein levels of NOX4 and its 
partner protein p22phox. This is as a result of NOX4 deglycosylation and decreased 
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p22phox RNA levels and protein degradation. Our data demonstrates the critical 
importance of FLT3-ITD localisation for the generation of pro-survival ROS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
3.3. Results 
3.3.1. Haematoxylin staining of fixed and permeabilised MV4-11 cells 
Fixation of cells using 4% PFA/PBS and permeabilisation using 0.2% Triton-
X-100 is the most commonly used fixative in immunofluorescence protocols. We 
analysed the effect of different fixation and permeabilisation protocols: ethanol, 
methanol/acetone and 4% PFA/PBS and 0.2% Triton-X-100 on the morphology of 
MV4-11 cells (Figure 3.1.). Although the cells morphology changed following 
fixation with 4% PFA/PBS and permeabilisation with 0.2% Triton-X-100, we found 
this to be the optimal fixation/permeabilisation for immunofluorescence colocalisation 
studies. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Haematoxylin staining of 
fixed and permeabilised MV4-11 cells. 
Cells were fixed and permeabilised using 
ethanol (a), methanol/acetone (b) and 4% 
PFA/PBS and 0.2% Triton-X-100 (c) 
followed by incubation with haematoxylin 
for 3-4 min. 
 
b) 
a) 
c) 
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3.3.2. FLT3-ITD expression colocalises to the plasma membrane and 
endoplasmic reticulum of MV4-11 cell line 
FLT3-ITD is the most common mutation expressed in 15-35% of AML cases 
(Stirewalt and Radich, 2003). In order to study the role of the FLT3-ITD mutation in 
redox signalling in AML, we chose the MV4-11 human cell line as our model. MV4-
11 cell line is a well-established model of patient derived AML that expresses 
homozygous FLT3-ITD.  
FLT3-WT receptor in its unstimulated form is found at the plasma membrane, 
unphosphorylated with an inactive tyrosine kinase domain (Köthe et al., 2013, Grafone 
et al., 2012). Upon interaction with FL, the receptor autophosphorylates and undergoes 
a conformational change resulting in activation of the tyrosine kinase domain (Levis 
and Small, 2003). FLT3-ITD is the most prevalent FLT3 mutation resulting in ligand-
independent constitutive activation of the receptor at the plasma membrane and 
impaired trafficking of the receptor in intracellular compartments, such as the ER 
(Choudhary et al., 2009, Jayavelu et al., 2016b, Moloney et al., 2017b). 
Immunofluorescence studies confirmed the colocalisation of FLT3-ITD to the ER 
(Figure 3.2.) and plasma membrane (Figure 3.7.) in MV4-11 cells. 
 
Figure 3.2. FLT3 is localised to the endoplasmic reticulum in MV4-11 cells. Colocalisation of FLT3 
with ER marker KDEL in untreated MV4-11 cells. The scale bar represents 30µm. 
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3.3.3. FLT3-ITD expressing cells express significantly higher levels of 
the FLT3 receptor at the plasma membrane compared to FLT3-WT 
expressing cells 
In addition to the FLT3-ITD AML expressing MV4-11 cell line, we also 
employed an overexpression of the FLT3 system. FLT3-WT or mutated FLT3-ITD 
plasmids were stably transfected into 32D cells. 32D is a murine immortalised 
myeloblast-like cell line that is grown in IL-3 supplemented medium. Post 
transfection, due to strong cytokine-like FLT3-ITD signalling, 32D/FLT3-ITD cells 
became IL-3 independent (Mizuki et al., 2000, Fenski et al., 2000). Both wild-type 
and mutated FLT3 receptor have been found to colocalise to the plasma membrane 
(Choudhary et al., 2009). FLT3-ITD has been found to be activated independently of 
FLT3 ligand stimulation and is constitutively activated. We analysed the expression 
of the FLT3 receptor at the plasma membrane of 32D/FLT3-WT- and 32D/FLT3-ITD-
expressing cells by fluorescently labelling the FLT3 receptor at the plasma membrane 
in live cells. 32D/FLT3-ITD cells were found to express a 250-fold increase in FLT3 
expression at the plasma membrane compared to their wild-type counterpart (Figure 
3.3.). 
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Figure 3.3. 32D/FLT3-ITD cells express significantly higher levels of FLT3 at the plasma 
membrane compared to 32D/FLT3-WT cells. Flow cytometric analysis of FLT3 fluorescence at the 
plasma membrane of 32D cells stably transfected with FLT3-WT and FLT3-ITD (a). Bar chart shows 
relative mean FLT3 fluorescence at the plasma membrane of 32D/FLT3-ITD cells expressed as a % of 
32D/FLT3-WT cells (b). Results are presented as mean ± SD from three independent experiments. 
Asterisks indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test.  
 
3.3.4. Receptor trafficking inhibitors, tunicamycin and brefeldin A, 
induce ER retention of FLT3-ITD 
We have shown that FLT3-ITD colocalises to the ER and plasma membrane 
of MV4-11 cells. In order to analyse the role of cellular localisation of FLT3-ITD in 
the generation of ROS and its signalling outcome, cells were treated with tunicamycin 
and brefeldin A to inhibit glycosylation of FLT3-ITD, resulting in impaired trafficking 
of the FLT3-ITD receptor to the plasma membrane. Tunicamycin prevents 
glycosylation of plasma membrane receptors, retaining receptors in intracellular 
compartments, by blocking the formation of protein N-glycosidic linkages and 
consequently blocking the first step of glycoprotein synthesis (Helenius and Aebi, 
b) a) 
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2004, Bassik and Kampmann, 2011). Brefeldin A inhibits mature and complex 
glycosylation of plasma membrane receptors through inhibition of guanine-nucleotide 
exchange factors that are required for ADP-ribosylation factor (ARF) GTPases, 
resulting in disruption of the structure and function of the Golgi apparatus (Fujiwara 
et al., 1988). We show that treatment of MV4-11 cells with tunicamycin and brefeldin 
A result in retention of FLT3-ITD in a compartment of the biosynthetic route, such as 
the ER (Figure 3.4.).  We found the optimal concentration with the largest decrease in 
mean relative FLT3 fluorescence at the plasma membrane with the least effect on cell 
viability to be 5 µg/ml tunicamycin (Figure 3.5.) and 10 µg/ml brefeldin A (Figure 
3.6.). We demonstrated that both of these treatments resulted in a decrease of 50-60% 
of FLT3-ITD expression at the plasma membrane when compared to vehicle control 
(tunicamycin; DMSO and brefeldin A; Ethanol) as quantified by flow cytometry 
(Figure 3.7.).  
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Figure 3.4. FLT3 localises to the endoplasmic reticulum following treatment with tunicamycin 
and brefeldin A. Colocalisation of FLT3 with ER marker KDEL in MV4-11 cell line. Untreated (a), 
tunicamycin treated (5 µg/ml overnight) (b) and brefeldin A treated (10 µg/ml overnight) (c). The scale 
bar represents 30µm. 
 
 
 
 
 
 
 
 
 
a) 
b) 
c) 
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Figure 3.5. Tunicamycin induced ER retention of FLT3-ITD in MV4-11 cells. % FLT3 
fluorescence at the plasma membrane of MV4-11 cells following treatment with receptor trafficking 
inhibitor tunicamycin. Flow cytometric analysis of mean relative FLT3 fluorescence at the plasma 
membrane using 1 μg/ml - 10 μg/ml range tunicamycin concentrations in MV4-11 cells treated 
overnight (a). Bar chart shows relative mean FLT3 fluorescence of treated cells expressed as % of 
control (b). Results are presented as mean ± SD from three independent experiments. Asterisks indicate 
statistically significant differences (***p<0.001, ****p<0.0001) as analysed by Student’s t-test. Bar 
chart of % cell viability following treatment with the indicated concentrations of tunicamycin compared 
to vehicle controls (N=2) (c). 
 
 
a) 
b) c) 
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c) 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Brefeldin A induced ER retention of FLT3-ITD in MV4-11 cells. % FLT3 fluorescence 
at the plasma membrane of MV4-11 cells following treatment with receptor trafficking inhibitor 
brefeldin A. Flow cytometric analysis of mean relative FLT3 fluorescence at the plasma membrane 
using 1 μg/ml - 10 μg/ml range brefeldin A concentrations in MV4-11 cells treated overnight (a). Bar 
chart shows relative mean FLT3 fluorescence of treated cells expressed as % of control (b). Results are 
presented as mean ± SD from three independent experiments. Asterisks indicate statistically significant 
differences (***p<0.001, ****p<0.0001) as analysed by Student’s t-test. Bar chart of % cell viability 
following treatment with the indicated concentrations of brefeldin A compared to vehicle controls 
(N=2) (c). 
 
 
a) 
b) 
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a) 
b) 
c) 
e) 
d) 
Figure 3.7. Tunicamycin and 
brefeldin A induce ER retention of 
FLT3-ITD in MV4-11 cells. Live 
cell immunofluorescence of FLT3 at 
the plasma membrane in MV4-11 cell 
line, untreated (a), tunicamycin 
treated (5 µg/ml overnight) (b) and 
brefeldin A treated (10 µg/ml 
overnight) (c). Phase contrast 
pictures were taken to show the 
presence of cells with a decrease in 
FLT3 fluorescence at the plasma 
membrane. The scale bar represents 
30µm. Flow cytometric analysis of 
mean relative FLT3 fluorescence at 
the plasma membrane in MV4-11 cell 
line treated with tunicamycin (d) and 
brefeldin A (e). Bar charts show 
relative mean FLT3 fluorescence of 
treated cells expressed as % of 
control. Results are presented as 
mean ± SD from three independent 
experiments. Asterisks indicate 
statistically significant differences 
(****p<0.0001) as analysed by 
Student’s t-test.  
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3.3.5. p22phox has many hydrophobic regions and boiling of cell lysates 
results in p22phox protein aggregation 
p22phox is a partner protein of NOX1-4 and is required for NOX activation. We 
prepared unboiled and boiled samples of equal protein concentrations from the same 
MV4-11 cell lysates and carried out western blot analysis. We observed that p22phox 
protein levels were undetectable in boiled cell lysates compared to unboiled cell 
lysates (Figure 3.8. a). Firstly, we investigated if protein aggregation was an issue. 
Denaturation of the proteins in cell lysates resulted in protein aggregation evident by 
the presence of proteins at the top of the gel and membrane (Figure 3.8. b and c). 
Moreover, to validate p22phox protein aggregation following boiling of cell lysates, we 
examined the amino acid sequence for p22phox and identified the presence of several 
hydrophobic amino acids including alanine, glycine, isoleucine, leucine, methionine, 
phenylalanine, proline and valine (Figure 3.8. d) suggesting that the p22phox protein 
aggregates following denaturation of cell lysates. Therefore, in future studies 
investigating p22phox protein levels and the levels and expression of proteins who 
require p22phox for fully functioning proteins such as NOX4, cell lysates should not be 
boiled/denatured. 
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>sp|P13498|CY24A_HUMAN Cytochrome b-245 light chain 
OS=Homo sapiens GN=CYBA PE=1 SV=3 
MGQIEWAMWANEQALASGLILITGGIVATAGRFTQWYFGAYSIVAGVFVCLLEYPR
GKRKKGSTMERWGQKYMTAVVKLFGPFTRNYYVRAVLHLLLSVPAGFLLATILGTA
CLAIASGIYLLAAVRGEQWTPIEPKPRERPQIGGTIKQPPSNPPPRPPAEARKKPS
EEEGGPQVNPIPVTDEVV 
 
Figure 3.8. Boiling of MV4-11 cell lysates results in p22phox protein aggregation. Western blot 
analysis of p22phox protein levels in unboiled and boiled cell lysates (a). β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. Western blots are representative of three 
independent experiments. Analysis of total protein levels in unboiled cell lysates (lanes 2-4) and boiled 
cell lysates (Lane 6-8) by means of staining the gel with Coomassie brilliant blue overnight (b) and 
incubating the nitrocellulose membrane with Ponceau (c). p22phox amino acid sequence (d). The 
hydrophobic amino acids are represented in bold. Alanine (A), glycine (G), isoleucine (I), leucine (L), 
methionine (M), phenylalanine (F), proline (P), valine (V). 
a) 
b) 
d) 
c) 
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3.3.6. Impaired trafficking of the FLT3-ITD receptor to the plasma 
membrane results in a decrease in protein levels of NOX4 and its 
partner protein p22phox 
FLT3-ITD expressing cell lines have been shown to express higher levels of 
endogenous ROS in comparison to FLT3-WT receptor cell line (Sallmyr et al., 2008a, 
Stanicka et al., 2015). The mechanism in which FLT3-ITD driven pro-survival ROS 
leads to the aggressive form of AML remains unknown. We examined the effect of 
ER retention of FLT3-ITD on p22phox and NOX4 protein levels. p22phox and NOX4 
protein levels decreased significantly following treatment with both receptor 
trafficking inhibitors, tunicamycin and brefeldin A (Figure 3.9.). This suggests that for 
FLT3-ITD to produce NOX-generated pro-survival ROS it has to be located at the 
plasma membrane. This is supported by previous work from our laboratory showing 
that ligand-stimulated FLT3-WT results in an increase in p22phox protein levels 
(Stanicka et al., 2015).  
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Figure 3.9. Plasma membrane FLT3-ITD is required for p22phox and NOX4 expression at the 
protein level. p22phox and NOX4 protein levels following ER induced retention of FLT3-ITD. Western 
blot analysis of p22phox and NOX4 protein levels in untreated (UT), vehicle control (control) and 
following treatment with tunicamycin (5 µg/ml) (a) and brefeldin A (10 µg/ml) (b) overnight. β-actin 
is shown as a loading control. Bar charts show relative mean p22phox and NOX4 protein levels following 
treatment with tunicamycin (5 µg/ml) (a) and brefeldin A (10 µg/ml) (b) overnight as quantified by 
densitometry. The data are expressed as % of control, where the ratio in the control was defined as 1. 
Results are presented as mean ± SD from four independent experiments. Asterisks indicate statistically 
significant differences (***p<0.001, ****p<0.0001) as analysed by Student’s t-test. 
 
a) b) 
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3.3.7. p22phox knockdown had no effect on NOX4 protein levels 
We have shown that impaired trafficking of the mutated FLT3 receptor to the 
plasma membrane results in decreased p22phox and NOX4 protein levels (Figure 3.9.). 
p22phox is a partner protein and is required for functionally active NOX1-4 (Ambasta 
et al., 2004). Specific p22phox knockdown allowed us to investigate the effects of 
p22phox on NOX4 protein expression. Knockdown of p22phox had no effect on NOX4 
protein levels (Figure 3.10.). 
 
 
Figure 3.10. Knockdown of p22phox in FLT3-ITD expressing MV4-11 cells had no effect on NOX4 
protein levels. p22phox siRNA knockdown effect on NOX4 protein levels. Western blot analysis of 
p22phox and NOX4 protein levels in MV4-11 cells following treatment with p22phox siRNA compared 
with the non-targeting scrambled (Scr) siRNA treated control. β-actin is shown as a loading control. 
Western blot is representative of three independent experiments. 
 
3.3.8. NOX-generated ROS contribute to total pro-survival ROS in 
AML 
Our group has shown previously that knocking down p22phox resulted in almost 
20% decrease in total and nuclear H2O2, and knocking down NOX4 resulted in 
approximately 30% decrease of total cellular H2O2 and 20% decrease of nuclear H2O2 
(Stanicka et al., 2015). Given that ER retention of FLT3-ITD resulted in a significant 
decrease in p22phox and NOX4 protein levels (Figure 3.9.), we decided to investigate 
the effect of ER retention of FLT3-ITD on total endogenous H2O2 using the probe 
92 
 
Peroxy Orange 1 (PO1). This revealed that tunicamycin treated cells resulted in 
approximately 35% decrease and brefeldin A treated cells resulted in approximately 
25% decrease of total endogenous H2O2 as quantified by flow cytometry. (Figure 
3.11.) 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
d) 
a) 
c) 
Figure 3.11. Production of NOX4-
generated ROS from FLT3-ITD at 
the plasma membrane contributes 
to total endogenous H2O2 in MV4-
11 cells. Cellular H2O2 levels 
following retention of FLT3-ITD in 
compartments of the endomembrane 
system. Live cell 
immunofluorescence of total cellular 
H2O2 levels in vehicle control 
(control) and tunicamycin treated (5 
µg/ml overnight) (a) and brefeldin A 
treated (10 µg/ml overnight) (b) 
MV4-11 cells as measured by H2O2-
probe, Peroxy Orange 1 (PO1). The 
scale bar represents 30µm. Flow 
cytometric analysis of mean relative 
PO1 fluorescence in MV4-11 cell 
line treated with tunicamycin 
overnight (c), and brefeldin A 
overnight (d). Bar charts show 
relative mean PO1 fluorescence of 
treated cells expressed as % of 
control. Results are presented as 
mean ± SD from three independent 
experiments. Asterisks indicate 
statistically significant differences 
(**p<0.01, ****p<0.0001) as 
analysed by Student’s t-test.  
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3.3.9. Cyclooxygenase-generated ROS do not contribute to total 
endogenous H2O2 in AML; while mitochondrial-generated ROS 
contribute to total endogenous H2O2 in AML.  
p22phox and NOX4 contribute to approximately 25-35% total endogenous H2O2 
(Figure 3.11.). We investigated other potential sources of ROS that may contribute to 
total endogenous H2O2 in FLT3-ITD expressing AML MV4-11 cells. We used 
cyclooxygenase inhibitor, diclofenac, and mitochondrial ROS inhibitor, rotenone, and 
measured their effect on total endogenous H2O2 using PO1. Quantification by flow 
cytometry revealed that cyclooxygenase-generated ROS do not contribute 
significantly to total endogenous H2O2 (Figure 3.12.). However, inhibition of 
mitochondrial-generated ROS, using rotenone at high concentrations (50 µM), 
resulted in approximately 30% decrease of total endogenous H2O2. (Figure 3.13.)  
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Figure 3.12. Cyclooxygenase-generated ROS do not contribute to total endogenous H2O2 in MV4-
11 cells. Cellular H2O2 levels following inhibition of cyclooxygenase-generated ROS using diclofenac. 
Flow cytometric analysis of mean relative PO1 fluorescence using 1 μM - 50 μM range diclofenac 
concentrations in MV4-11 cells for 2 h (a). Bar chart shows relative mean PO1 fluorescence of treated 
cells expressed as % of control (b). Results are presented as mean ± SD from three independent 
experiments. Bar chart of % cell viability following treatment with the indicated concentrations of 
diclofenac compared to vehicle controls (N=2) (c). 
a) 
b) c) 
95 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Mitochondrial-generated ROS contribute to total endogenous H2O2 in MV4-11 cells. 
Cellular H2O2 levels following inhibition of mitochondrial-generated ROS using rotenone. Flow 
cytometric analysis of mean relative PO1 fluorescence using 1 μM - 50 μM range rotenone 
concentrations in MV4-11 cells for 1 h (a). Bar chart shows relative mean PO1 fluorescence of treated 
cells expressed as % of control (b). Results are presented as mean ± SD from three independent 
experiments. Asterisks indicate statistically significant differences (****p<0.0001) as analysed by 
Student’s t-test. Bar chart of % cell viability following treatment with the indicated concentrations of 
rotenone compared to vehicle controls (N=2) (c). 
a) 
b) c) 
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3.3.10. Inhibition of FLT3-ITD in MV4-11 cells reduces total 
endogenous H2O2 
We have shown that impaired trafficking of the mutated FLT3 receptor to the 
plasma membrane in MV4-11 cells resulted in a decrease of 25-35% total endogenous 
H2O2 (Figure 3.11.). To study the molecular events downstream of FLT3-ITD at the 
plasma membrane and ER, we employed a small tyrosine kinase inhibitor (TKI) of 
FLT3, PKC412, recently approved by FDA for the treatment of AML patients 
expressing the FLT3-ITD mutation (Rydapt, 2017, Stone et al., 2017). Inhibition of 
the FLT3 receptor in MV4-11 cells using PKC412 resulted in a decrease of 45-50% 
of total endogenous H2O2 (Figure 3.14.). 
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Figure 3.14. Inhibition of the FLT3 receptor in FLT3-ITD expressing MV4-11 cells reduces total 
endogenous H2O2. Levels of cellular H2O2 following FLT3-ITD inhibition. Flow cytometric analysis 
of mean relative PO1 fluorescence in MV4-11 cell line treated with PKC412 (50 nM, 200 nM and 250 
nM) for 24 h (a). Bar chart shows relative mean PO1 fluorescence of PKC412 treated cells expressed 
as % of control (b). Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test. Bar chart 
of % cell viability following treatment with the indicated concentrations of PKC412 compared to 
vehicle controls (N=2) (c). 
 
 
 
 
b) c) 
a) 
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3.3.11. Impaired trafficking of the FLT3-ITD receptor to the plasma 
membrane and FLT3-ITD inhibition results in decreased p22phox 
mRNA levels  
Given that ER retention of FLT3-ITD results in a significant decrease in NOX4 
and p22phox protein levels in MV4-11 cells (Figure 3.9.), we investigated whether this 
effect was mediated at the transcriptional or at the translational level. In order to 
examine the effects of tunicamycin and brefeldin A on p22phox and NOX4 at mRNA 
level, we employed and tested Qiagen QuantiTect Primer Assays to amplify β-actin 
(ACTB), Beta-2-microglobulin (B2M), Proteasome (prosome/macropain) subunit, 
beta type, 2 (PSMB2), p22phox/Cytochrome b-245, alpha polypeptide and NOX4. 
Primer efficiency was first examined for each QuantiTect Primer Assay set as 
described in Section 2.11. All primer sets were between 86% and 105% efficient 
(Figure 3.15.) and within 20% efficiency of each other, as is recommended 
(Schmittgen and Livak, 2008). However, the Qiagen QuantiTect NOX4 Primer Assay 
failed to amplify the NOX4 mRNA transcript in MV4-11 cells. We tested four 
predesigned NOX4 primer sets, yet only one primer set successfully amplified NOX4 
in MV4-11 cells, NOX4_4 (fourth primer set). As a result this NOX4 primer set 
(NOX4_4), previously shown to amplify the NOX4 mRNA transcript in MV4-11 cells 
were employed (Reddy et al., 2011). By comparison of both sets of primers we 
identified that FLT3-ITD expressing MV4-11 cells express the NOX4 transcript 
variant X3 (Figure 3.16.). Qiagen QuantiTect NOX4 Primer Assay does not amplify 
this transcript hence the failure to detect NOX4 using these primers. 
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Gene R2 value Slope Amplification Factor Primer Efficiency (%) 
β-actin 0.9946 -3.3371 1.99 99.37 
B2M 0.9958 -3.1985 2.05 105.42 
PSMB2 0.9978 -3.2409 2.03 103.5 
p22phox 0.9961 -3.7049 1.86 86.17 
 
Figure 3.15.  RT-qPCR primer efficiency plots. Mean quantification cycle (Cq) values of each set of 
serial dilution plotted against the logarithm of cDNA template (from untreated MV4-11 cells) 
concentration.  
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Gene Qiagen Primer 
set 
Product size Ref Seq ID# Transcript variant, mRNA 
NOX4 QT00057498 77 bp NM_001143836 Homo sapiens NOX4, transcript variant NOX4B, 
mRNA 
   NM_001143837 Homo sapiens NOX4, transcript variant 3, mRNA 
   NM_016931 Homo sapiens NOX4, transcript variant 1, mRNA 
   NM_026571 Replaced by NM_001291926 
   NM_001291926 Homo sapiens NOX4, transcript variant 4, mRNA 
   NM_001291927 Homo sapiens NOX4, transcript variant 5, mRNA 
   NM_001291929 Homo sapiens NOX4, transcript variant 6, mRNA 
   NM_001300995 Homo sapiens NOX4, transcript variant 8, mRNA 
   XM_006718848 Record removed 
   XM_006718849 Predicted: Homo sapiens NOX4, transcript variant 
X2, mRNA 
   XM_006718852 Record removed 
   XM_006718853 Record removed 
 
 
 
 
Figure 3.16. Hs_NOX4_1_SG QuantiTect Primer Assay does not amplify Homo sapiens NADPH 
oxidase 4 (NOX4), transcript variant X3, mRNA sequence (Ref Seq ID# XM_011542857.2); 
NOX4_4 primers (Eurofins) amplify NOX4, transcript variant X3. Table of 
Hs_NOX4_1_SG_QuantiTect Primer Assay (QT00057498) detected transcripts (a). NOX4_4 primers 
(Eurofins) (yellow) amplify Homo sapiens NOX4, transcript variant X3, mRNA sequence expressed in 
MV4-11 cells (b). 
 
b) 
a) 
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The integrity of isolated RNA was examined by separation of 5 µg of isolated 
RNA on 1% SYBR Safe agarose gel. RNA integrity was confirmed if distinct, sharp 
bands for 28S and 18S ribosomal RNA (rRNA) were distinguishable, with no 
smearing of the sample or additional bands (Figure 3.17. a). Amplification of the 
intended transcript variants was confirmed by the appearance of a single band at the 
appropriate size following amplification (Figure 3.17. b). 
 
                                                                                   
 
Figure 3.17. Integrity of RNA and confirmation of amplified RT-qPCR products. 5 µg  of isolated 
RNA and 1 µg cDNA were separated on 1% SYBR Safe agarose gel with 28S and 18S rRNA bands 
indicated (a). RT-qPCR products run on 2% SYBR Safe agarose gel. Amplification of the intended 
target transcripts. Lane 1-5: β-actin, B2M, PSMB2, p22phox (all from Qiagen) and NOX4 (Eurofins) (b). 
 
 The NOX4_4 Eurofins primer set melt curve analysis identified a variety of 
PCR products following amplification. Primer efficiency was tested and identified the 
primer set to be inefficient (Figure 3.18. a). On the other hand, subsequent gene 
200 bp 
100 bp 
18S rRNA 
28S rRNA 
a) b) 
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sequencing was carried out by GATC Biotech and confirmed the amplification and 
expression of NOX4 transcript variant X3 in FLT3-ITD expressing MV4-11 cells 
(Figure 3.18. b). Due to issues with NOX4 primer inefficiency we decided not to 
continue with NOX4 mRNA studies. 
 
 
Gene R2 value Slope 
NOX4 0.0358 -0.1951 
 
 
 
 
Figure 3.18.  RT-qPCR primer efficiency plot for NOX4_4 primers. Inefficient NOX4_4 primers 
amplified NOX4, transcript variant X3 in MV4-11 cells. Mean quantification cycle (Cq) values of 
each set of serial dilution plotted against the logarithm of cDNA template (from untreated MV4-11 
cells) concentration (a). BLAST alignment of NOX4_4 product compared to NCBI database (b). 
‘Query’ is the sequence of the sample amplified, and the ‘Sbjct’ is NADPH oxidase 4 (NOX4), 
transcript variant X3 mRNA sequence in the NCBI database. The two sequences are an exact match. 
y = -0.1951x + 36.707
R² = 0.0358
35.5
36
36.5
37
37.5
38
38.5
39
39.5
-6 -4 -2 0
C
q
 v
al
u
es
Log10 cDNA values
NOX4_4 Standard Curve
a) 
b) 
103 
 
 Following confirmation of the amplification of the intended transcripts (Figure 
3.17. b), we examined the effect of impaired trafficking of FLT3-ITD to the plasma 
membrane on p22phox regulation at the transcriptional level. p22phox mRNA levels 
decreased approximately 60% following treatment with tunicamycin and 
approximately 75% following treatment with brefeldin A (Figure 3.19.). Taken 
together these results suggest that p22phox is regulated at the transcriptional level 
following treatment with both receptor trafficking inhibitors.  
 
                       
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. Treatment of MV4-11 cells with tunicamycin and brefeldin A results in a decrease in 
p22phox RNA expression. p22phox RNA expression following treatment with receptor trafficking 
inhibitors tunicamycin (5 µg/ml overnight) (a) and brefeldin A (10 µg/ml overnight) (b) in MV4-11 
cells.  Results are presented as mean ± SD from four independent experiments. Asterisks indicate 
statistically significant differences (****p<0.0001) as analysed by Student’s t-test.  
 
Previous studies in our laboratory have reported p22phox to be regulated at the 
post-translational level following inhibition of FLT3-ITD using PKC412 (Woolley et 
al., 2012). Therefore, we examined the effect of FLT3-ITD inhibition via PKC412 on 
p22phox mRNA levels. FLT3-ITD inhibition resulted in approximately 40% decrease 
a) b) 
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in p22phox mRNA levels (Figure 3.20.). Collectively p22phox is regulated at both RNA 
and protein levels following inhibition of FLT3-ITD in MV4-11 cells. 
 
 
3.3.12. Serine protease inhibitor 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (AEBSF) inhibits NOX4 protein levels 
 We have shown previously that ER retention of FLT3-ITD resulted in 
decreased p22phox mRNA levels (Figure 3.19.). We decided to investigate if p22phox 
was also regulated at the translational level, as well as investigating the effect of 
impaired FLT3-ITD receptor trafficking on the regulation of NOX4 at the translational 
level.  At the beginning of this study, some western blotting issues were encountered. 
NOX4, β-actin and α-tubulin proteins were not detected in freshly prepared MV4-11 
cell lysates (Figure 3.21. a) compared to previously prepared MV4-11 cell lysates 
(Figure 3.21. b). It was crucial to solve this issue for future western blotting studies. 
 
 
Figure 3.20. FLT3-ITD inhibition results in a 
decrease in p22phox RNA expression. p22phox RNA 
expression following treatment with PKC412 200 
nM for 24 h in MV4-11 cells. Results are presented 
as mean ± SD from three independent experiments. 
Asterisks indicate statistically significant 
differences (****p<0.0001) as analysed by 
Student’s t-test.  
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a) 
                    
 
Figure 3.21. Failure to detect NOX4, β-actin and α-tubulin protein levels in freshly prepared 
MV4-11 cell lysates. Western blot analysis of p22phox, NOX4 and β-actin protein levels in fresh lysates: 
untreated (UT), vehicle control (control), following treatment with tunicamycin (5 µg/ml) and 
tunicamycin in combination with 20S proteasome inhibitor lactacystin (5 µM) overnight (a). β-actin is 
shown as a loading control. Western blot analysis of p22phox, NOX4, β-actin and α-tubulin protein levels 
in previously prepared lysates (positive control): vehicle control (control) and following treatment with 
indicated concentrations of PKC412 for 24 hr (b). β-actin and α-tubulin are shown as loading controls. 
 
Using NOX4-expressing lysates as a positive control, we investigated total 
protein levels in the SDS-PAGE gel stained with Coomassie brilliant blue and the 
nitrocellulose membrane stained with Ponceau. Decreased levels of proteins ranging 
from 38 kDa to 90 kDa in weight were detected in freshly prepared lysates compared 
to our positive controls. The decreased protein levels corresponds to the molecular 
weights of NOX4, β-actin and α-tubulin (Figure 3.22.). 
 
 
 
 
b) 
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Figure 3.22. Decreased levels of protein bands ranging from 38 kDa to 90 kDa in size detected in 
freshly prepared lysates. Analysis of total protein levels in freshly prepared lysates (Lane 2-6) and 
previously prepared lysates (Lane 7-10 (positive control)) by means of staining the gel with Coomassie 
brilliant blue overnight (a) and incubating the nitrocellulose membrane with Ponceau (b). Western blot 
analysis of p22phox, NOX4 and α-tubulin protein levels in freshly prepared lysates compared to positive 
control lysates (c). 
 
 Next we investigated if the proteins were aggregating in the stacking gel and 
if the cells were lysing efficiently with RIPA buffer. We demonstrated that protein 
aggregation was not an issue due to the absence of protein in the stacking gel of the 
SDS-PAGE gel (Figure 3.23. a). We validated cells were lysed instantly and efficiently 
b) a) 
c) 
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by the lack of protein in pellets following cell lysis with RIPA buffer (Figure 3.23. b 
and c). Following the purchase and lysing of new MV4-11 cells, the issue still 
remained. We therefore turned our attention to components in the RIPA lysis buffer. 
We focused on protease inhibitors due to the lack of protein detection between 38 kDa 
and 90 kDa molecular weight marker in the new vial of cells (Figure 3.23. d-f). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
c) 
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Figure 3.23. RIPA buffer lysed MV4-11 cells efficiently. Analysis of total protein levels in freshly 
prepared and positive control MV4-11 cell lysates in the stacking and resolving gels of the SDS-PAGE 
gel following staining overnight with Coomassie brilliant blue (a). Phase contrast imaging of MV4-11 
cells in 1X PBS, RIPA buffer and RIPA plus an extra 1% NP-40 (b). Staining of the SDS-PAGE gel 
containing lysates prepared with old (L1 and L2) and new (L3 and L4) vial of cocktail protease 
inhibitors and pellet extractions with old (P1 and P2) and new (P3 and P4) vial of cocktail protease 
inhibitors overnight with Coomassie brilliant blue (c). Analysis of whole cell lysis of a new vial of 
MV4-11 cells from DSMZ (Braunschweig, Germany) by means of staining the SDS-PAGE gel with 
Coomassie brilliant blue overnight (d) and incubating the nitrocellulose membrane in Ponceau (e). 
Western blot analysis of NOX4 and α-tubulin protein levels in new DSMZ MV4-11 cell lysates (f). 
 
Prior to these western blotting issues, one of the protease inhibitors in the RIPA 
lysis buffer was changed. 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) is one of the most commonly used serine protease inhibitors and from this 
study it is demonstrated as having an effect on NOX4 protein levels. Reverting back 
to Phenylmethylsulfonyl fluoride (PMSF), a serine protease inhibitor and 
acetylcholinesterase resulted in detection of NOX4, β-actin and α-tubulin proteins 
(Figure 3.24.). Interestingly, the serine protease inhibitor AEBSF has been identified 
as a proposed inhibitor of NOXs (Diatchuk et al., 1997, Drummond et al., 2011, 
d) e) f) 
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Altenhöfer et al., 2015). Taken together, these findings suggest that the serine protease 
inhibitor PMSF should be used as an alternative to AEBSF when preparing lysates to 
study the expression and activity of NOX proteins. 
 
 
 
 
Figure 3.24. Serine protease inhibitor 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
(AEBSF) inhibits NOX4 protein levels; serine protease inhibitor and acetylcholinesterase 
Phenylmethylsulfonyl fluoride (PMSF) should be used as an alternative when preparing cell 
lysates. Analysis of whole cell lysis of MV4-11 cells using serine protease inhibitors, AEBSF and 
PMSF alongside a positive control lysate by means of staining the SDS-PAGE gel with Coomassie 
brilliant blue overnight (a) and incubating the nitrocellulose membrane with Ponceau (b). Western blot 
analysis of NOX4 and α-tubulin protein levels using RIPA buffer containing AEBSF and PMSF (c). 
 
3.3.13. Inhibition of FLT3-ITD cell surface expression results in 
proteasomal degradation of p22phox and deglycosylation of NOX4 
Our group has shown that inhibition of FLT3-ITD using PKC412 results in 
proteasomal degradation of p22phox by the ubiquitin proteasome pathway (Woolley et 
al., 2012). Given that p22phox and NOX4 protein levels decrease significantly 
following treatment with tunicamycin and brefeldin A (Figure 3.9.), we decided to 
b) c) a) 
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investigate whether impaired trafficking of FLT3-ITD resulted in regulation of p22phox 
and NOX4 at the translational level. To this end, we treated cells with tunicamycin 
and brefeldin A in the presence of 20S proteasome inhibitor, lactacystin. ER retention 
of FLT3-ITD resulted in NOX4 deglycosylation and p22phox degradation by the 
proteasome. Inhibition of the 20S proteasome prevented proteasomal degradation of 
p22phox (Figure 3.25. a and b). Interestingly, this increase in p22phox protein levels to 
basal level did not coincide with an increase in endogenous H2O2 (Figure 3.26. a and 
b). 
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Figure 3.25. Tunicamycin and brefeldin A induce ER retention of FLT3-ITD, resulting in NOX4 
deglycosylation and p22phox proteasomal degradation. p22phox and NOX4 protein levels following 
ER retention of FLT3-ITD and inhibition of the 20S proteasome. Western blot analysis of p22phox and 
NOX4 protein levels in untreated (UT), vehicle control (control), following treatment with tunicamycin 
(5 µg/ml) (a) and brefeldin A (10 µg/ml) (b) overnight and also in combination with 20S proteasome 
inhibitor lactacystin (5 µM) overnight. β-actin is shown as a loading control. Bar charts show relative 
mean p22phox and NOX4 protein levels following treatment with tunicamycin (5 µg/ml) (a) and 
brefeldin A (10 µg/ml) (b) overnight and in combination with lactacystin (5 µM) as quantified by 
densitometry. The data are expressed as % of control, where the ratio in the control was defined as 1. 
Results are presented as mean ± SD from three independent experiments. Asterisks indicate statistically 
significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as analysed by one-way 
ANOVA with multiple comparisons. 
b)(i) a)(i) 
a)(ii) b)(ii) 
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Figure 3.26. Prevention of p22phox degradation had no effect on total endogenous H2O2 levels in 
MV4-11 cells. Cellular H2O2 levels following retention of FLT3-ITD in compartments of the 
endomembrane system and inhibition of the 20S proteasome. Flow cytometric analysis of mean relative 
PO1 fluorescence in MV4-11 cell line treated with lactacystin and tunicamycin overnight (a), and 
brefeldin A overnight (b). Bar charts show relative mean PO1 fluorescence of treated cells expressed 
as % of control. Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
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3.4. Discussion 
Oncogenic kinases act as drivers of ROS production in myeloid leukaemia 
(Behrend et al., 2003). Mutations in tyrosine kinases are commonly found in cancer 
and act as  primary or secondary mediators of oncogenic signalling (Blume-Jensen 
and Hunter, 2001). FLT3-ITD is the most prevalent FLT3 mutation expressed in 15-
35% of AML cases. Constitutive activation of FLT3-ITD at the plasma membrane and 
ER is associated with a poor prognosis (Kayser et al., 2009). The FLT3-WT and FLT3-
ITD receptors have been shown to colocalise to the plasma membrane, however, the 
mutated FLT3 receptor has been associated with an inferior outcome resulting in 
disease development and progression. Here we analysed the expression of the FLT3 
receptor at the plasma membrane of FLT3-ITD-expressing cells and found that they 
express 250-fold increase of FLT3 protein and cell surface expression compared to 
their wild-type counterpart (Figure 3.3.). This validates that the localisation of the 
mutated FLT3 receptor to the plasma membrane of FLT3-ITD-expressing cells is 
associated with oncogenic signalling and disease progression.  
A number of studies have investigated the function of ROS, specifically 
NOX4-generated ROS in AML. Our group has shown that NADPH oxidases (NOX), 
in particular NOX4 and p22phox, a small membrane subunit of the NOX complex, are 
major sources of ROS in AML (Woolley et al., 2012, Stanicka et al., 2015). However, 
the molecular mechanism describing how mislocalised activation of FLT3-ITD and 
the aberrant signalling of downstream pathways (PI3K/AKT, ERK/MAPK and 
STAT5) leads to the production of ROS remains unknown.  
NOX-derived ROS have been shown to have numerous effects in leukaemia 
including a differentiation block, cell proliferation and resistance to apoptosis 
(Naughton et al., 2009, Reddy et al., 2011). Leukaemic oncogenes have been widely 
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documented in the regulation of the expression of the NOX family and their partner 
protein, p22phox (Jayavelu et al., 2016a, Naughton et al., 2009, Landry et al., 2013, 
Hurtado-Nedelec et al., 2013). p22phox is a membrane-bound protein and is an essential 
component required for fully functioning NOX1-4 (Ambasta et al., 2004). Our group 
demonstrated that cells expressing FLT3-ITD produce higher levels of pro-survival 
reactive oxygen species (ROS) in comparison to FLT3-wild type (Stanicka et al., 
2015). 
In this study, we investigated the role of trafficking of the oncogenic FLT3-
ITD receptor and its effect on the production of ROS utilising receptor trafficking 
inhibitors, tunicamycin and brefeldin A. We found that tunicamycin and brefeldin A 
cause ER retention of FLT3-ITD (Figure 3.4. - Figure 3.7.) by inhibiting glycosylation 
of the FLT3-ITD receptor (Choudhary et al., 2009, Moloney et al., 2017b). p22phox and 
NOX4 protein levels decrease significantly following ER retention of FLT3-ITD 
(Figure 3.9.) suggesting that p22phox and NOX4 protein expression is dependent on 
FLT3-ITD being present at the plasma membrane. Importantly, to our knowledge, this 
is the first study that finds FLT3-ITD cellular organisation to play an essential role in 
the production of NOX4-generated pro-survival ROS and p22phox stability.  
p22phox is a partner protein of NOX4 and is required for NOX4 activation 
(Ambasta et al., 2004). We found that p22phox knockdown in MV4-11 cells had no 
significant effect on NOX4 protein levels (Figure 3.10.). However, previous studies 
demonstrated that NOX4 knockdown in human umbilical vein endothelial cells 
(HUVECs) had no effect on p22phox at mRNA level yet resulted in a substantial 
decrease in p22phox protein levels (Kuroda et al., 2005). These observations suggested 
that NOX4 forms a complex with p22phox resulting in the stabilisation of p22phox at the 
protein level. 
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Plasma membrane FLT3-ITD and endoplasmic reticulum FLT3-ITD 
contribute to total endogenous H2O2 in FLT3-ITD expressing AML (Figure 3.14.). 
Here, we show that a decrease in p22phox and NOX4 protein levels following ER 
retention of FLT3-ITD correlates with a decrease in endogenous H2O2 (Figure 3.11.). 
This data suggests that p22phox- and NOX4-generated H2O2 contribute to total 
endogenous H2O2 in FLT3-ITD AML. Also we found that mitochondrial-generated 
ROS contribute to endogenous H2O2 in FLT3-ITD expressing AML (Figure 3.13.). 
Interestingly, we have shown that cyclooxygenase-generated ROS do not contribute 
to total pro-survival ROS in FLT3-ITD expressing AML (Figure 3.12.).  
Tunicamycin and brefeldin A inhibit glycosylation of many proteins. For this 
reason they are not suitable for the treatment of FLT3-ITD expressing AML cases. 
They have however previously been used to examine the effects of cellular localisation 
of oncogenic FLT3-ITD and its effect on pro-survival signalling pathways (Choudhary 
et al., 2009). In this study, a mutant of FLT3-ITD was created that contained a deletion 
of the extracellular ligand-binding domain of FLT3-ITD (FLT3-ITD ΔECD). This 
mutation eliminated many potential sites of glycosylation, resulting in glycosylation-
independent trafficking of the FLT3-ITD receptor. The findings in this study not only 
support the current study, highlighting a crucial role for FLT3-ITD at the plasma 
membrane activating oncogenic signalling, but it also endorses the use of receptor 
trafficking inhibitors, such as tunicamycin and brefeldin A, as a method to investigate 
the effect of subcellular localisation of FLT3-ITD on the generation of ROS. This 
study will be discussed in further detail in the next chapter.  
Our group has previously shown that inhibition of FLT3-ITD results in 
decreased p22phox protein levels as a result of protein degradation by the ubiquitin 
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proteasome pathway (Woolley et al., 2012). We have shown that inhibition of FLT3-
ITD results in regulation of p22phox at both RNA and protein levels (Figure 3.20.). 
We have demonstrated that ER retention of FLT3-ITD results in regulation of 
p22phox at the transcriptional level (Figure 3.19.) and proteasomal degradation of 
p22phox (Figure 3.25.). Receptor trafficking inhibitors, tunicamycin and brefeldin A 
inhibit glycosylation. NOX4 is glycosylated at two asparagines, amino acid position 
133 and 230 (Goyal et al., 2005). Treatment of FLT3-ITD AML expressing cells with 
these inhibitors results in deglycosylation of NOX4 (Figure 3.25.). Degradation of 
p22phox was prevented following treatment with the 20S proteasome inhibitor 
lactacystin (Figure 3.25.). Interestingly, p22phox function was not recovered, as we 
observed by no significant increase in endogenous H2O2 (Figure 3.26.). 
In conclusion, we propose that FLT3-ITD at the plasma membrane is 
responsible for the activation and expression of p22phox- and NOX4-generated pro-
survival ROS in FLT3-ITD expressing AML cells. p22phox is essential for the 
maintenance of pro-survival signalling in AML. For FLT3-ITD to generate its 
oncogenic effects it has to be located at the plasma membrane. ER retention of FLT3-
ITD results in NOX4 deglycosylation and decreased mRNA levels and proteasomal 
degradation of p22phox. This study presents FLT3-ITD at the plasma membrane as a 
potential therapeutic target, in preventing downstream ROS-driven oncogenic effects. 
The production of p22phox- and NOX4-generated pro-survival H2O2 downstream of 
FLT3-ITD at the plasma membrane is studied in further detail in Chapter 4. 
Further studies have identified glycan biosynthesis as a therapeutic target for 
cancer (Contessa et al., 2010). Inhibition of N-glycosylation of RTKs including FLT3-
ITD and c-KIT has been shown to have anti-leukaemic activity in AML using 2-
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deoxy-glucose and fluvastatin. Loss of surface expression of FLT3-ITD and c-KIT 
results in the induction of apoptotic cell death, mitigation of resistance to TKIs 
including the most potent FLT3 inhibitor currently in clinical trials, quizartinib, and 
also restores sensitivity to chemotherapy drug cytarabine (Williams et al., 2012). More 
recently, our collaborators have demonstrated the synergistic killing of FLT3-ITD 
expressing AML MV4-11 cell line and primary cells through combined inhibition of 
FLT3-ITD tyrosine kinase activity and N-glycosylation using low doses of 
tunicamycin (Tsitsipatis et al., 2017). Taken together these studies confirm FLT3-ITD 
surface expression as a promising therapeutic target in AML. 
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Chapter 4. Mislocalised activation of 
FLT3-ITD initiates aberrant signalling 
from pro-survival pathways  
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4.1. Abstract 
Aberrant activation of oncogenic kinases at intracellular locations is frequently 
observed in cancer. Internal tandem duplication of the juxtamembrane domain of 
FMS-like tyrosine kinase 3 receptor (FLT3-ITD) is the most prevalent mutation in 
acute myeloid leukaemia (AML), resulting in constitutive activation of the FLT3 
receptor at the plasma membrane and ‘impaired trafficking’ of the receptor in 
compartments of its biosynthetic route, such as the endoplasmic reticulum (ER). We 
have shown that NADPH oxidase (NOX)-and p22phox-generated reactive oxygen 
species (ROS) are located downstream of FLT3-ITD at the plasma membrane where 
they are contributing to cell survival and proliferation, a differentiation block and 
disease progression. The mechanism describing how mislocalised activation of FLT3-
ITD at the plasma membrane leads to the production of NOX4- and p22phox- pro-
survival ROS remains unknown. The purpose of this study was to investigate which 
pro-survival pathways are activated downstream of FLT3-ITD at the plasma 
membrane and are responsible for the production of NOX4- and p22phox-generated 
hydrogen peroxide (H2O2) in AML. Receptor trafficking inhibitors, tunicamycin and 
brefeldin A inhibit surface expression of FLT3-ITD. FLT3-ITD at the plasma 
membrane is responsible for the activation of AKT and ERK1/2 signalling and 
inhibition of the GSK3β pro-survival pathway. We found that PI3K/AKT signalling 
only occurs when FLT3-ITD is expressed at the plasma membrane and is required for 
the production of NOX4- and p22phox-generated ROS. Taken together these findings 
and previous findings indicate that FLT3-ITD at the plasma membrane is responsible 
for the production of NOX4- and p22phox-generated H2O2 and presents FLT3-ITD at 
the plasma membrane as a potential therapeutic target in AML. 
120 
 
4.2. Introduction 
In the previous chapter, we began to elucidate the importance of FLT3-ITD 
subcellular localisation on the production of NOX4- and p22phox-generated ROS in 
AML. FLT3-ITD expressing cells have been shown to produce elevated levels of H2O2 
compared to their wild-type counterpart and the elevated production of ROS are 
known to contribute to enhanced cell proliferation and cell survival, differentiation 
block as well as drug resistance and disease progression. We showed that FLT3-ITD 
expressing cells express significantly higher levels of the FLT3 receptor at the plasma 
membrane compared to FLT3-WT expressing cells, presenting FLT3-ITD at the 
plasma membrane as a mediator of oncogenic signalling. We have suggested that 
FLT3-ITD at the plasma membrane is responsible for the production of p22phox-
generated H2O2, and in this chapter, we further investigate the production of NOX4-
generated H2O2 downstream of FLT3-ITD at the plasma membrane. This study 
therefore aimed to examine the mechanism by which mislocalised activation of FLT3-
ITD at the plasma membrane leads to the activation and production of p22phox- and 
NOX4-generated H2O2. From this, we aimed to get a further understanding of the 
localisation and regulation of pro-survival pathways activated downstream of FLT3-
ITD in MV4-11 cells. 
 Different types of tumour cells express elevated levels of ROS compared to 
their normal counterparts. The overproduction of ROS has been shown to induce a 
variety of biological effects including enhanced cell proliferation and cell survival, 
DNA damage and genetic instability, adaptation, cellular injury and apoptosis, 
autophagy and drug resistance (Moloney and Cotter, 2017). ROS have a well-
established role in cell signalling, where an increase in ROS such as O2
•- and H2O2 has 
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been implicated in enhanced cell proliferation and cell survival, increased cellular 
growth and the development of cancer through the regulation of MAPK/ERK1/2, 
PI3K/AKT and PKD signalling pathways to name a few. Increased ROS also function 
through negative regulation of phosphatases, such as PTEN and PTP1B, regulation of 
NF-κB activating pathways, as well as mutations in transcription factors and tumour 
suppressor genes including Nrf2 and p53 (Moloney and Cotter, 2017).  
 Growth factors and KRAS stimulated pathways have been shown to 
activate the MAPK/ERK1/2 pathway in cancer, and this has a role in increased cellular 
proliferation (Khavari and Rinn, 2007, Roberts and Der, 2007). H2O2 is produced as a 
by-product of oestrogen metabolism in breast tumour cells and is responsible for the 
activation of ERK1/2 signalling pathway, resulting in increased proliferation (Irani et 
al., 1997, Reddy and Glaros, 2007) and the activation of the pro-survival PI3K/AKT 
signalling pathway (Burdick et al., 2003, Park et al., 2009). ERK1/2 has additional 
roles other than proliferation. It has a role in cell survival, anchorage-independent 
growth and motility in a variety of cancers including breast, leukaemia, melanoma and 
ovarian cancer (Roberts and Der, 2007, McCubrey et al., 2007, Steelman et al., 2008). 
PKD1 has also been shown to promote cell survival through activation of ERK1/2 and 
down-regulation of the pro-apoptotic c-Jun N terminal protein kinase (JNK) pathway 
(Singh and Czaja, 2007). Other members of the PKD family are implicated in various 
other cancers; PKD2 and PKD3 are found to be highly expressed in breast cancer (Hao 
et al., 2013), increased expression of PKD1 and PKD3 found in prostate carcinoma 
tissue compared to normal prostate tissue (Chen et al., 2008a). PKD2 is also highly 
expressed in both high- and low-grade gliomas (Azoitei et al., 2011). The regulation 
of ROS function in cell survival is cell specific (Chan et al., 2008, Lee et al., 2005, 
Rygiel et al., 2008). 
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The AKT pathway functions in cell survival through the phosphorylation and 
inactivation of its target proteins including pro-apoptotic Bcl-2-associated death 
promoter (Bad), Bcl-2-like protein 4 (Bax), Bcl-2-like 11 (Bim) and forkhead 
transcription factor (Foxo) transcription factors (Brunet et al., 1999, Kawamura et al., 
2007, Limaye et al., 2005, Pastorino et al., 1999, Qi et al., 2006, Xin and Deng, 2005). 
Epidermal growth factor (EGF)-derived H2O2 production has been shown to activate 
AKT in ovarian cancer (Liu et al., 2006). H2O2 acts by oxidising and inactivating the 
phosphatases PTEN and PTP1B, negative regulators of PI3K/AKT signalling, 
resulting in cell survival (Lee et al., 2002, Salmeen et al., 2003). Inactivation of PTEN 
is frequently found in a variety of cancers including breast, endometrial cancers, 
glioblastomas, melanoma and prostate cancer (Wu et al., 2003).  
 Previous studies have investigated the effects of subcellular localisation of 
FLT3-ITD on the activation of pro-survival pathways in 32D cells stably transfected 
with the FLT3-ITD mutation (Choudhary et al., 2009). In this study they employed 
tunicamycin and brefeldin A to inhibit surface expression of FLT3-ITD alongside a 
mutant created of FLT3-ITD, which contained a deletion of the extracellular ligand-
binding domain (FLT3-ITD ∆ECD) thus eliminating any glycosylation sites. Both the 
receptor trafficking inhibitors and FLT3-ITD ∆ECD identified the MAPK/ERK1/2 
and PI3K/AKT pro-survival signalling pathways to be activated downstream of FLT3-
ITD at the plasma membrane and STAT5 signalling pathway to be activated 
downstream of FLT3-ITD at the endoplasmic reticulum (Choudhary et al., 2009). 
These findings endorse the receptor trafficking inhibitors tunicamycin and brefeldin 
A as a method to investigate the effect of subcellular localisation of FLT3-ITD on the 
activation of pro-survival pathways and the generation of pro-survival ROS. 
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4.3. Results 
4.3.1. FLT3-ITD at the plasma membrane is responsible for the 
activation of AKT signalling and inhibition of GSK3β signalling  
In the previous chapter, we began to elucidate the importance of FLT3-ITD 
localisation to the plasma membrane on the production of NOX4- and p22phox-
generated ROS in AML. However, the mechanism in which FLT3-ITD at the plasma 
membrane contributes to the production of NOX and p22phox-generated H2O2 is 
unclear. FLT3-ITD-induced up-regulation of ROS production in AML has been linked 
to enhanced cell survival and proliferation, a differentiation block and genetic 
instability. Constitutive activation of FLT3 switches on downstream pro-survival 
signalling pathways such as PI3K/AKT, MAPK/ERK1/2 and STAT5. Previous 
studies in our laboratory have identified the PI3K/AKT and GSK3β signalling 
pathways to be activated as a result of BCR-ABL induced up-regulation of NOX4-
generated ROS in CML (Naughton et al., 2009, Landry et al., 2013). Therefore, we 
investigated the outcome of treating MV4-11 cells with tunicamycin and brefeldin A 
on AKT and GSK3β pro-survival pathways. Impaired trafficking of the FLT3-ITD 
receptor to the plasma membrane resulting in ER retention of FLT3-ITD revealed a 
decrease in AKT and GSK3β phosphorylation, as well as a decrease in total AKT and 
GSK3β (Figure 4.1.). Thus suggesting that the AKT and GSK3β cell signalling 
pathways are located downstream of FLT3-ITD at the plasma membrane.  
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Figure 4.1. FLT3-ITD at the plasma membrane is responsible for the activation of AKT signalling 
and inhibition of GSK3β signalling. Western blot analysis of AKT and GSK3β signalling in untreated 
(UT), vehicle control (control), and following treatment with tunicamycin (5 µg/ml) overnight (a); in 
untreated (UT), vehicle control (control) and following treatment with brefeldin A (10 µg/ml) overnight 
(b). β-actin is shown as a loading control. Bar charts show relative mean pAKT, AKT, pAKT/AKT, 
pGSK3β, GSK3β and pGSK3β/GSK3β protein levels following treatment with tunicamycin (5 µg/ml) 
(a) and brefeldin A (10 µg/ml) (b) overnight as quantified by densitometry. The data are expressed as 
% of control, where the ratio in the control was defined as 1. Results are presented as mean ± SD from 
three independent experiments. Asterisks indicate statistically significant differences (**p<0.01, 
***p<0.001, ****p<0.0001) as analysed by Student’s t-test. 
 
 
a) b) 
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4.3.2. PI3K/AKT pathway needs to be activated in order for FLT3-
ITD at the plasma membrane to produce its oncogenic effects 
Given that both AKT and GSK3β are switched on downstream of ligand-
independent constitutively activated FLT3-ITD receptor, we investigated which 
signalling pathways are responsible for the aberrant production of NOX4- and p22phox- 
generated pro-survival ROS. The PI3K/AKT inhibitor LY294002 and GSK3β 
inhibitors SB216763 and lithium chloride (LiCl) were used in this study.  
We found the optimal LY294002 concentration with a significant decrease in 
AKT phosphorylation and a minimal effect on cell viability to be 50 µM (Figure 4.2.).  
SB216763 is described as an inhibitor of GSK3β, and GSK3β is inhibited when 
it is phosphorylated. In disagreement with this, SB216763 was found to decrease 
pGSK3β (Ser9) levels significantly in MV4-11 cells suggesting that it is acting as an 
activator of GSK3β (Figure 4.3. b). It is possible that SB216763 could have different 
effects in other cell types. However, based on our findings, we advise careful 
consideration and assessment of pGSK3β levels when using this drug. We found the 
optimal SB216763 concentration with the largest decrease in GSK3β phosphorylation 
and minimal effect on cell viability to be 5 µM (Figure 4.3.). 
Lithium chloride (LiCl) is widely used as a GSK3β inhibitor (Cohen and 
Goedert, 2004). Inhibition of GSK3β using LiCl caused a significant increase in 
GSK3β phosphorylation (Figure 4.4.) in MV4-11 cells, indicative of inhibition of the 
pathway with minimal effect on cell viability. 
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Figure 4.2. Inhibition of PI3K/AKT signalling in MV4-11 cells using LY294002. Bar chart of % 
cell viability following treatment with the indicated concentrations of LY294002 compared to vehicle 
controls (N=2) (a). Western blot analysis of AKT signalling in vehicle control (control), and following 
treatment with LY294002 (20 µM, 30 µM and 50 μM) for 16 h (b). β-actin and total protein (REVERT 
total protein stain) are shown as loading controls. Bar chart shows relative mean pAKT, AKT and 
pAKT/AKT protein levels following treatment with LY294002 (20 µM, 30 µM and 50 µM) for 16 h as 
quantified by densitometry. The data are expressed as % of control, where the ratio in the control was 
defined as 1.  Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (**p<0.01, ***p<0.001, ****p<0.0001) as analysed by 
Student’s t-test. 
 
 
a) 
b) 
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Figure 4.3. Activation of GSK3β signalling in MV4-11 cells using SB216763. Bar chart of % cell 
viability following treatment with the indicated concentrations of SB216763 compared to vehicle 
controls (N=2) (a). Western blot analysis of GSK3β signalling in vehicle control (control), and 
following treatment with SB216763 (1 µM, 2 µM and 5 µM) for 16 h (b). β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. Bar chart shows relative mean pGSK3β, 
GSK3β and pGSK3β/GSK3β protein levels following treatment with SB216763 (1 µM, 2 µM and 5 
µM) for 16 h as quantified by densitometry. The data are expressed as % of control, where the ratio in 
the control was defined as 1.  Results are presented as mean ± SD from three independent experiments. 
Asterisks indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test. 
 
 
 
a) 
b) 
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Figure 4.4. Inhibition of GSK3β signalling in MV4-11 cells using lithium chloride (LiCl). Bar chart 
of % cell viability following treatment with the indicated concentrations of LiCl compared to vehicle 
controls (N=2) (a). Western blot analysis of GSK3β signalling in vehicle control (control), and 
following treatment with LiCl (10 mM, 20 mM and 50 mM) for 16 h (b). β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. Bar chart shows relative mean pGSK3β, 
GSK3β and pGSK3β/GSK3β protein levels following treatment with LiCl (10 mM, 20 mM and 50 
mM) for 16 h as quantified by densitometry. The data are expressed as % of control, where the ratio in 
the control was defined as 1.  Results are presented as mean ± SD from three independent experiments. 
Asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ****p<0.0001) as analysed 
by Student’s t-test. 
 
 
a) 
b) 
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Inhibition of the AKT pathway using the PI3K inhibitor, LY294002 (LY), 
resulted in a significant decrease in p22phox and NOX4 protein levels (Figure 4.5. (i) a 
and Figure 4.5. (ii) a). Activation of GSK3β using SB216763 (SB) was found to have 
no noticeable effect on NOX4 and p22phox protein levels (Figure 4.5. (i) b and Figure 
4.5. (ii) b) whereas inhibition of GSK3β using LiCl caused a significant increase in 
NOX4 protein levels. Interestingly, p22phox protein levels decreased significantly 
following treatment with 50 mM LiCl (Figure 4.5. (i) c and Figure 4.5. (ii) c). Thus, 
AKT needs to be phosphorylated and activated in order for FLT3-ITD at the plasma 
membrane to produce its oncogenic effects.  
 
              
 
 
 
 
 
 
 
                             
 
 
 
 
 
Figure 4.5. (i) NOX4- and p22phox-generated pro-survival ROS require AKT activation. Western 
blot analysis of p22phox and NOX4 protein levels in MV4-11 cells following treatment with PI3K/AKT 
inhibitor LY294002 (LY; 50 µM) (a), GSK3β activator SB216763 (SB; 5 µM) (b) and GSK3β inhibitor 
lithium chloride (10 mM, 20 mM and 50 mM) (c) for 16 h. β-actin is shown as a loading control. 
Western blots are representative of three independent experiments. 
a) b) 
c) 
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Figure 4.5. (ii) NOX4- and p22phox-generated pro-survival ROS require AKT activation. Bar charts 
show relative mean p22phox, NOX4, pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β and pGSK3β/GSK3β 
protein levels following treatment with LY294002 (50 µM) (a), SB216763 (5 µM) (b) and LiCl (10 
mM, 20 mM and 50 mM) (c) for 16 h as quantified by densitometry. The data are expressed as % of 
vehicle control (control), where the ratio in the control was defined as 1. Results are presented as mean 
± SD from three independent experiments. Asterisks indicate statistically significant differences 
(*p<0.05, **p<0.01, ****p<0.0001) as analysed by Student’s t-test.  
a) b) 
c) 
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 Given that inhibition of PI3K/AKT signalling in MV4-11 cells resulted in 
increased GSK3β phosphorylation, indicative of GSK3β inhibition (Figure 4.5.), we 
investigated the effect of combined AKT inhibition and GSK3β activation on NOX4 
and p22phox protein levels in MV4-11 cells. 50 µM LY294002 (Figure 4.2.) and 5 µM 
SB216763 (Figure 4.3.) were identified as the optimal concentrations. Treatment of 
MV4-11 cells with LY294002 in combination with SB216763 had no synergistic 
effects on NOX4 and p22phox protein levels (Figure 4.6. (i) b and Figure 4.6. (ii)). 
 
                                      
 
Figure 4.6. (i) Inhibition of AKT signalling and activation of GSK3β signalling in combination 
had no synergistic effects on NOX4 and p22phox protein levels in MV4-11 cells. Bar chart of % cell 
viability following treatment with the indicated concentrations of LY294002 and SB216763 in 
combination for 16 h compared to vehicle control (N=2) (a). Western blot analysis of p22phox and NOX4 
protein levels in MV4-11 cells following treatment with LY294002 and SB216763 in combination 
(LY+SB; 50 µM + 5 µM) (b) for 16 h. β-actin is shown as a loading control. Western blots are 
representative of three independent experiments. 
 
b) a) 
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Figure 4.6. (ii) Inhibition of AKT signalling and activation of GSK3β signalling in combination 
had no synergistic effects on NOX4 and p22phox protein levels in MV4-11 cells. Bar charts show 
relative mean p22phox, NOX4, pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β and pGSK3β/GSK3β 
protein levels following treatment with LY294002 (50 µM) and SB216763 (5 µM) for 16 h as quantified 
by densitometry. The data are expressed as % of vehicle control (control), where the ratio in the control 
was defined as 1. Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (*p<0.05, ***p<0.001, ****p<0.0001) as analysed by 
Student’s t-test. 
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 In the previous chapter, we have demonstrated that inhibition of FLT3-ITD 
cell surface expression resulted in a significant decrease in p22phox protein levels 
(Figure 3.9. and Figure 3.25.). MV4-11 cells were treated with tunicamycin and 
brefeldin A in the presence of 20S proteasome inhibitor, lactacystin, which prevented 
p22phox degradation (Figure 3.25.). However, endogenous H2O2 levels were not 
restored suggesting p22phox function was not restored (Figure 3.26.). We identified 
PI3K/AKT signalling to be activated and GSK3β signalling to be inhibited 
downstream of FLT3-ITD at the plasma membrane (Figure 4.1.). Treatment of MV4-
11 cells with tunicamycin and brefeldin A in the presence of lactacystin had no effect 
on AKT and GSK3β signalling, both AKT and GSK3β remained dephosphorylated 
(Figure 4.7.). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Tunicamycin and brefeldin A induce ER retention of FLT3-ITD, resulting in 
decreased phosphorylation of AKT and GSK3β. pAKT, AKT, pGSK3β and GSK3β protein levels 
following ER retention of FLT3-ITD and inhibition of the 20S proteasome. Western blot analysis of 
pAKT, AKT, pGSK3β and GSK3β protein levels in untreated (UT), vehicle control (control), following 
treatment with tunicamycin (5 µg/ml) (a) and brefeldin A (10 µg/ml) (b) overnight and also in 
combination with 20S proteasome inhibitor lactacystin (5 µM) overnight. β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. Western blots are representative of three 
independent experiments.  
b) a) 
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Inhibition of FLT3-ITD using PKC412, a drug recently approved by the FDA 
for the treatment of FLT3-ITD expressing AML (Rydapt, 2017, Stone et al., 2017), 
resulted in a significant decrease in p22phox, NOX4, pAKT and pGSK3β protein levels 
as expected (Figure 4.8.). 
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Figure 4.8. Inhibition of FLT3-ITD using PKC412 resulted in a decrease in p22phox, NOX4, pAKT 
and pGSK3β protein levels in MV4-11 cells. Western blot analysis of p22phox, NOX4, pAKT, AKT, 
pGSK3β and GSK3β protein levels in  vehicle control (control), and following treatment with PKC412 
(50 nM, 200 nM and 250 nM) for 24 h in MV4-11 cells. β-actin is shown as a loading control. Bar 
charts show relative mean p22phox, NOX4, pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β and 
pGSK3β/GSK3β protein levels following treatment with PKC412 (50 nM, 200 nM and 250 nM) for 24 
h as quantified by densitometry. There was a separate control for each drug concentration. The data are 
expressed as % of control, where the ratio in the control was defined as 1. Results are presented as mean 
± SD from three independent experiments. Asterisks indicate statistically significant differences 
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as analysed by Student’s t-test. 
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Figure 4.9. A schematic of the proposed mechanism in which FLT3-ITD at the plasma membrane 
and its downstream pro-survival pathways lead to the production of NOX4 pro-survival ROS in 
FLT3-ITD-expressing AML cells. FLT3-ITD at the plasma membrane is responsible for the 
phosphorylation and activation of the AKT signalling pathway and the production of p22phox- and 
NOX4-generated H2O2. 
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4.3.3. Constitutive activation of the FLT3 receptor switches on 
downstream pro-survival signalling pathways such as AKT, GSK3β, 
ERK1/2 and STAT5 
Previous studies in our laboratory have reported that FLT3-ITD-expressing 
cells produce elevated levels of ROS compared to FLT3-WT-expressing cells 
(Stanicka et al., 2015). Increased ROS levels are linked to increased transformation 
potential and activation of aberrant signalling cascades contributing to cell survival 
and disease progression. However, the cellular mechanisms describing the activation 
and regulation of these aberrant signalling pathways downstream of the FLT3-ITD 
mutation remains unclear. Therefore, we decided to analyse and further our knowledge 
on the role of cellular organisation of FLT3-ITD in controlling the outcome of 
enhanced cell survival. Firstly, we investigated which pro-survival pathways were 
activated downstream of FLT3-ITD in MV4-11 AML cells. Inhibition of the FLT3 
receptor using TKI, PKC412, resulted in significantly decreased phosphorylation of 
AKT, GSK3β, ERK1/2 and STAT5 (Figure 4.10.). Together these data suggest that 
constitutive activation of FLT3 switches on downstream pro-survival signalling 
pathways including AKT, GSK3β, ERK1/2 and STAT5. 
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Figure 4.10. Inhibition of FLT3-ITD using PKC412 resulted in a decrease in pAKT, pGSK3β, 
pERK1/2 and pSTAT5 protein levels in MV4-11 cells. Western blot analysis of AKT, GSK3β, 
ERK1/2 and STAT5 signalling in vehicle control (control), and following treatment with PKC412 (50 
nM, 200 nM and 250 nM) for 24 h.  α-tubulin is shown as a loading control. Bar charts show relative 
mean pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β, pGSK3β/GSK3β, pERK1/2, ERK1/2, 
pERK1/2/ERK1/2, pSTAT5, STAT5 and pSTAT5/STAT5 protein levels following treatment with 
PKC412 (50 nM, 200 nM and 250 nM) for 24 h as quantified by densitometry. The data are expressed 
as % of control, where the ratio in the control was defined as 1. Results are presented as mean ± SD 
from three independent experiments. Asterisks indicate statistically significant differences (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001) as analysed by Student’s t-test. 
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4.3.4. FLT3-ITD at the plasma membrane is responsible for the 
activation of ERK1/2 signalling and FLT3-ITD at the endoplasmic 
reticulum is responsible for the activation of STAT5 signalling  
 Previous studies have endorsed the use of tunicamycin and brefeldin A, as a 
method to investigate the effect of subcellular localisation of FLT3-ITD on the 
initiation of aberrant signalling cascades (Choudhary et al., 2009). Both receptor 
trafficking inhibitors prevent cell surface expression of FLT3-ITD in MV4-11 cells 
(Figure 3.4. - Figure 3.7.). Impaired trafficking of FLT3-ITD to the plasma membrane 
resulted in decreased pAKT, pGSK3β and pERK1/2 protein levels (Figure 4.11. (i) 
and Figure 4.11. (ii)). Thus suggesting that the AKT, GSK3β and ERK1/2 signalling 
pathways are located downstream of FLT3-ITD at the plasma membrane. 
Interestingly, in contrast to the activation of GSK3β signalling and the inactivation of 
AKT and ERK1/2 signalling, phosphorylation of STAT5 increased following ER 
retention of FLT3-ITD in MV4-11 cells when compared to the vehicle control (Figure 
4.11. (i) and Figure 4.11. (ii)). This increase in pSTAT5 has been shown to coincide 
with an increase in the expression of STAT5 target genes including Pim-1 and Pim-2 
in 32D/FLT3-ITD cells (Choudhary et al., 2009). These findings support the current 
study that STAT5 signalling is activated downstream of FLT3-ITD at the endoplasmic 
reticulum in MV4-11 cells. 
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Figure 4.11. (i) PI3K/AKT and ERK1/2 are activated and GSK3β signalling is inhibited 
downstream of FLT3-ITD at the plasma membrane and STAT5 signalling is activated 
downstream of FLT3-ITD at the endoplasmic reticulum in MV4-11 cells. Western blot analysis of 
AKT, GSK3β, ERK1/2 and STAT5 signalling in untreated (UT), vehicle control (control), and 
following treatment with tunicamycin (5 µg/ml) overnight (a); in untreated (UT), vehicle control 
(control) and following treatment with brefeldin A (10 µg/ml) overnight (b). β-actin and α-tubulin are 
shown as loading controls. Western blots are representative of three independent experiments. 
 
 
 
 
 
a) b) 
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Figure 4.11. (ii) PI3K/AKT and ERK1/2 are activated and GSK3β signalling is inhibited 
downstream of FLT3-ITD at the plasma membrane and STAT5 signalling is activated 
downstream of FLT3-ITD at the endoplasmic reticulum in MV4-11 cells. Bar charts show relative 
mean pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β, pGSK3β/GSK3β, pERK1/2, ERK1/2, 
pERK1/2/ERK1/2, pSTAT5, STAT5 and pSTAT5/STAT5 protein levels following treatment with 
tunicamycin (5 µg/ml) (a) and brefeldin A (10 µg/ml) (b) overnight as quantified by densitometry. The 
data are expressed as % of vehicle control (control), where the ratio in the control was defined as 1. 
Results are presented as mean ± SD from three independent experiments. Asterisks indicate statistically 
significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as analysed by Student’s t-
test. 
a) b) 
142 
 
4.3.5. GSK3β pathway is inhibited downstream of ERK1/2 signalling 
in FLT3-ITD expressing AML 
 Previous studies have demonstrated that PI3K/AKT signalling phosphorylates 
and inactivates GSK3β signalling downstream of the JAK2 V617F and BCR-ABL 
oncoproteins in myelodysplastic syndromes and CML. In a previous study it was 
determined that inhibition of the PI3K/AKT/GSK3β signalling pathway downstream 
of JAK2 V617F and BCR-ABL resulted in down-regulation of DNA damage-induced 
Chk1 activation, as well as G2/M arrest-enhancing the induction of apoptosis (Kurosu 
et al., 2013). Interestingly, we have found that inhibition of PI3K/AKT signalling 
using PI3K inhibitor, LY294002, resulted in significantly increased phosphorylation 
and inhibition of GSK3β signalling (Figure 4.5. a and Figure 4.12.). This finding 
suggests that GSK3β signalling is not inhibited downstream of PI3K/AKT signalling 
in FLT3-ITD expressing AML. 
We have identified ERK1/2 signalling to be activated and GSK3β signalling 
to be inhibited downstream of FLT3-ITD at the plasma membrane (Figure 4.11. (i) 
and Figure 4.11. (ii)). Therefore, we investigated the effect of ERK1/2 inhibition using 
ERK1/2 inhibitor, monoethanolate (U0126) on GSK3β signalling. ERK1/2 
inactivation resulted in a significant decrease in GSK3β phosphorylation, indicative 
of activation of GSK3β signalling (Figure 4.13.). Thus, GSK3β signalling is inhibited 
downstream of ERK1/2 signalling in MV4-11 cells. 
Although we have shown STAT5 signalling to be phosphorylated and 
activated downstream of FLT3-ITD at the endoplasmic reticulum, we questioned the 
effect of STAT5 inhibition using STAT5 inhibitor, pimozide, on GSK3β signalling in 
MV4-11 cells. Interestingly, we have found that inhibition of STAT5 signalling using 
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STAT5 inhibitor, pimozide, resulted in significantly increased phosphorylation and 
inhibition of GSK3β signalling (Figure 4.14.).  
Together these findings demonstrated that the GSK3β pathway is inhibited 
downstream of FLT3-ITD-induced ERK1/2 signalling at the plasma membrane 
(Figure 4.15.) 
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Figure 4.12. Inhibition of AKT signalling results in increased inhibition of GSK3β signalling in 
MV4-11 cells. Western blot analysis of AKT signalling and GSK3β signalling in vehicle control 
(control), and following treatment with LY294002 (20 µM, 30 µM and 50 µM) for 16 h.  β-actin is 
shown as a loading control. Bar charts show relative mean pAKT, AKT, pAKT/AKT, pGSK3β, GSK3β 
and pGSK3β/GSK3β protein levels following treatment with LY294002 (20 µM, 30 µM and 50 µM) 
for 16 h as quantified by densitometry. The data are expressed as % of control, where the ratio in the 
control was defined as 1. There was a separate control for each drug concentration. Results are presented 
as mean ± SD from three independent experiments (except for relative mean pGSK3β, GSK3β and 
pGSK3β/GSK3β protein levels following treatment with 20 µM LY294002 (N=1)). Asterisks indicate 
statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as analysed by 
Student’s t-test. 
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Figure 4.13. GSK3β signalling is located downstream of ERK1/2 signalling in FLT3-ITD 
expressing MV4-11 cells. Western blot analysis of ERK1/2 signalling (a) and GSK3β signalling (b) in 
vehicle control (control), and following treatment with U0126 (10 µM, 20 µM, 50 µM and 100 μM) for 
16 h. α-tubulin and total protein (REVERT total protein stain) are shown as loading controls. Bar charts 
show relative mean pERK1/2, ERK1/2, pERK1/2/ERK1/2, pGSK3β, GSK3β and pGSK3β/GSK3β 
protein levels following treatment with U0126 (10 µM, 20 µM, 50 µM and 100 µM) for 16 h as 
quantified by densitometry. The data are expressed as % of control, where the ratio in the control was 
defined as 1.  Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as 
analysed by Student’s t-test. 
 
 
  
a) b) 
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Figure 4.14. Inhibition of STAT5 signalling results in increased inhibition of GSK3β signalling in 
MV4-11 cells. Western blot analysis of STAT5 signalling and GSK3β signalling in vehicle control 
(control), and following treatment with pimozide (5 µM and 10 μM) for 16 h.  α-tubulin and total protein 
(REVERT total protein stain) are shown as loading controls. Bar charts show relative mean pSTAT5, 
STAT5, pSTAT5/STAT5, pGSK3β, GSK3β and pGSK3β/GSK3β protein levels following treatment 
with pimozide (5 µM and 10 µM) for 16 h as quantified by densitometry. The data are expressed as % 
of control, where the ratio in the control was defined as 1.  Results are presented as mean ± SD from 
three independent experiments. Asterisks indicate statistically significant differences (*p<0.05, 
**p<0.01, ***p<0.001) as analysed by Student’s t-test. 
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Figure 4.15. A schematic of the pro-survival pathways activated downstream of FLT3-ITD at the 
plasma membrane and endoplasmic reticulum. FLT3-ITD at the plasma membrane is responsible 
for the phosphorylation and activation of AKT- and ERK1/2-signalling pathways. Activation of 
ERK1/2 signalling inhibits GSK3β signalling through phosphorylation of GSK3β on serine 9. FLT3-
ITD at the endoplasmic reticulum is responsible for the phosphorylation and activation of STAT5 
signalling pathway. 
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4.4. Discussion 
 In this study, we validate the importance of FLT3-ITD subcellular localisation 
on the production of NOX4- and p22phox-generated ROS in AML. In the previous 
chapter, we have suggested that FLT3-ITD at the plasma membrane is responsible for 
the activation and expression of p22phox-generated pro-survival ROS in FLT3-ITD 
expressing AML cells (Figure 3.9. and Figure 3.11.). The aim of this work was to 
investigate if FLT3-ITD at the plasma membrane was responsible for the activation of 
NOX4-generated ROS in FLT3-ITD expressing AML. Secondly, we wished to 
investigate the mechanism in which mislocalised activation of FLT3-ITD at the 
plasma membrane initiates the activation of pro-survival signalling pathways resulting 
in the production of NOX4- and p22phox-generated H2O2 in MV4-11 cells. 
 FLT3-ITD expressing cells have been shown to express increased levels of 
NOX4 and p22phox proteins as well as elevated ROS production compared to FLT3-
WT expressing cells (Stanicka et al., 2015). The overproduction of ROS has been 
shown to induce a variety of biological effects including enhanced cell survival and 
disease progression through the regulation of pro-survival signalling pathways such 
as MAPK/ERK1/2, PI3K/AKT, STAT5 and PKD to name a few. Increased ROS 
levels also function through negative regulation of phosphatases, such as PTEN and 
PTPRJ/DEP-1, regulation of NF-κB activating pathways, as well as, mutations in 
transcription factors and tumour suppressor genes including Nrf2 (Moloney and 
Cotter, 2017). 
 Previous studies in our laboratory have identified the PI3K/AKT and GSK3β 
signalling pathways to be activated as a result of BCR-ABL induced up-regulation of 
NOX-generated ROS in CML, identifying a role for PI3K/AKT and GSK3β signalling 
in BCR-ABL-induced NOX4 pro-survival signalling in CML (Naughton et al., 2009). 
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Therefore, we aimed to investigate the effect of ER retention of FLT3-ITD on AKT 
and GSK3β signalling and examine their effects on the production of NOX4- and 
p22phox-generated H2O2 downstream of FLT3-ITD at the plasma membrane. We 
suggest that FLT3-ITD at the plasma membrane is responsible for the activation of 
AKT signalling and inhibition of GSK3β signalling (Figure 4.1.). Inhibition of both of 
these signalling pathways revealed that the PI3K/AKT pathway is responsible for the 
activation and generation of NOX4-generated ROS in MV4-11 cells (Figure 4.5.). 
Although the GSK3β pathway is located downstream of FLT3-ITD at the plasma 
membrane, it has minimal effect on p22phox and NOX4 protein levels (Figure 4.5.). 
This result demonstrated that PI3K/AKT regulates p22phox and NOX4 expression and 
may be responsible for the production of pro-survival ROS in FLT3-ITD expressing 
AML. In the previous chapter we have shown that inhibition of cell surface FLT3-ITD 
expression results in proteasomal degradation of p22phox using 20S proteasome 
inhibitor (Figure 3.25.), although p22phox function was not restored (Figure 3.26.). 
Inhibition of the 20S proteasome had no effect on AKT and GSK3β signalling, AKT 
and GSK3β remained dephosphorylated as expected (Figure 4.7.). Interestingly, 
inhibition of AKT signalling resulted in increased inhibition of GSK3β (Figure 4.5. 
and Figure 4.12.). AKT inactivation and activation of GSK3β signalling in 
combination had no synergistic effects on NOX4 and p22phox protein levels (Figure 
4.6.). Thus, validating PI3K/AKT induced production of NOX4-generated ROS in 
FLT3-ITD expressing AML. 
 We also studied which pro-survival pathways were activated downstream of 
FLT3-ITD and examined the effect of FLT3-ITD subcellular localisation on the 
regulation and activation of aberrant signalling cascades. Ligand-independent 
constitutive activation of FLT3 stimulates downstream signalling pathways including 
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PI3K/AKT, GSK3β, ERK1/2 and STAT5 (Figure 4.8. and Figure 4.10.). We have 
demonstrated that ER retention of FLT3-ITD results in decreased pAKT, pGSK3β, 
and pERK1/2 protein levels, however, phosphorylation of STAT5 increased in MV4-
11 cells (Figure 4.11.). These findings support previous studies investigating the role 
of mislocalised activation of FLT3-ITD on the initiation of aberrant signalling 
cascades in 32D cells expressing the FLT3-ITD mutation (Choudhary et al., 2009). 
The PI3K/AKT and ERK1/2 signalling pathways are activated and the GSK3β 
signalling pathway is inhibited downstream of FLT3-ITD at the plasma membrane. 
STAT5 signalling is activated downstream of FLT3-ITD at the endoplasmic 
reticulum. Interestingly, we found that inhibition of PI3K/AKT signalling results in 
further inhibition of the GSK3β pathway (Figure 4.12.). Previous studies have 
identified the PI3K/AKT pathway to regulate GSK3β signalling through 
phosphorylation of GSK3β on serine 9 resulting in the inhibition of GSK3β signalling 
(Kurosu et al., 2013). We identified GSK3β signalling to be inhibited downstream of 
ERK1/2 activation in FLT3-ITD expressing AML (Figure 4.13.).  
Tunicamycin and brefeldin A inhibit glycosylation of many proteins. For this 
reason they are not suitable for the treatment of FLT3-ITD expressing AML cases. 
They have however previously been used to examine the effects of cellular localisation 
of oncogenic FLT3-ITD and its effect on pro-survival signalling pathways (Choudhary 
et al., 2009). In this study, a mutant of FLT3-ITD was created that contained a deletion 
of the extracellular ligand-binding domain of FLT3-ITD (FLT3-ITD ΔECD). This 
mutation eliminated many potential sites of glycosylation, resulting in glycosylation-
independent trafficking of the FLT3-ITD receptor. Inhibition of FLT3-ITD ΔECD 
with PKC412 resulted in a loss of pro-survival signalling, as indicated by a decrease 
in pERK1/2 and pAKT. Due to the mutation in glycosylation sites recognised by 
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tunicamycin, treatment with this inhibitor had no effect on trafficking of the receptor 
and pERK1/2 and pAKT levels remained high. Brefeldin A inhibits glycosylation of 
receptors indirectly by disruption of the structure and function of the Golgi apparatus. 
Treatment with brefeldin A therefore successfully inhibited trafficking of the receptor 
to the plasma membrane and as a result, pERK1/2 and pAKT levels decreased. As 
further support, they showed that wild-type FLT3, found only at the plasma 
membrane, in the presence of FLT3 ligand leads to the activation of PI3K and ERK1/2 
signalling (Choudhary et al., 2009). These findings not only support the current study, 
highlighting a crucial role for FLT3-ITD at the plasma membrane in stimulating pro-
survival signalling, but it also endorses the use of inhibitors, such as tunicamycin and 
brefeldin A, as a method to investigate the effect of subcellular localisation of FLT3-
ITD on the production of pro-survival ROS. 
In conclusion, we propose that FLT3-ITD at the plasma membrane is 
responsible for the activation and expression of NOX4- and p22phox-generated pro-
survival ROS in FLT3-ITD expressing AML cells. p22phox is an essential component 
of NOX1-4 and is required to produce functionally active NOX. For FLT3-ITD to 
generate its oncogenic effects it has to be located at the plasma membrane. Plasma 
membrane FLT3-ITD induced activation of PI3K/AKT pro-survival signalling is 
responsible for the activation and generation of p22phox- and NOX4-generated ROS in 
AML (Figure 4.9.). In terms of activation of other pro-survival signalling pathways, 
FLT3-ITD at the plasma membrane activates ERK1/2 signalling resulting in the 
inhibition of GSK3β signalling and FLT3-ITD at the endoplasmic reticulum is 
responsible for the activation of STAT5 signalling (Figure 4.15.). Together these 
findings further present FLT3-ITD at the plasma membrane as a potential therapeutic 
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target in the treatment of AML in preventing downstream pro-tumourigenic driven 
oncogenic effects. 
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Chapter 5. Nuclear membrane-localised 
NOX4D generates pro-survival ROS in 
FLT3-ITD-expressing AML 
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5.1. Abstract 
Internal tandem duplication of the juxtamembrane domain of FMS-like 
tyrosine kinase 3 (FLT3-ITD) is the most prevalent genetic aberration present in 15-
35% of acute myeloid leukaemia (AML) cases and is associated with a poor prognosis. 
FLT3-ITD expressing cells have been shown to express elevated levels of NADPH 
oxidase 4 (NOX4)-generated pro-survival hydrogen peroxide (H2O2) contributing to 
increased levels of DNA oxidation and double strand breaks (dsbs). NOX4 is 
constitutively active and has been found to have various isoforms expressed at 
multiple locations within a cell. The purpose of this study was to investigate the 
expression, localisation and regulation of NOX4 28 kDa splice variant, NOX4D. 
NOX4D has previously been shown to localise to the nucleus and nucleolus in various 
cell types and is implicated in the generation of reactive oxygen species (ROS) and 
DNA damage. Here, we demonstrate that FLT3-ITD expressing-AML patient 
samples, as well as cell lines that express the NOX4D isoform, result in elevated H2O2 
levels compared to FLT3-WT expressing cells, as quantified by flow cytometry using 
the cell-permeable H2O2 -probe Peroxy Orange 1(PO1). Cell fractionation indicated 
that NOX4D is nuclear membrane-localised in FLT3-ITD expressing cells. Treatment 
of MV4-11 cells with receptor trafficking inhibitors, tunicamycin and brefeldin A, 
resulted in deglycosylation of NOX4 and NOX4D. Inhibition of the FLT3 receptor 
revealed that the FLT3-ITD oncogene is responsible for the production of NOX4D-
generated H2O2 in AML. We found that inhibition of the PI3K/AKT and STAT5 
pathways resulted in down-regulation of NOX4D-generated pro-survival ROS. Taken 
together these findings indicate that nuclear membrane-localised NOX4D-generated 
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pro-survival H2O2 may be contributing to genetic instability in FLT3-ITD expressing 
AML. 
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5.2. Introduction 
Aberrant signalling of receptor tyrosine kinases (RTKs) is associated with 
tumour development and transformation (Blume-Jensen and Hunter, 2001, Köthe et 
al., 2013, Regad, 2015). FMS-like tyrosine kinase 3 (FLT3) is a type III RTK 
expressed in approximately 90% of acute myeloid leukaemia (AML) and plays a 
critical role in normal haematopoiesis (Stirewalt and Radich, 2003, Gilliland and 
Griffin, 2002). Internal tandem duplication (ITD) of sequences in the juxtamembrane 
domain is the most prevalent genetic aberration of FLT3, with a gain of function 
mutation, implicated in 15-35% of AML patients (Gilliland and Griffin, 2002, 
Network, 2013, Jayavelu et al., 2016b). Patients with this mutation have a particularly 
poor prognosis with a high incidence of relapse (Small, 2008, Konig and Levis, 2015). 
Constitutive activation of the tyrosine kinase domain of FLT3-ITD results in 
autophosphorylation and activation of downstream pro-survival cascades including 
PI3K/AKT, ERK1/2 and STAT5 resulting in the promotion of cell survival, 
proliferation and transformation in myeloid leukaemia (Brandts et al., 2005, 
Choudhary et al., 2005a, Choudhary et al., 2009, Choudhary et al., 2007, Mizuki et 
al., 2000, Hayakawa et al., 2000). It has been demonstrated that AML cells expressing 
the FLT3-ITD mutation produce higher levels of reactive oxygen species (ROS) and 
DNA damage compared to their wild-type counterpart (Sallmyr et al., 2008a, Godfrey 
et al., 2012, Woolley et al., 2012, Stanicka et al., 2015). 
ROS have been long implicated in leukaemia cancer pathology due to their 
ability to induce DNA damage (Rassool et al., 2007, Hole et al., 2011). The NADPH 
oxidase (NOX) family consisting of NOX1-5 and dual oxidase (DUOX) 1 and 2, are 
well established producers of ROS (Bedard and Krause, 2007), with NOX2 and NOX4 
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playing a central role in the increased production of hydrogen peroxide (H2O2) in AML 
(Stanicka et al., 2015, Jayavelu et al., 2016a, Moloney et al., 2017b). NOX proteins 
vary in structure, subcellular localisation, biochemical characteristics and regulatory 
subunits (p22phox, p47phox, p67phox and RAC1/2). p22 phagocyte oxidase (p22phox) is a 
partner protein and is required for functionally active NOX1-4 (Brandes et al., 2014, 
Ambasta et al., 2004). Among the NOX family members NOX4 is unique. It is 
constitutively activated, generating H2O2, unlike its family members NOX1 and 
NOX2, which require an agonist for activation (Martyn et al., 2006, Serrander et al., 
2007, Takac et al., 2011). Oxidation of protein tyrosine phosphatases (PTPs) occurs 
in FLT3-ITD expressing AML cells. NOX4-driven ROS formation causes partial 
inactivation of DEP-1/PTPRJ, a transmembrane PTP responsible for negative 
regulation of FLT3 signalling, contributing to unfavourable downstream signalling 
(Jayavelu et al., 2016a). 
NOX4 subcellular localisation plays an important role, given its constitutive 
activity. NOX4 has been reported to be localised in the cytoskeleton (Hilenski et al., 
2004), endoplasmic reticulum (ER) (Ambasta et al., 2004, Chen et al., 2008b, Helmcke 
et al., 2008, Zhang et al., 2011), mitochondria (Block et al., 2009, Case et al., 2013), 
plasma membrane (Zhang et al., 2011, Lee et al., 2006) and nucleus (Anilkumar et al., 
2013, Kuroda et al., 2005, Matsushima et al., 2013) in different cell types. Previous 
studies in our laboratory have shown that NOX4 and p22phox colocalise to the nuclear 
membrane by immunofluorescence in FLT3-ITD expressing MV4-11 AML cell line 
contributing to DNA oxidation and double strand breaks (dsbs), possibly driving 
genetic instability (Stanicka et al., 2015).  
Previous studies identified NOX4 isoforms, expressed at varying levels, in the 
presence of the prototype in the human lung cancer cell line, A549 cells. The truncated 
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NOX4 splice variant D (28 kDa) lacks the majority of the transmembrane domain and 
has been shown to produce higher levels of ROS and DNA damage compared to its 
prototype (Goyal et al., 2005). NOX4D retains the NADPH and FAD-binding domains 
required for electron transfer activity and ROS production despite its truncation 
(Nisimoto et al., 2010). NOX4D is localised to the nucleus and nucleolus in vascular 
smooth muscle cells (VSMC), A7R5 cells and in many other cells including human 
aortic vascular smooth muscle cells, human umbilical vein endothelium cells 
(HUVEC), H9C2 rat cardiomyocytes, human embryonic kidney fibroblasts (HEK), 
mouse primary cardiac fibroblasts and rat neonatal cardiomyocytes. NOX4D is 
expected to be soluble rather than membrane-localised (Anilkumar et al., 2013).  
To investigate if FLT3-ITD expressing AML cells express NOX4D and in 
order to identify the localisation of NOX4D, we utilised subcellular fractionation, 
inhibitors of FLT3-ITD and pro-survival signalling pathways, siRNA, alongside ROS 
specific probes and antibodies. Experiments were carried out in de novo primary AML 
samples, human patient-derived AML cell line MV4-11 and in the murine 
haematopoietic 32D cell line stably expressing FLT3-wild type (FLT3-WT) receptor 
and FLT3-ITD mutation. 
We show that FLT3-ITD expressing AML patient samples and cell lines 
express the NOX4D 28 kDa splice variant. FLT3-ITD expressing AML cells express 
NOX4D in the nuclear membrane, which may be contributing to genetic instability in 
AML. NOX4D expression is dependent on the FLT3-ITD mutation. NOX4 partner 
protein p22phox does not regulate NOX4 or NOX4D protein levels. Inhibition of the 
PI3K and STAT5 pro-survival pathways results in decreased NOX4D protein levels, 
alongside a decrease in endogenous H2O2 detected using the H2O2 specific probe 
Peroxy Orange 1 (PO1). Inhibition of ERK1/2 signalling had no effect on NOX4D 
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protein levels, however a decrease in p22phox protein levels alongside a decrease in 
endogenous H2O2 was observed. Inhibition of GSK3β resulted in increased levels of 
NOX4D, however, a slight decrease in endogenous H2O2 was observed. This 
demonstrates that NOX4D is downstream of FLT3-ITD signalling in AML, located in 
the nuclear membrane where it may be contributing to DNA damage and disease 
progression. 
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5.3. Results 
5.3.1. FLT3-ITD expressing AML patient samples express the NOX4 
splice variant NOX4D 28 kDa  
FLT3-ITD expressing AML cells have been shown previously to express 
higher levels of total endogenous H2O2, DNA oxidation and dsbs compared to FLT3-
WT cells (Jayavelu et al., 2016b, Stanicka et al., 2015). NOX4 has been well 
established as a producer of pro-survival ROS in FLT3-ITD expressing AML, 
contributing to DNA damage and disease progression (Stanicka et al., 2015, Jayavelu 
et al., 2016a). As mentioned previously, NOX4 is unique to other members of the 
NOX family of proteins, as it is constitutively activated. Therefore, NOX4 subcellular 
localisation plays an important role in cellular regulation. Our group has previously 
shown that NOX4 and p22phox colocalise to the nuclear membrane in MV4-11 cells 
(Stanicka et al., 2015). Previous studies identified the presence of NOX4 isoforms, 
including NOX4 splice variant NOX4D (28 kDa), to be expressed and localised to the 
nucleus and nucleolus of VSMC where it is contributing to ROS production, DNA 
damage and genetic instability (Anilkumar et al., 2013). We investigated if FLT3-ITD- 
and FLT3-WT-expressing AML patient samples expressed the NOX4D isoform. We 
show that NOX4D is expressed in FLT3-ITD expressing patient samples, but is absent 
in FLT3-WT patient samples (Figure 5.1.).  
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Figure 5.1. FLT3-ITD expressing AML patient samples express the NOX4D 28 kDa isoform. 
Western blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein levels in FLT3-ITD- and FLT3-
WT-expressing patient samples using Abcam NOX4 antibody (cat# Ab109225 (UOTR1B492)). β-actin 
and Vinculin are shown as loading controls (a). Western blot analysis of NOX4D 28 kDa protein levels 
in FLT3-ITD- and FLT3-WT-expressing patient samples using Professor Ajay Shah’s in-house NOX4 
antibody. Vinculin is shown as a loading control (b). Figure courtesy of Dr Ashok Kumar Jayavelu. 
 
 
 
 
 
 
a) 
b) 
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5.3.2. Specificity of Abcam NOX4 (Ab109225) antibody 
Studies have raised issues with NOX4 antibody specificity in the past, due to 
difficulties in detecting NOX4 protein levels. Therefore, a key issue concerned the use 
of the Abcam NOX4 antibody (Ab109225) and the Novus Biologicals NOX4 antibody 
(NB110-58849) in our study. For this reason, a series of control experiments were first 
performed to validate the NOX4 antibodies employed in this study. 
Previous studies identified the expression of NOX4 isoforms including NOX4 
67 kDa and NOX4D 28 kDa to be expressed and localised to the nucleus and nucleolus 
of VSMC using an in-house NOX4 antibody (Anilkumar et al., 2008, Anilkumar et 
al., 2013). In this study they demonstrated the specificity of this in-house antibody for 
NOX4 67 kDa and NOX4D 28 kDa by means of siRNA against NOX4 exon 14 
(expressed in NOX4D) and NOX4 exon 3 (not expressed in NOX4D) (Anilkumar et 
al., 2013). To validate the specificity of the Abcam NOX4 antibody (Ab109225) 
against NOX4 67 kDa and NOX4D 28 kDa in primary AML samples in this study, we 
also used Prof. Ajay Shah’s in-house antibody to support our finding that NOX4D is 
expressed in FLT3-ITD expressing patient samples and is absent in FLT3-WT patients 
(Figure 5.1. b). Specific NOX4 knockdowns using NOX4 targeted siRNA and shRNA 
in 32D/FLT3-ITD cells resulted in depletion of NOX4 67 kDa protein levels detected 
using Abcam NOX4 antibody (Figure 5.2.). Together, these experiments validated that 
the Abcam NOX4 (Ab109225) antibody used in this study was specific for NOX4 67 
kDa and NOX4D 28 kDa. 
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Figure 5.2. Abcam NOX4 (Ab109225) antibody specificity. Western blot analysis of NOX4 67 kDa 
protein levels in 32D/FLT3-ITD whole cell lysates at 48 h following NOX4 siRNA (a) and shRNA 
transfection (b). Non-targeting scrambled (Scr) siRNA and shRNA were used as negative controls. β-
actin is shown as a loading control. Western blots are representative of three independent experiments. 
Figure courtesy of Dr Ashok Kumar Jayavelu. 
 
5.3.3. FLT3-ITD expressing MV4-11 and 32D/FLT3-ITD cells 
express the NOX4 splice variant NOX4D 28 kDa in the nuclear 
membrane 
We investigated if FLT3-ITD- and FLT3-WT-expressing AML patient 
samples expressed the NOX4D isoform (Figure 5.1.) and also examined the 
expression and localisation of NOX4D 28 kDa in two cell lines: FLT3-ITD-expressing 
AML MV4-11 cell line and 32D cell line stably transfected with FLT3-WT or FLT3-
ITD. Localisation of NOX4D was assessed by means of subcellular fractionation. We 
show that NOX4D is expressed in FLT3-ITD expressing cells (Figure 5.3. - Figure 
5.6.), but is absent in 32D cells transfected with the FLT3-WT receptor (Figure 5.5. 
and Figure 5.6.). NOX4D is present in the membrane and soluble nuclear fractions of 
MV4-11 cells (Figure 5.3. and Figure 5.4.) and the membrane, soluble nuclear and 
chromatin bound nuclear (chr.b.nuclear) fractions of 32D cells stably transfected with 
a) b) 
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FLT3-ITD (Figure 5.5. and Figure 5.6.). In support of previous work, we have 
identified the NOX4 prototype (67 kDa) in the soluble nuclear fraction and p22phox in 
the membrane and soluble nuclear fractions in both MV4-11 cells (Figure 5.3. and 
Figure 5.4.) and 32D/FLT3-ITD cells (Figure 5.5. and Figure 5.6.) (Stanicka et al., 
2015, Woolley et al., 2012). Interestingly, we found NOX4 67 kDa was lacking from 
the membrane fraction in MV4-11 cells (Figure 5.3. and Figure 5.4.). In contrast 
NOX4 67 kDa was observed in the membrane fraction of 32D/FLT3-ITD cells (Figure 
5.5. and Figure 5.6.). There are therefore clear differences in NOX4 67 kDa subcellular 
localisation between these cell lines. We are unsure why there are differences between 
MV4-11 and 32D/FLT3-ITD cells, nonetheless, it was a clear observation.  
 
Figure 5.3. FLT3-ITD expressing AML MV4-11 cells express the NOX4D 28 kDa isoform. 
Subcellular fractionation was carried out in FLT3-ITD expressing AML cell line, MV4-11, using a 
subcellular fractionation kit and RIPA lysis buffer. Expression of NOX4 67 kDa, NOX4D 28 kDa and 
p22phox was assessed by means of western blot analysis. Equal loading of samples and verification of 
the subcellular fractions were demonstrated by probing for nuclear-localised NUP98 and Histone H3, 
membrane-localised calreticulin and cytosolic-localised GAPDH. Western blots are representative of 
five independent experiments. 
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Figure 5.4. FLT3-ITD expressing AML MV4-11 cells express the NOX4D 28 kDa isoform. 
Subcellular fractionation was carried out in FLT3-ITD expressing AML cell line, MV4-11, using a 
subcellular fractionation kit. Expression of NOX4 67 kDa, NOX4D 28 kDa and p22phox was assessed 
by means of western blot analysis (a and b). Subcellular fractionation technique was optimised from 
(a) to (b) in order to obtain higher protein concentrations and cleaner fractions. Equal loading of samples 
and verification of the subcellular fractions were demonstrated by probing for nuclear-localised NUP98 
and Histone H3, membrane-localised calreticulin and cytosolic-localised GAPDH and α-tubulin. 
Western blots are representative of five independent experiments. 
 
a) 
b) 
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Figure 5.5. FLT3-ITD expressing 32D cells express the NOX4D 28 kDa isoform. Subcellular 
fractionation was carried out in 32D cells transfected with FLT3-WT or FLT3-ITD using a subcellular 
fractionation kit and RIPA lysis buffer. Expression of NOX4 67 kDa, NOX4D 28 kDa and p22phox was 
assessed by means of western blot analysis. Equal loading of samples and verification of the subcellular 
fractions were demonstrated by probing for nuclear-localised NUP98, membrane-localised KDEL and 
cytosolic-localised GAPDH. Western blots are representative of five independent experiments. 
 
 
Figure 5.6. FLT3-ITD expressing 32D cells express the NOX4D 28 kDa isoform. Subcellular 
fractionation was carried out in 32D cells transfected with FLT3-WT or FLT3-ITD using a subcellular 
fractionation kit. Expression of NOX4 67 kDa, NOX4D 28 kDa and p22phox was assessed by means of 
western blot analysis. Equal loading of samples and verification of the subcellular fractions were 
demonstrated by probing for nuclear-localised HDAC1 and Histone H3, membrane-localised KDEL 
and cytosolic-localised GAPDH. Western blots are representative of five independent experiments. 
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5.3.4. Specificity of Novus Biologicals NOX4 (NB110-58849) antibody 
As mentioned previously, studies have raised issues with NOX4 antibody 
specificity in the past. Therefore, a key issue concerned the use of the Novus 
Biologicals NOX4 (NB110-58849) antibody in our study. For this reason, a series of 
control experiments were first performed to validate the Novus Biologicals (NB110-
58849) NOX4 antibody employed in this study. 
The Abcam NOX4 (Ab109225) antibody was employed for the primary FLT3-
ITD expressing AML patients studies. The remainder of the experiments in this study 
employed the Novus Biologicals NOX4 antibody (NB110-58849). In order to 
demonstrate specificity of this antibody for NOX4 67 kDa, HEK-293-T cells were 
transfected with empty vector (EV)-HA or p-CMV3-C-HA encoding full length 
cDNA clone of Homo sapiens NOX4 (#HG15189-CY; Sino Biological, UK) and were 
analysed 48 h post transfection by western blot. NOX4 overexpression in HEK 293-T 
cells resulted in increased NOX4 67 kDa protein expression in the presence of HA 
protein expression at the corresponding molecular weight compared to HEK 293-T 
cells transfected with EV (Figure 5.7.). Unexpectedly, an increase in NOX4D 28 kDa 
protein expression was also observed. 
 Figure 5.7. Novus Biologicals NOX4 (NB110-58849) 
antibody specificity. HEK293-T cells were transfected 
with EV-HA or pCMV3-C-HA encoding full length 
cDNA clone of Homo sapiens NOX4 (#HG15189-CY; 
Sino Biological, UK) using calcium phosphate. Western 
blot analysis of NOX4 67 kDa and NOX4D 28 kDa 
protein levels in HEK 293-T whole cell lysates following 
transfection with EV-HA or NOX4-HA for 48 h. Total 
protein (REVERT total protein stain) is shown as a 
loading control. Western blot is representative of three 
independent experiments. 
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5.3.5. 32D cells stably transfected with FLT3-ITD express higher 
levels of endogenous H2O2 compared to FLT3-WT 
FLT3-ITD expressing AML cells have been shown to produce elevated levels 
of ROS and DNA damage compared to their wild-type counterpart (Stanicka et al., 
2015). Having confirmed that FLT3-ITD expressing AML patient samples and 32D 
cells express NOX4D; whereas, FLT3-WT expressing patient samples and 32D cells 
do not, we investigated the effect of NOX4D expression on total endogenous H2O2. 
We demonstrate that 32D cells stably transfected with FLT3-ITD produced 
approximately 170% more endogenous H2O2 than 32D cells stably transfected with 
FLT3-WT receptor, as assessed with a H2O2 specific probe-PO1 (Figure 5.8.). 
 
 
 
 
 
 
 
 
Figure 5.8. 32D cells stably transfected with FLT3-ITD express higher levels of endogenous H2O2 
compared to FLT3-WT. 32D cells  transfected with FLT3-WT and FLT3-ITD were IL-3 starved 
overnight, followed by ROS visualisation with H2O2 specific probe, Peroxy Orange 1 (PO1), for 1 h 
before flow cytometric analysis (a). Bar chart shows relative mean PO1 fluorescence of 32D/FLT3-
ITD cells expressed as a % of 32D/FLT3-WT cells (b). Results are presented as mean ± SD from three 
independent experiments. Asterisks indicate statistically significant differences (****p<0.0001) as 
analysed by Student’s t-test.  
 
 
a) b) 
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5.3.6. p22phox knockdown had no effect on NOX4 67 kDa and NOX4D 
28 kDa protein levels 
p22phox is a partner protein and is required for functionally active NOX1-4 
(Ambasta et al., 2004). Specific p22phox knockdown allowed us to investigate the 
effects of p22phox on NOX4 67 kDa and NOX4D 28 kDa protein levels. Knockdown 
of p22phox had no effect on NOX4 67 kDa and NOX4D 28 kDa protein levels (Figure 
5.9.). 
 
 
Figure 5.9. Knockdown of p22phox in FLT3-ITD expressing MV4-11 cells had no effect on NOX4 
67 kDa and NOX4D 28 kDa protein levels. Western blot analysis of p22phox, NOX4 67 kDa and 
NOX4D 28 kDa protein levels in MV4-11 whole cell lysates at 24 h following p22phox siRNA 
transfection compared with the scrambled (Scr) siRNA treated control. A non-targeting scrambled 
siRNA was utilised as a negative control. β-actin is shown as a loading control. Western blot is 
representative of three independent experiments. 
 
5.3.7. Inhibition of glycosylation in MV4-11 cell line resulted in NOX4 
67 kDa and NOX4D 28 kDa deglycosylation 
Previous studies in our laboratory have found NOX4 67 kDa to be glycosylated 
in FLT3-ITD expressing AML MV4-11 cells (Figure 3.25.) (Moloney et al., 2017b). 
We investigated if NOX4D 28 kDa is glycosylated in the MV4-11 cell line. Cells were 
treated with glycosylation inhibitor, tunicamycin and receptor trafficking inhibitor, 
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brefeldin A. Treatment of MV4-11 cells with glycosylation and receptor trafficking 
inhibitors resulted in deglycosylation of NOX4D 28 kDa as seen by the presence of a 
lower molecular weight band marked by asterisks (Figure 5.10.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. NOX4D 28 kDa is glycosylated in FLT3-ITD expressing AML. Western blot analysis 
of NOX4 67 kDa and NOX4D 28 kDa protein levels in whole cell lysates following treatment with 
tunicamycin (5 μg/ml) (a) and brefeldin A (10 μg/ml) (b) overnight. (Asterisks indicate a shift in protein 
molecular weight). β-actin and total protein (REVERT total protein stain) are shown as loading controls. 
Western blots are representative of three independent experiments. 
 
a) b) 
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5.3.8. Inhibition of FLT3-ITD in MV4-11 cell line and 32D cells 
transfected with FLT3-ITD causes a decrease in NOX4 67 kDa and 
NOX4D 28 kDa protein levels as well as reductions in total 
endogenous H2O2 
32D cells transfected with FLT3-ITD and FLT3-WT receptor, in addition to 
MV4-11 cells, were treated with FLT3-ITD inhibitor, PKC412. The inhibition of 
FLT3 receptor resulted in a decrease in total endogenous H2O2 in 32D/FLT3-ITD 
cells, but not in 32D/FLT3-WT cells. As shown previously in Figure 5.8. 32D/FLT3-
ITD cells possess approximately 170% more total endogenous H2O2 compared to their 
wild-type counterpart. Moreover, inhibition of FLT3 resulted in approximately 40% 
decrease in total endogenous H2O2 following treatment with 50 nM and 200 nM 
PKC412 specifically in 32D cells expressing the FLT3-ITD mutation and not in cells 
expressing FLT3-WT receptor (Figure 5.11.). 
 
 
 
 
 
 
 
Figure 5.11. Inhibition of the FLT3 receptor following treatment with PKC412, results in a 
decrease in total endogenous H2O2 in 32D/FLT3-ITD cells but not in 32D/FLT3-WT cells.  
32D/FLT3-WT and 32D/FLT3-ITD cells were IL-3 starved overnight and treated for 24 h with PKC412 
(50 nM and 200 nM), followed by staining with H2O2 specific probe PO1 for 1 h before FACS reading. 
Bar charts show relative mean PO1 fluorescence of treated cells expressed as % of vehicle control 
(control). Results are presented as mean ± SD from four independent experiments. Asterisks indicate 
statistically significant differences (****p<0.0001) as analysed by Student’s t-test.  
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FLT3-ITD expressing MV4-11 cells were treated with PKC412. Inhibition of 
the FLT3 receptor in MV4-11 cells resulted in significantly decreased NOX4 67 kDa 
and NOX4D 28 kDa protein levels in whole cell lysates, significantly decreased 
p22phox protein levels in the membrane and soluble nuclear fractions (Figure 5.12.) and 
reduced total endogenous H2O2. 50 nM and 200 nM PKC412 treatments resulted in a 
significant decrease of 45-50% in total endogenous H2O2 (Figure 5.13.). The inhibition 
of FLT3-ITD  using AC220, another commonly used and very selective FLT3 receptor 
inhibitor, resulted in decreased NOX4D 28 kDa protein levels in the nuclear fractions 
of MV4-11 cells (Figure 5.14. a) and 32D/FLT3-ITD cells (Figure 5.14. b). These 
results suggest that both FLT3-ITD and NOX4D proteins play a role in the generation 
of H2O2 in MV4-11 and 32D/FLT3-ITD cells and that FLT3-ITD activity is 
presumably an upstream regulator of NOX4D-generated pro-survival ROS. 
In Figure 5.14. Lamin A/C is used as a marker for nuclear fractions. Lamin 
A/C is cleaved by caspase-6 and serves as a marker of caspase-6 activation. During 
apoptosis, Lamin A/C is specifically cleaved to a large (40-45 kDa) and a small (28 
kDa) fragment. The cleavage of Lamin A/C results in nuclear dysregulation and death.  
The Cell Signaling Technology Lamin A/C (2032) antibody employed in this 
study detects endogenous levels of total full length Lamin A (and Lamin C) (70 kDa), 
as well as the small (28 kDa) fragment of Lamin A (and Lamin C) resulting from 
cleavage at aspartic acid 230. 
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Figure 5.12. Inhibition of the FLT3 receptor using PKC412 in FLT3-ITD expressing MV4-11 cells 
reduces NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels. Western blot analysis of NOX4 
67 kDa and NOX4D 28 kDa protein levels in MV4-11 whole cell lysates following treatment with 
PKC412 (50 nM and 200 nM) for 24 h (a). β-actin is shown as a loading control. p22phox protein levels 
in membrane and soluble nuclear fractions of MV4-11 cells following treatment with PKC412 (50 nM, 
200 nM and 250 nM) for 24 h (b). Equal loading of samples is shown by total protein (REVERT total 
protein stain) and verification of subcellular fractions were assessed by probing for nuclear-localised 
NUP98 and membrane-localised calreticulin. Bar charts show relative mean NOX4 67 kDa and NOXD 
28 kDa protein levels in whole cell lysates (a) and p22phox protein levels in membrane and soluble 
nuclear fractions (b) following treatment with PKC412 for 24 h at indicated concentrations as quantified 
by densitometry. The data are expressed as % of vehicle control (control), where the ratio in the control 
was defined as 1. Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (*p<0.05, ***p<0.001, ****p<0.0001) as analysed by 
Student’s t-test. 
a) b) 
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Figure 5.13. Inhibition of the FLT3 receptor in FLT3-ITD expressing MV4-11 cells reduces total 
endogenous H2O2. Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells 
treated with PKC412 (50 nM and 200 nM) for 24 h (a). Bar chart shows relative mean PO1 fluorescence 
of treated cells expressed as % of vehicle control (control) (b). Results are presented as mean ± SD from 
three independent experiments. Asterisks indicate statistically significant differences (****p<0.0001) 
as analysed by Student’s t-test.  
 
 
 
 
 
a) 
b) 
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Figure 5.14. Inhibition of the FLT3 receptor using AC220 in FLT3-ITD expressing MV4-11 cells 
and 32D/FLT3-ITD cells reduces NOX4D 28 kDa protein levels. Western blot analysis of NOX4D 
28 kDa protein levels in the nuclear fraction following treatment with AC220 (10 nM, 20 nM and 30 
nM) for 12 h in MV4-11 cells (a) and 32D cells transfected with FLT3-ITD (b). Equal loading of nuclear 
fractions was demonstrated by probing for nuclear-localised Lamin A/C. Western blots are 
representative of three independent experiments. Figure courtesy of Dr Ashok Kumar Jayavelu. 
 
 
 
 
a) 
b) 
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5.3.9. Inhibition of the FLT3 receptor in the MOLM13 cell line causes 
a decrease in NOX4D 28 kDa protein levels 
 Patient-derived AML MV4-11 and MOLM13 (heterozygous for the FLT3-
ITD mutation) cells both harbour endogenously expressing FLT3-ITD. To further 
validate the dependence of NOX4D expression on the activation of FLT3-ITD 
signalling, we treated MOLM13 cells, heterozygous for FLT3-ITD mutation with the 
selective FLT3-ITD kinase inhibitor, AC220 (5 nM, 10 nM, 20 nM and 30 nM) for 12 
h. Inhibition of the FLT3 receptor resulted in decreased NOX4D protein levels (Figure 
5.15.). 
 
 
 
Figure 5.15. Inhibition of the FLT3 receptor using AC220 in MOLM13 cells reduces NOX4D 28 
kDa protein levels. Western blot analysis of NOX4D 28 kDa protein levels in the nuclear fraction of 
MOLM13 cells following treatment with AC220 (5 nM, 10 nM, 20 nM and 30 nM) for 12 h. Equal 
loading of nuclear fractions was demonstrated by probing for nuclear-localised Lamin A/C. Western 
blot is representative of three independent experiments. Figure courtesy of Dr Ashok Kumar Jayavelu. 
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5.3.10. PI3K/AKT pathway is required for FLT3-ITD mediated-
NOX4 67 kDa and -NOX4D 28 kDa generation of pro-survival H2O2 
Constitutively activated FLT3-ITD kinase stimulates aberrant proliferative 
signalling through downstream signalling pathways including PI3K/AKT, ERK1/2, 
STAT5 and GSK3β (Figure 4.10.).  We have shown previously that NOX4- and 
p22phox-generated pro-survival ROS require AKT activation in MV4-11 cells (Figure 
4.5.) (Moloney et al., 2017b). Therefore, we examined the effect of PI3K/AKT 
inhibition on NOX4D 28 kDa protein levels in membrane and soluble nuclear fractions 
of MV4-11 cells. Inhibition of AKT signalling (Figure 5.16. (i) a and Figure 5.16. (ii)) 
using PI3K inhibitor, LY294002, resulted in slight decreases in NOX4 67 kDa and 
more noticeable decreases in NOX4D 28 kDa and p22phox protein levels in the soluble 
nuclear fraction (Figure 5.16. (i) b). The observed decreases were statistically 
significant (Figure 5.16. (ii)). As shown, NOX4D 28 kDa protein levels are weak in 
the membrane fraction and it is therefore difficult to detect any change. We next 
examined the effect of AKT inhibition on the generation of total endogenous H2O2. 
AKT inhibition resulted in approximately 25% decrease in total endogenous H2O2 
following treatment with 20 μM and 30 μM LY294002 and approximately 35% 
decrease following treatment with 50 μM LY294002 (Figure 5.16. (i) c and d). Thus, 
activation of the AKT pathway is required for FLT3-ITD to produce NOX4D-
generated ROS. 
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Figure 5.16. (i) NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS require AKT 
activation. Western blot analysis of AKT signalling in FLT3-ITD expressing MV4-11 cells following 
treatment with LY294002 (20 μM, 30 μM and 50 μM) for 16 h (a). β-actin and total protein (REVERT 
total protein stain) are shown as loading controls. NOX4 67 kDa, NOX4D 28 kDa and p22phox protein 
levels in membrane and soluble nuclear fractions of MV4-11 cells following treatment with LY294002 
for 16 h at indicated concentrations (b). Equal loading of samples is shown by total protein (REVERT 
total protein stain) and verification of subcellular fractions were assessed by probing for nuclear-
localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of three 
independent experiments. Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells 
treated with LY294002 for 16 h at indicated concentrations (c). Bar chart shows relative mean PO1 
b) a) 
c) 
d) 
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fluorescence of treated cells expressed as % of vehicle control (control) (d). Results are presented as 
mean ± SD from three independent experiments. Asterisks indicate statistically significant differences 
(****p<0.0001) as analysed by Student’s t-test.  
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Figure 5.16. (ii) NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS require AKT 
activation. Bar charts show relative mean pAKT, AKT and pAKT/AKT protein levels in whole cell 
lysates and NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels in membrane and soluble nuclear 
fractions following treatment with LY294002 (20 µM, 30 µM and 50 µM) for 16 h as quantified by 
densitometry. The data are expressed as % of vehicle control (control), where the ratio in the control 
was defined as 1.  Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (*p<0.05, **p<0.05, ***p<0.001, ****p<0.0001) as 
analysed by Student’s t-test. 
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5.3.11. NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival 
ROS are independent of ERK1/2 signalling however p22phox-mediated 
H2O2 production requires ERK1/2 activation 
The ERK1/2 pathway is known to be activated downstream of constitutively 
activated FLT3-ITD. We investigated the effect of ERK1/2 signalling inhibition using 
U0126 in MV4-11 cells (Figure 5.17. (i) a and Figure 5.17. (ii)) on NOX4D 28 kDa 
protein levels. Inhibition of ERK1/2 signalling did not cause a significant decrease in 
NOX4 67 kDa and NOX4D 28 kDa protein levels when compared to control, however, 
p22phox protein levels decreased significantly following treatment with 100 µM U0126 
(Figure 5.17. (i) b and Figure 5.17. (ii)). This suggests that NOX4 67 kDa- and 
NOX4D 28 kDa-generated pro-survival ROS are independent of ERK1/2 signalling. 
A decrease of 40-45% in total endogenous H2O2 was observed following treatment 
with 50 μM and 100 μM U0126 (Figure 5.17. (i) c and d). 
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Figure 5.17. (i) NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent 
of ERK1/2 signalling. p22phox-generated H2O2 requires ERK1/2 activation. Western blot analysis 
of ERK1/2 signalling in FLT3-ITD expressing MV4-11 cells following treatment with U0126 (10 μM, 
20 μM, 50 μM and 100 μM) for 16 h. α-tubulin and total protein (REVERT total protein stain) are 
shown as loading controls (a). NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels in membrane 
and soluble nuclear fractions of MV4-11 cells following treatment with U0126 for 16 h at indicated 
concentrations (b). Equal loading of samples is shown by total protein (REVERT total protein stain) 
and verification of subcellular fractions was assessed by probing for nuclear-localised NUP98 and 
membrane-localised calreticulin. Western blot analysis is representative of three independent 
experiments. Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with 
a) b) 
c) 
d) e) 
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U0126 for 16 h at indicated concentrations (c). Bar chart shows relative mean PO1 fluorescence of 
treated cells expressed as % of vehicle control (control) (d). Results are presented as mean ± SD from 
four independent experiments. Asterisks indicate statistically significant differences (*p<0.05, 
***p<0.001, ****p<0.0001) as analysed by Student’s t-test. Bar chart of % cell viability following 
treatment with the indicated concentrations of U0126 compared to vehicle controls (N=2) (e). 
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Figure 5.17. (ii) NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent 
of ERK1/2 signalling. p22phox-generated H2O2 requires ERK1/2 activation. Bar charts show relative 
mean pERK1/2, ERK1/2 and pERK1/2/ERK1/2 protein levels in whole cell lysates and NOX4 67 kDa, 
NOX4D 28 kDa and p22phox protein levels in membrane and soluble nuclear fractions following 
treatment with U0126 (10 µM, 20 µM, 50 µM and 100 µM) for 16 h as quantified by densitometry. The 
data are expressed as % of vehicle control (control), where the ratio in the control was defined as 1.  
Results are presented as mean ± SD from three independent experiments. Asterisks indicate statistically 
significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) as analysed by Student’s t-
test. 
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5.3.12. NOX4 67 kDa and NOX4D 28 kDa generate pro-survival ROS 
downstream of STAT5 signalling 
Previous studies have shown that FLT3-ITD drives evident activation of 
STAT5 signalling compared to FLT3-WT resulting in increased mRNA and protein 
levels of NOX4 (Jayavelu et al., 2016a, Choudhary et al., 2005b, Grundler et al., 
2005). Given that treatment with pimozide clearly reduced NOX4 mRNA in FLT3-
ITD expressing MV4-11 cells (Jayavelu et al., 2016a), we investigated the effect of 
STAT5 inhibition in MV4-11 cells (Figure 5.18. (i) a and Figure 5.18. (ii)) on NOX4D 
28 kDa protein levels. Treatment with indicated concentrations of pimozide resulted 
in a significant decrease in NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels 
following treatment with 20 µM pimozide (Figure 5.18. (i) b and Figure 5.18. (ii)). 
Furthermore, inhibition of STAT5 signalling caused a decrease of 30-40% in total 
endogenous H2O2 at all concentrations (Figure 5.18. (i) c and d), indicating a role for 
STAT5 signalling in the production of NOX4D-generated pro-survival ROS. 
Inhibition of STAT5 signalling had a substantial effect on cell viability at all 
concentrations, particularly following treatment with 20 µM pimozide (Figure 5.18. 
(i) e). This can also be seen by the increase in counts (peak) in pimozide treated cells 
in the flow cytometry histograms (Figure 5.18. (i) c) in order to record 10,000 viable 
cell counts. 
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Figure 5.18. (i) NOX4 67 kDa and NOX4D 28 kDa generate H2O2 downstream of STAT5 
activation.  Western blot analysis of STAT5 signalling in FLT3-ITD expressing MV4-11 cells 
following treatment with pimozide (5 μM, 10 μM and 20 μM) for 16 h (a). β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. NOX4 67 kDa, NOX4D 28 kDa and 
p22phox protein levels in membrane and soluble nuclear fractions of MV4-11 cells following treatment 
with pimozide for 16 h at indicated concentrations (b). Equal loading of samples is shown by total 
protein (REVERT total protein stain) and verification of subcellular fractions were assessed by probing 
for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is 
representative of three (a) or four (b) independent experiments. Flow cytometric analysis of mean 
relative PO1 fluorescence in MV4-11 cells treated with pimozide for 16 h at indicated concentrations 
a) b) 
d) e) 
c) 
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(c). Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of vehicle control 
(control) (d). Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test. Bar chart 
of % cell viability following treatment with the indicated concentrations of pimozide compared to 
vehicle controls (N=2) (e). 
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Figure 5.18. (ii) NOX4 67 kDa and NOX4D 28 kDa generate H2O2 downstream of STAT5 
activation.  Bar charts show relative mean pSTAT5, STAT5 and pSTAT5/STAT5 protein levels in 
whole cell lysates and NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels in membrane and 
soluble nuclear fractions following treatment with pimozide (5 µM, 10 µM and 20 µM) for 16 h as 
quantified by densitometry. The data are expressed as % of vehicle control (control), where the ratio in 
the control was defined as 1.  Results are presented as mean ± SD from three (pSTAT5, STAT5 and 
pSTAT5/STAT5) or four (NOX4 67 kDa, NOX4D 28 kDa and p22phox) independent experiments. 
Asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
as analysed by Student’s t-test. 
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5.3.13. Inhibition of GSK3β signalling in MV4-11 cell line increases 
NOX4D 28 kDa protein levels and decreases p22phox protein levels 
Previous studies in our laboratory have demonstrated that PKC412-mediated 
p22phox down-regulation at protein level requires GSK3β activation, establishing a role 
for GSK3β signalling in post-translational regulation of NOX4 partner protein p22phox 
(Woolley et al., 2012). SB216763, a drug described as an inhibitor of GSK3β (Dash 
et al., 2011, Tao et al., 2013) was found to decrease pGSK3β (Ser9) protein levels 
significantly in MV4-11 cells, therefore resulting in the activation of GSK3β 
signalling (Figure 5.19. (i) a and Figure 5.19. (ii)).Treatment of MV4-11 cells with 
indicated concentrations of SB216763 showed no obvious effect on NOX4 67 kDa, 
NOX4D 28 kDa and p22phox protein levels in membrane and soluble nuclear fractions 
(Figure 5.19. (i) b and Figure 5.19. (ii)). However, activation of GSK3β signalling 
increased total endogenous H2O2 by 45-50% following treatment with 1 µM and 2 µM 
SB216763 and approximately 40% following treatment with 5 µM SB216763 (Figure 
5.19. (i) c and d). Lithium chloride (LiCl) is widely used as a GSK3β inhibitor (Cohen 
and Goedert, 2004). Inhibition of GSK3β using LiCl caused an increase in pGSK3β 
(Ser9) protein levels (Figure 5.20. (i) a and Figure 5.20. (ii)) in MV4-11 cells, 
indicative of inhibition of the pathway. This increase coincided with a significant 
increase in NOX4D 28 kDa protein levels in membrane and soluble nuclear fractions. 
Interestingly, p22phox protein levels decreased significantly following treatment with 
50 mM LiCl in both membrane and soluble nuclear fractions (Figure 5.20. (i) b and 
Figure 5.20. (ii)). Inhibition of GSK3β activation had little or no effect on total 
endogenous H2O2 levels (Figure 5.20. (i) c and d). 
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Figure 5.19. (i) GSK3β activation had no noticeable effect on NOX4 67 kDa and NOX4D 28 kDa 
protein levels. Western blot analysis of GSK3β signalling in FLT3-ITD expressing MV4-11 cells 
following treatment with SB216763 (1 μM, 2 μM and 5 μM) for 16 h (a). β-actin and total protein 
(REVERT total protein stain) are shown as loading controls. NOX4 67 kDa, NOX4D 28 kDa and 
p22phox protein levels in membrane and soluble nuclear fractions of MV4-11 cells following treatment 
with SB216763 for 16 h at indicated concentrations (b). Equal loading of samples is shown by total 
protein (REVERT total protein stain) and verification of subcellular fractions were assessed by probing 
for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is 
a) b) 
c) 
d) 
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representative of three (a) or four (b) independent experiments. Flow cytometric analysis of mean 
relative PO1 fluorescence in MV4-11 cells treated with SB216763 for 16 h at indicated concentrations 
(c). Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of vehicle control 
(control) (d). Results are presented as mean ± SD from three independent experiments. Asterisks 
indicate statistically significant differences (***p<0.001, ****p<0.0001) as analysed by Student’s t-
test.  
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Figure 5.19. (ii) GSK3β activation had no noticeable effect on NOX4 67 kDa and NOX4D 28 kDa 
protein levels. Bar charts show relative mean pGSK3β, GSK3β and pGSK3β/GSK3β protein levels in 
whole cell lysates and NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels in membrane and 
soluble nuclear fractions following treatment with SB216763 (1 µM, 2 µM and 5 µM) for 16 h as 
quantified by densitometry. The data are expressed as % of vehicle control (control), where the ratio in 
the control was defined as 1.  Results are presented as mean ± SD from three (pGSK3β, GSK3β and 
pGSK3β/GSK3β) or four (NOX4 67 kDa, NOX4D 28 kDa and p22phox) independent experiments. 
Asterisks indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test. 
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Figure 5.20. (i) Inhibition of GSK3β signalling results in elevated NOX4D 28 kDa protein levels. 
Western blot analysis of GSK3β signalling in FLT3-ITD expressing MV4-11 cells following treatment 
with lithium chloride (10 mM, 20 mM and 50 mM) for 16 h (a). β-actin and total protein (REVERT 
total protein stain) are shown as loading controls. NOX4 67 kDa, NOX4D 28 kDa and p22phox protein 
levels in membrane and soluble nuclear fractions of MV4-11 cells following treatment with lithium 
chloride for 16 h at indicated concentrations (b). Equal loading of samples is shown by total protein 
(REVERT total protein stain) and verification of subcellular fractions were assessed by probing for 
nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative 
c) 
d) 
b) a) 
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of three independent experiments. Flow cytometric analysis of mean relative PO1 fluorescence in MV4-
11 cells treated with lithium chloride for 16 h at indicated concentrations (c). Bar chart shows relative 
mean PO1 fluorescence of treated cells expressed as % of vehicle control (control) (d). Results are 
presented as mean ± SD from four independent experiments. Asterisks indicate statistically significant 
differences (**p<0.01, ***p<0.001) as analysed by Student’s t-test.  
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Figure 5.20. (ii) Inhibition of GSK3β signalling results in elevated NOX4D 28 kDa protein levels. 
Bar charts show relative mean pGSK3β, GSK3β and pGSK3β/GSK3β protein levels in whole cell 
lysates and NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels in membrane and soluble nuclear 
fractions following treatment with lithium chloride (LiCl) (10 mM, 20 mM and 50 mM) for 16 h as 
quantified by densitometry. The data are expressed as % of vehicle control (control), where the ratio in 
the control was defined as 1. Results are presented as mean ± SD from three independent experiments. 
Asterisks indicate statistically significant differences (*p<0.05, **p<0.01, ****p<0.0001) as analysed 
by Student’s t-test. 
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5.3.14. FLT3-ITD-driven NOX4D-generated H2O2 in AML 
 Together with previous findings we have identified that ligand-independent 
constitutive activation of the FLT3 receptor, FLT3-ITD, activates PI3K/AKT, ERK1/2 
and STAT5 signalling and inhibits GSK3β signalling. We have shown that FLT3-ITD 
is an upstream regulator of NOX4D-generated pro-survival H2O2. Activation of AKT 
and STAT5 signalling by FLT3-ITD results in the activation and production of 
NOX4D-generated H2O2 at the nuclear membrane where it may be contributing to 
DNA damage and disease progression (Figure 5.21.).  
 
Figure 5.21. A schematic of the proposed mechanism of FLT3-ITD-driven NOX4D-generated 
H2O2 in AML. GSK3β, ERK1/2, PI3K/AKT and STAT5 pro-survival pathways are located 
downstream of FLT3-ITD. Phosphorylation and activation of AKT and STAT5 signalling by the FLT3-
ITD oncogene results in the activation and production of DNA damaging NOX4D-generated H2O2 at 
the nuclear membrane. 
 
197 
 
5.3.15. BCR-ABL expressing CML K562 cells express the NOX4 
splice variant NOX4D 28 kDa primarily in the cytoplasm 
The BCR-ABL mutation in CML is involved in a cycle of genomic instability 
similar to that of the FLT3-ITD mutation. BCR-ABL is known to activate downstream 
pro-survival pathways, for example, PI3K/AKT, JAK/STAT, and Raf/MEK/ERK, 
resulting in resistance to apoptosis and proliferation. BCR-ABL-expressing cells have 
been reported to generate increased levels of ROS compared to untransformed cells 
(Jayavelu et al., 2016b). Naughton et al., reported that NOX4-generated ROS 
contribute significantly to total endogenous ROS on BCR-ABL induction (Naughton 
et al., 2009). The oncogenic effects of BCR-ABL cause increased levels of ROS 
production, leading to enhanced DNA damage and compromised DNA repair. Not 
only are levels of DNA damage much higher in BCR-ABL-transformed cells 
compared with non-transformed cells, the rate of DNA repair is also much higher 
because of unfaithful end joining systems (Nowicki et al., 2004). Importantly, the 
resulting accumulation of DNA damage and genetic abnormalities contributes to 
resistance against drugs that are commonly used in the treatment of CML including 
imatinib (Koptyra et al., 2006). 
Moreover, we investigated if BCR-ABL expressing CML cells express 
NOX4D. We show that BCR-ABL expressing CML K562 cells express the NOX4D 
28 kDa splice variant primarily in the cytoplasmic fraction. NOX4D is also expressed 
in the membrane and soluble nuclear fractions of K562 cells (Figure 5.22.).  
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Figure 5.22. BCR-ABL expressing CML K562 cells express the NOX4D 28 kDa isoform. 
Subcellular fractionation was carried out in BCR-ABL expressing CML cell line, K562, using a 
subcellular fractionation kit. Expression of NOX4 67 kDa, NOX4D 28 kDa and p22phox was assessed 
by means of western blot analysis. Equal loading of samples and verification of the subcellular fractions 
were demonstrated by probing for nuclear-localised NUP98 and Histone H3, membrane-localised 
calreticulin and cytosolic-localised GAPDH. Western blots are representative of three independent 
experiments. 
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5.4. Discussion 
FLT3-ITD is the most prevalent mutation in AML accounting for 15-35% of 
patient cases (Gilliland and Griffin, 2002, Network, 2013, Jayavelu et al., 2016b) and 
has been associated with an aggressive phenotype (Small, 2008, Konig and Levis, 
2015). NOX-derived ROS have been shown to have numerous roles in leukaemia 
including cell survival, cell proliferation and a differentiation block (Naughton et al., 
2009, Reddy et al., 2011). Leukaemic oncogenes have been widely documented in the 
regulation of NOX proteins and their partner protein p22phox (Jayavelu et al., 2016b, 
Landry et al., 2013, Moloney et al., 2017b). Our group has shown that 32D cells 
transfected with FLT3-ITD possess higher NOX4 and p22phox levels than their wild-
type counterpart contributing to genomic instability in FLT3-ITD expressing AML. 
Furthermore, 32D/FLT3-ITD cells exhibit higher levels of total endogenous and 
nuclear H2O2 and DNA damage than 32D/FLT3-WT cells (Stanicka et al., 2015). 
Unlike other NOX family members, NOX4 is constitutively activated (Martyn 
et al., 2006). Subcellular localisation of NOX4 is key to its role in ROS production 
and genetic instability. NOX4 has been reported to be expressed in the nucleus 
(Spencer et al., 2011, Gordillo et al., 2010, Weyemi and Dupuy, 2012, Weyemi et al., 
2012, Guida et al., 2013, Guida et al., 2014, Maraldi et al., 2015, Weyemi et al., 2015) 
amongst other previously identified locations including the cytoskeleton (Hilenski et 
al., 2004), ER (Ambasta et al., 2004, Chen et al., 2008b, Helmcke et al., 2008, Zhang 
et al., 2011), mitochondria  (Block et al., 2009, Case et al., 2013) and plasma 
membrane (Zhang et al., 2011, Lee et al., 2006). Our laboratory has previously shown 
that NOX4 and p22phox colocalise to the nuclear membrane (Stanicka et al., 2015) and 
that p22phox also colocalises to the ER (Woolley et al., 2012) of FLT3-ITD expressing 
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MV4-11 cells. Previous studies have identified the presence of NOX4 isoforms or 
splice variants (Goyal et al., 2005). NOX4D 28 kDa is of particular interest, as it is 
found in the nucleus and nucleolus of multiple cell types including human aortic 
smooth muscle cells, HUVECs, H9C2 rat cardiomyocyte cells, HEK cells, mouse 
primary cardiac fibroblasts and rat neonatal cardiomyocytes, where it contributes to 
ROS production and DNA damage (Anilkumar et al., 2013). 
To investigate if FLT3-ITD expressing AML cells express NOX4D and in 
order to identify the localisation of NOX4D we utilised subcellular fractionation. 
Following optimisation of the subcellular fractionation technique, it proved very 
difficult to detect the membrane-localised markers, calreticulin and KDEL, in the 
membrane fraction only. The membrane-localised markers were detected in the 
soluble nuclear fractions of MV4-11, 32D/FLT3-ITD and 32D/FLT3-WT cells 
(Figure 5.3. - Figure 5.6., Figure 5.12. b, Figure 5.16. - Figure 5.20.). The MV4-11, 
32D/FLT3-ITD and 32D/FLT3-WT cell structures did not facilitate in the generation 
of clean fractions. Leukaemia cells have very little cytoplasm, a large nucleus and 
distinct nucleoli (Lowenberg et al., 1999). We have shown this in MV4-11 cells 
stained with haematoxylin (Figure 3.1.). Previous studies in our laboratory have shown 
MV4-11 cells to have a large endoplasmic reticulum using an ER marker and have 
also shown that the ER is in close proximity with the nuclear membrane (Woolley et 
al., 2012). In support of previous work, we confirmed the ER as being a large organelle 
in the MV4-11 cell structure (Figure 3.2. and Figure 3.4.). Further studies in our 
laboratory have identified MV4-11 cells as having a large nucleus using the nuclear 
marker, Hoechst, and that Hoechst strongly correlates with the nuclear H2O2 specific 
probe, Nuclear Peroxy Emerald 1 (NucPE1) (Stanicka et al., 2015). The ER marker 
strongly correlated with PO1 (Woolley et al., 2012). PO1 and NucPE1 are in very 
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close proximity (Stanicka et al., 2015), the nuclear membrane is contiguous with the 
lumen of the ER. These findings confirm that the MV4-11 cell structure does not 
facilitate in the collection of clean fractions, particularly soluble nuclear fractions. 
This might account for the detection of membrane-localised calreticulin marker in the 
soluble nuclear fractions of MV4-11 cells. The membrane-localised marker, 
calreticulin, has previously been detected in the cytosol of HeLa and MDA-MB-435 
cells and the perinuclear region of MDA-MB-435 cells (Shaiken and Opekun, 2014). 
The ER permeates much of the cytoplasm and this might be an explanation for the 
detection of calreticulin in the cytoplasmic fraction of MV4-11 cells (Burke, 2015). 
In this study, we investigated the expression, localisation and regulation of 
NOX4D-generated pro-survival ROS in FLT3-ITD expressing AML. We found that 
FLT3-ITD expressing AML patients and cells possess the NOX4D splice variant 
(Figure 5.1., Figure 5.3. - Figure 5.6.). FLT3-ITD expressing AML cells express 
NOX4D in the membrane and soluble nuclear fractions. NOX4D was not detected in 
the FLT3-WT expressing patient samples and cells (Figure 5.1., Figure 5.5. and Figure 
5.6.), suggesting a role for nuclear membrane-localised NOX4D 28 kDa in the 
generation of pro-survival ROS in FLT3-ITD expressing AML. In line with previous 
work, we detected NOX4 67 kDa in the soluble nuclear fraction and its partner protein 
p22phox in the membrane and soluble nuclear fractions of MV4-11 and 32D/FLT3-ITD 
cells (Figure 5.3. - Figure 5.6.). Although the soluble nuclear fraction contains 
membrane-localised protein, calreticulin, NOX4 67 kDa was detected in the soluble 
nuclear fraction and not in the membrane fraction, justifying its localisation to the 
nuclear membrane of MV4-11 cells. 32D cells stably transfected with FLT3-ITD 
express NOX4D 28 kDa and possess elevated levels of total endogenous H2O2 
compared to their wild-type counterpart (Figure 5.8.). Importantly, to our knowledge, 
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this is the first study to identify the role of nuclear membrane-localised NOX4D 28 
kDa in pro-survival ROS production and genomic instability in FLT3-ITD expressing 
AML cells. 
p22phox is a partner protein of NOX1-4 and is required for NOX4 activation 
(Ambasta et al., 2004). We found that p22phox knockdown had no significant effect on 
NOX4 67 kDa and NOX4D 28 kDa protein levels (Figure 5.9.). Interestingly, previous 
studies have shown that NOX4 knockdown resulted in depletion of p22phox protein 
levels in HUVECs with no change in p22phox mRNA expression (Kuroda et al., 2005). 
This suggests that the formation of NOX4 and p22phox complex in the nucleus of 
HUVECs is responsible for the stabilisation of p22phox at the protein level. 
Recent studies in our laboratory have revealed that NOX4 67 kDa is 
glycosylated in FLT3-ITD expressing MV4-11 cells (Figure 3.25.) (Moloney et al., 
2017b). We show that NOX4D 28 kDa is also glycosylated in MV4-11 cells, by using 
a glycosylation inhibitor, tunicamycin, and a receptor trafficking inhibitor, brefeldin 
A. By inhibiting glycosylation, NOX4D 28 kDa was observed at a lower molecular 
weight (Figure 5.10.). Indeed, NOX4D 28 kDa is glycosylated in A549 cells (Goyal 
et al., 2005). We have shown that deglycosylation of NOX4 67 kDa  and now NOX4D 
28 kDa coincides with significant decreases in total endogenous H2O2 (Figure 3.11.) 
(Moloney et al., 2017b).  This suggests that the glycosylation of NOX4 67 kDa and 
NOX4D 28 kDa may be important for their role in the production of pro-survival ROS 
and DNA damage in AML. Tunicamycin and brefeldin A have recently been shown 
to inhibit receptor trafficking of the FLT3-ITD receptor to the plasma membrane 
which caused inactivation of both the AKT and ERK1/2 pathways (Choudhary et al., 
2009, Moloney et al., 2017b). Although tunicamycin and brefeldin A inhibit many 
glycosylated proteins, mild inhibition of glycosylation using tunicamycin in 
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combination with FLT3 kinase inhibitors has shown therapeutic potential for the 
treatment of FLT3-ITD expressing AML (Tsitsipatis et al., 2017). 
It has been previously demonstrated that FLT3-ITD is involved in the up-
regulation of NOX4 both at mRNA and protein levels (Stanicka et al., 2015, Jayavelu 
et al., 2016a). Inhibition of FLT3-ITD activity using several FLT3 receptor inhibitors 
including AC220, tyrphostin (AG1295) and PKC412 caused a decrease in NOX4 
mRNA and protein levels (Jayavelu et al., 2016a, Moloney et al., 2017b) presenting a 
role for FLT3-ITD in NOX4-generated ROS production in AML. Here, we have 
shown that FLT3-ITD patient samples and FLT3-ITD expressing MV4-11 and 32D 
cells express the NOX4D 28 kDa splice variant alongside a dramatic increase in total 
endogenous H2O2 compared to their wild-type counterpart that do not express NOX4D 
(Figure 5.8.). Inhibition of the FLT3 receptor using PKC412 caused a decrease in total 
endogenous H2O2 in 32D/FLT3-ITD cells compared to 32D/FLT3-WT cells (Figure 
5.11.). FLT3-ITD inhibition in MV4-11 cells treated with PKC412 resulted in down-
regulation of NOX4 67 kDa, NOX4D 28 kDa and p22phox protein levels alongside a 
decrease in H2O2 levels (Figure 5.12. and Figure 5.13.). Treatment of MV4-11 and 
32D/FLT3-ITD cells with FLT3 receptor inhibitor AC220 also led to decreased levels 
of NOX4D 28 kDa (Figure 5.14.). Inhibition of the FLT3 receptor in MOLM13 cells 
treated with AC220 also resulted in decreased NOX4D 28 kDa protein levels (Figure 
5.15.).  PKC412 (midostaurin) has recently been approved by the FDA and AC220 is 
currently being tested in clinical trials for the treatment of AML (Smith et al., 2012, 
Stone et al., 2012, AML, 2017). Previous studies have shown that FLT3-ITD 
inhibition using PKC412 and NOX inhibition via diphenyleneiodonium (DPI) in 
32D/FLT3-ITD cells resulted in approximately 25-40% decrease in γH2AX levels, a 
marker of dsbs (Stanicka et al., 2015). Together these findings suggest that the FLT3-
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ITD oncogene is responsible for the regulation and production of nuclear membrane-
localised NOX4D-generated H2O2 in AML contributing to genetic instability and an 
aggressive phenotype.  
Three major pro-survival pathways are activated downstream of FLT3-ITD in 
AML: PI3K/AKT, ERK1/2 and STAT5 pathways (Figure 4.10.) (Choudhary et al., 
2009). We have shown that the PI3K/AKT pathway needs to be activated in order for 
NOX4 to generate its oncogenic effects in AML (Figure 4.5.) (Moloney et al., 2017b). 
Inhibition of the PI3K/AKT pathway revealed that the PI3K/AKT pathway is 
responsible for the generation of NOX4-, NOX4D- and p22phox-generated H2O2 
(Figure 5.16.). Although the ERK1/2 pathway is located downstream of FLT3-ITD, 
inhibition of ERK1/2 signalling was found to have no noticeable effect on NOX4- and 
NOX4D-protein levels. However, inactivation of ERK1/2 signalling revealed that 
ERK1/2 activation is involved in the stimulation and production of p22phox-mediated 
H2O2 production in AML (Figure 5.17.). p22
phox is a partner protein of NOX1, NOX2 
and NOX3 as well as NOX4, all of which have a role in ROS production. We have 
previously demonstrated that NOX2 is also involved in ROS production and DNA 
damage contributing to genetic instability in FLT3-ITD expressing AML. This same 
study confirmed that NOX1 does not contribute significantly to ROS production or 
dsbs (Stanicka et al., 2015). Patient derived FLT3-expressing myeloid cells have been 
shown to express NOX2, NOX4 and NOX5. However, their murine counterpart have 
been shown to express NOX1, NOX2 and NOX4. These cells did not express NOX3 
(Reddy et al., 2011). Therefore it is likely that ERK1/2 activation is involved in the 
production of NOX2-generated H2O2 in FLT3-ITD expressing AML. Recent findings 
have identified STAT5 signalling downstream of FLT3-ITD and its requirement for 
the up-regulation of NOX4-generated H2O2, alongside the inactivation of DEP-1 PTP 
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a negative regulator of FLT3 signalling activity (Jayavelu et al., 2016a). Inhibition of 
STAT5 signalling revealed that activated STAT5 is required for the production of 
NOX4-, NOX4D- and p22phox-generated ROS (Figure 5.18.). This suggests that 
NOX4D may also have a role in the partial inactivation of DEP-1 PTP resulting in 
cellular transformation in FLT3-ITD expressing AML. 
GSK3β is another pathway known to be located downstream of FLT3-ITD. 
Inhibition of the PI3K/AKT pathway in MV4-11 cells resulted in increased levels of 
pGSK3β (Ser9) suggesting that the GSK3β pathway is not located downstream of the 
PI3K/AKT pathway (Figure 4.5. and Figure 4.12.) (Moloney et al., 2017b). 
Phosphorylation of GSK3β at Serine 9 decreased following ERK1/2 inhibition 
suggesting that the GSK3β pathway is located downstream of ERK1/2 (Figure 4.13.). 
Inhibition of FLT3-ITD signalling caused a decrease in phosphorylation of GSK3β 
(Ser9), resulting in increased GSK3β activation (Figure 4.8. and Figure 4.10.) which 
has been shown previously to play a crucial role in the post-translational regulation of 
p22phox (Woolley et al., 2012, Moloney et al., 2017b). SB216763 is described as an 
inhibitor of GSK3β, and GSK3β is inhibited when it is phosphorylated. In 
disagreement with this, SB216763 was found to decrease levels of pGSK3β in MV4-
11 cells (Figure 5.19.), suggesting that it is acting as an activator of GSK3β. It is 
possible that SB216763 could have different effects in other cell types. However, 
based on our findings, we advise careful consideration and assessment of pGSK3β 
levels when using this drug. Activation of GSK3β was found to have no noticeable 
effect on NOX4-, NOX4D- and p22phox protein levels, however an increase in H2O2 
levels was observed (Figure 5.19.). The activation of GSK3β signalling has been found 
to be pro-apoptotic in several systems and can provoke mitochondrial injury and this 
may be responsible for the increase in H2O2 levels (Bijur et al., 2000, Macanas-Pirard 
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et al., 2005, Maurer et al., 2006). Lithium chloride, also described as an inhibitor of 
GSK3β, resulted in the expected increase in pGSK3β in MV4-11 cells, indicating 
inhibition (Figure 5.20.). Inhibition of GSK3β signalling using LiCl revealed an 
increase in NOX4D protein levels, however, p22phox protein levels decreased. 
Moreover, inhibition of GSK3β signalling had little or no effect on total endogenous 
H2O2 (Figure 5.20.). 
The BCR-ABL mutation in CML is involved in a cycle of genomic instability 
similar to that of the FLT3-ITD mutation in AML. BCR-ABL mutation  is known to 
activate several pro-survival signalling pathways, for example, PI3K/AKT, STAT and 
ERK resulting in elevated ROS production compared to their wild-type counterpart, 
particularly NOX4-generated ROS, leading to enhanced DNA damage and 
compromised DNA repair (Jayavelu et al., 2016b, Naughton et al., 2009, Nowicki et 
al., 2004). We investigated the expression and localisation of  NOX4D 28 kDa in K562 
cells. We found that BCR-ABL expressing CML cells possess the NOX4D splice 
variant in the cytoplasmic, membrane and soluble nuclear fractions (Figure 5.22.). 
NOX4D is primarily located in the cytoplasm of BCR-ABL expressing K562 cells, 
however, NOX4D is localised to the nuclear membrane of FLT3-ITD expressing 
MV4-11 cells, suggesting that nuclear membrane-localised NOX4D-generated H2O2 
in FLT3-ITD expressing AML is associated with rapid disease progression due to 
close proximity with DNA in the nucleus resulting in an inferior outcome. 
In conclusion, we suggest that the FLT3-ITD oncogene is responsible for the 
activation and generation of NOX4D-generated pro-survival H2O2 at the nuclear 
membrane contributing to DNA damage and genetic instability in AML. 
Glycosylation of NOX4 and NOX4D is essential for the production of pro-survival 
ROS. Activation of PI3K/AKT and STAT5 signalling is required in order for NOX4D 
207 
 
to generate its oncogenic effects. These findings are summarised in Figure 5.21. This 
study emphasises the potential of NOX4 and NOX4D as an effective therapeutic target 
in FLT3-ITD expressing AML, as inhibition and deglycosylation of NOX4 and 
NOX4D can decrease the levels of H2O2 and DNA damage that would otherwise 
contribute to genetic instability. 
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Chapter 6. General Discussion 
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Until recently the strategy of AML treatment had not changed substantially in 
over 30 years. The worldwide standard of care for AML patients who are not 
participating in clinical trials, receive an induction of chemotherapy consisting of 
cytarabine and idarubicin/daunorubicin, followed by either one to four cycles of 
consolidation therapy and autologous or allogeneic stem cell transplantation (Roboz, 
2012). This standard treatment with chemotherapy maximally results in 70-80% 
patients less than 65 years achieving complete remission, most will eventually relapse 
and an overall survival rate of only 40-50% at 5 years (Emadi and Karp, 2014, Büchner 
et al., 2012). Several factors have been associated with more severe outcomes at 
relapse including unfavourable cytogenetics at diagnosis, old age and also prior history 
of haematopoietic stem cell transplantation (Breems et al., 2005). This demonstrates 
the importance and need for the development of new drugs for the treatment of AML. 
Furthermore, the high percentage of relapse in AML highlights the requirement for 
investigations into the molecular sources and mechanisms which are involved and 
contribute to drug resistance and relapse. 
Imatinib mesylate was the first small-molecule tyrosine kinase inhibitor (TKI) 
used as a standard cancer therapy targeting the BCR-ABL oncoprotein in CML. 
Treatment of CML patients in clinic with imatinib has increased the 5 year survival 
rate from 50% to 90%, demonstrating the effectiveness of molecular targeted 
chemotherapy in cancer (Druker, 2009). Following the proven effectiveness of 
imatinib, there has been great interest in the development of more specific and 
effective chemotherapeutics against other cancer-driving oncoproteins. 
Genetic alterations in AML have been classified into two classes collectively 
known as the ‘two-hit’ model. Class I mutations are mutations that result in the 
activation of signal transduction pathways that lead to increased cell survival and 
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proliferation, for example, FLT3, BCR-ABL, RAS and JAK2 (Conway O'Brien et al., 
2014). Class II mutations are mutations that affect differentiation preventing 
maturation of cells and also affect self-renewal, for instance, CEBPA, MLL and 
NPM1. In order for AML to develop, a class I mutation must be accompanied by a 
class II mutation (Shih et al., 2012, Naoe and Kiyoi, 2013).  
FLT3 is a type III RTK expressed in approximately 90% of AML cases and is 
involved in the early stages of haematopoiesis (Stirewalt and Radich, 2003, Gilliland 
and Griffin, 2002). Mutations in FLT3 are present in 25-45% of AML patients, making 
it the most prevalent genetic aberration in AML (Stirewalt and Radich, 2003) and an 
attractive therapeutic target. There are two types of FLT3 mutations implicated in 
AML; the FLT3 internal tandem duplication (FLT3-ITD) mutation and mutations of 
the activation loop of the tyrosine kinase domain of FLT3 (FLT3-TKD). The FLT3-
ITD mutation is the most common mutation expressed in 15-35% of AML cases, 1-
3% of ALL cases and 5-10% of patients with myelodysplastic syndromes (MDS) 
(Stirewalt and Radich, 2003).  In recent months, advances have been made in AML 
treatments. Midostaurin (Rydapt), a tyrosine kinase inhibitor has been approved by 
the FDA for the treatment of FLT3-positive AML (AML, 2017). This is a major 
improvement for the treatment of AML. More specific tyrosine kinase inhibitors 
including quizartinib are currently in clinical trials and are showing promising effects.  
Our laboratory and other laboratories have demonstrated that patient AML 
blasts generate increased levels of ROS (Stanicka et al., 2015, Hole et al., 2013), which 
are known to be involved in DNA damage and genetic instability. However, it is well 
established that ROS also act as cell signalling molecules in a wide array of processes 
regulating cell survival and differentiation, proliferation and growth (Clerkin et al., 
2008, Gough and Cotter, 2011, Schieber and Chandel, 2014). ROS have been long 
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associated with cancer where different types of tumour cells have been shown to 
produce elevated levels of ROS compared to their wild-type counterpart (Panieri and 
Santoro, 2016). Enhanced ROS production, particularly from NOXs, are thought to be 
oncogenic resulting in enhanced cell survival and proliferation, DNA damage and 
genetic instability, adaptation, cellular injury and cell death, autophagy and resistance 
to drugs (Moloney and Cotter, 2017). Regulation of ROS in tumour cells must be 
tightly regulated to prevent tumour cell death. An overproduction of ROS results in 
increased antioxidant levels. However, the antioxidant capacity cannot cope with the 
high concentrations of ROS and is involved in the maintenance of pro-tumourigenic 
signalling allowing disease progression and for the tumour cells to develop resistance 
against apoptosis (Gorrini et al., 2013). From a clinical point of view, adaptation of 
tumour cells to enhanced ROS production may result in tumour cells being less 
responsive to cytotoxic chemotherapy, which operates through severe oxidative stress 
(Schumacker, 2006, Pelicano et al., 2004, Trachootham et al., 2009). Therefore, 
delineation of the sources and mechanism of regulation and production could identify 
novel protein targets in cancer, which in combination with standard chemotherapy, 
would effectively increase and prolong the response of cancer to chemotherapy. 
A number of studies have investigated the function of ROS, specifically 
NOX4-generated ROS in AML. Our group has identified NOX4 and p22phox, a small 
membrane subunit of the NOX complex, as major sources of ROS in AML (Woolley 
et al., 2012, Stanicka et al., 2015). FLT3-ITD expressing cells have been shown to 
express increased levels of NOX4 and p22phox proteins as well as elevated ROS 
compared to FLT3-WT expressing cells (Stanicka et al., 2015). Furthermore, FLT3-
ITD expressing cells exhibit higher levels of total endogenous and nuclear H2O2 and 
DNA damage than FLT3-WT (Stanicka et al., 2015). The mechanism in which FLT3-
212 
 
ITD regulates and generates NOX4- and p22phox-generated ROS is not clear. The 
overall aim of this thesis was to delineate the mechanisms in which FLT3-ITD-
generated pro-survival ROS contribute to DNA damage and genetic instability in 
AML. 
The FLT3-ITD mutation results in ligand-independent constitutive activation 
of the receptor at the plasma membrane and impaired trafficking of the receptor in 
compartments of its biosynthetic route, such as the ER (Choudhary et al., 2009, 
Moloney et al., 2017b). FLT3-ITD expressing cells produced elevated levels of H2O2 
compared to FLT3-WT expressing cells (Stanicka et al., 2015). The molecular 
mechanism describing how mislocalised activation of FLT3-ITD stimulates the 
aberrant signalling of downstream pathways resulting in the production of pro-survival 
ROS is not known. Previous studies investigated the role of mislocalised activation of 
FLT3-ITD in AML using a mutant of FLT3-ITD, containing a deletion in the 
extracellular ligand-binding domain of FLT3-ITD, eliminating many sites of 
glycosylation, resulting in glycosylation independent trafficking of the FLT3-ITD 
receptor. In the same study, they used two receptor trafficking inhibitors, tunicamycin 
and brefeldin A, as an alternative method to study the effects of mislocalised activation 
of FLT3-ITD on aberrant signalling cascades (Choudhary et al., 2009). The findings 
in this study endorsed the use of receptor trafficking inhibitors, such as tunicamycin 
and brefeldin A, as a method for us to investigate the effect of subcellular localisation 
of FLT3-ITD on the generation of ROS in this study. In this study, we have shown 
that FLT3-ITD at the plasma membrane is responsible for the activation and 
expression of NOX4- and p22phox-generated pro-survival ROS in FLT3-ITD 
expressing AML cells. p22phox is an essential component of NOX1-4 and is required 
for NOX activity and is essential for the maintenance of pro-survival ROS signalling 
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in AML. For FLT3-ITD to generate its oncogenic effects it has to be located at the 
plasma membrane. Plasma membrane FLT3-ITD induced activation of PI3K/AKT 
signalling is responsible for the activation of NOX4- and p22phox- generated ROS in 
AML. ER retention of FLT3-ITD resulted in NOX4 deglycosylation, decreased 
p22phox mRNA levels and proteasomal degradation of p22phox protein. This work is 
published in Leukemia Research (Moloney et al., 2017b) and presents FLT3-ITD at 
the plasma membrane as a potential therapeutic target, in preventing downstream 
ROS-driven oncogenic effects (Chapter 3&4).  
Increased production of NOX4-generated ROS has been documented to have 
a role in cell survival, cell proliferation and a differentiation block in AML (Moloney 
and Cotter, 2017, Jayavelu et al., 2016b). In Chapter 4, we also studied which pro-
survival pathways were activated downstream of the FLT3-ITD receptor and 
examined the effects of FLT3-ITD subcellular localisation on the regulation and 
activation of aberrant signalling cascades. Activation of the FLT3-ITD receptor in 
AML stimulates downstream pro-survival signalling pathways including AKT, 
GSK3β, ERK1/2 and STAT5. In this study, we have demonstrated that the AKT and 
ERK1/2 signalling pathways are activated and the GSK3β signalling pathway is 
inhibited downstream of FLT3-ITD at the plasma membrane. The STAT5 signalling 
pathway is activated downstream of FLT3-ITD at the ER. These findings support 
previous studies investigating the effects of mislocalised activation of FLT3-ITD on 
the initiation of aberrant signalling cascades in 32D cells expressing the FLT3-ITD 
mutation (Choudhary et al., 2009). Previous studies have identified the PI3K/AKT 
pathway to be responsible for the regulation of GSK3β signalling through the 
phosphorylation of GSK3β on serine 9 resulting in the inhibition of GSK3β signalling 
(Kurosu et al., 2013). However, we have shown for the first time that GSK3β is 
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inhibited downstream of ERK1/2 activation in FLT3-ITD expressing AML.  Chapters 
3 and 4 nicely tie together the mechanism in which mislocalised activation of FLT3-
ITD at the plasma membrane results in the activation of AKT and ERK1/2 and 
inhibition of GSK3β signalling and FLT3-ITD at the ER activates STAT5 pro-survival 
signalling. The PI3K/AKT pathway is responsible for the activation and generation of 
NOX4- and p22phox-generated pro-survival ROS in AML. Together these findings 
delineate the mechanism involved in the activation and regulation of NOX4- and 
p22phox- generated H2O2 in AML, identifying FLT3-ITD at the plasma membrane as a 
potential therapeutic target. 
Our laboratory has identified NOX4 as a major source of ROS in FLT3-ITD 
expressing AML (Stanicka et al., 2015). Among the NOX family members, NOX4 is 
unique. It is constitutively activated, generating H2O2, unlike its family members 
NOX1 and NOX2, which require an agonist for activation (Martyn et al., 2006, 
Serrander et al., 2007, Takac et al., 2011). NOX4 subcellular localisation plays an 
important role given its constitutive activity. NOX4 and p22phox have been shown to 
colocalise to the nuclear membrane of FLT3-ITD expressing AML MV4-11 cell line 
contributing to DNA oxidation and dsbs, possibly driving genetic instability (Stanicka 
et al., 2015). Previous studies have identified NOX4 isoforms at varying levels in the 
presence of the prototype in the human lung cancer cell line, A549 (Goyal et al., 2005). 
NOX4 splice variant D (NOX4D 28 kDa) is of particular interest and has been shown 
to localise to the nucleus and nucleolus of VSMC, A7R5 cells as well as many other 
cell lines where it is contributing to elevated ROS production and DNA damage 
(Anilkumar et al., 2013, Goyal et al., 2005). In this study, we identified the expression 
of NOX4D in FLT3-ITD expressing patient samples and cells for the first time. 
NOX4D expression was absent from FLT3-WT expressing patient samples and cells. 
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We show that the FLT3-ITD oncogene is responsible for the activation and generation 
of NOX4D-generated pro-survival H2O2 at the nuclear membrane where it may be 
contributing to DNA damage and genetic instability in AML. Glycosylation of NOX4 
and NOX4D is essential for the production of pro-survival H2O2. Activation of 
PI3K/AKT and STAT5 signalling is required in order for NOX4D to generate its 
oncogenic effects. This study emphasises NOX4 and NOX4D as effective and 
attractive therapeutic targets in FLT3-ITD expressing AML (Chapter 5) as the 
inhibition and deglycosylation of NOX4 and NOX4D can decrease the levels of H2O2 
that would otherwise contribute to genetic instability. This work is published in 
Oncotarget (Moloney et al., 2017a). 
Together our findings from Chapter 3, 4 and 5 have identified FLT3-ITD at 
the plasma membrane, PI3K/AKT, STAT5, NOX4 and NOX4D as attractive 
therapeutic targets for the treatment of FLT3-ITD expressing AML. Further studies 
have supported our findings. Inhibition of N-glycosylation of RTKs such as FLT3-
ITD and c-KIT has been shown to have anti-leukaemic activity in AML. For example, 
loss of surface expression of FLT3-ITD and c-KIT results in induction of apoptotic 
cell death, mitigation of resistance to TKIs including the most potent FLT3 inhibitor 
currently in clinical trials, quizartinib, and also restores sensitivity to the 
chemotherapy drug cytarabine (Williams et al., 2012). More recently, our 
collaborators have demonstrated the synergistic killing of FLT3-ITD expressing AML 
MV4-11 cell line and primary cells through combined inhibition of FLT3-ITD 
tyrosine kinase activity and N-glycosylation using low doses of tunicamycin 
(Tsitsipatis et al., 2017). Taken together these studies confirm FLT3-ITD surface 
expression and NOX4 and NOX4D expression as promising therapeutic targets in 
AML. 
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In conclusion, this thesis has delineated the mechanism in which activation of 
the FLT3-ITD receptor at the plasma membrane and ER results in the activation of 
PI3K/AKT and STAT5 pro-survival signalling cascades, which are responsible for the 
activation and generation of NOX4-, NOX4D- and p22phox-generated pro-survival 
H2O2 in AML. Furthermore, it has been demonstrated that NOX4 and NOX4D are 
important producers of ROS. This confirms the importance of NOX proteins in pro-
tumourigenic signalling in leukaemia and highlights the importance of research in the 
area of ROS signalling in cancer and leukaemia. Together the data presented in this 
thesis identifies receptor trafficking inhibitors/glycosylation inhibitors and NOX 
inhibitors as potential therapies for the treatment of AML, which when treated in 
combination with standard chemotherapy may improve the effectiveness of the 
treatment. 
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